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ABSTRACT 
HUMAN GLUTATHIONE S-TRANSFERASES: CHARACTERIZATION, . 
TISSUE DISTRIBUTION AND KINETIC STUDIES 
ANNE VINT CORRIGALL 
UCT/MRC Liver Research Centre, Department of Medicine, University of Cape 
Town Medical School, Observatory, 7925, South Africa. 
In this study the purification of human basic and near-neutral liver, and 
human basic and acidic lung glutathione S-transferases (GSH S-T) was 
undertaken. Purification of the basic and near-neutral GSH S-T was achieved 
using a combination of affinity chromatography, chromatofocusing and 
immunoaffi.nity chromatography. Affinity and ion exchange chromatography 
were employed in the purification of the basic and acidic lung forms. The 
purified proteins had similar physicochemical characteristics to the GSH S-T 
purified by others. 
The binding of 1-chloro-2,4-dinitrobenzene (CDNB) to the 3 classes of 
human GSH S-T, viz. basic, near-neutral and acidic and the effects of such 
binding, if any, were examined. Human acidic lung GSH S-T is irreversibly 
inactivated by CDNB in the absence of the co-substrate glutathione (GSH). The 
time-dependent inactivation is pseudo-first order and demonstrates saturation 
kinetics, suggesting that inactivation occurs from an EI complex. GSH protects 
the enzyme against CDNB inactivation. In contrast, the basic and near-neutral 
GSH S-T are not significantly inactivated by CDNB. Incubation with 
[14C]-CDNB indicated covalent binding to all 3 classes of GSH S-T. When the 
basic and acidic GSH S-T were incubated with [14C]-CDNB and GSH, cleaved 
with cyanogen bromide, and chromatographed by HPLC, a single peptide 
fraction was found to be labelled in both classes. Incubation in the absence of 
GSH yielded 1 and 2 additional labelled peptide fractions for the basic and 
acidic transferases, respectively. These results suggest that while CDNB arylates 
all 3 classess of human GSH S-T, only the acidic GSH S-T posesses a specific 
GSH-sensitive CDNB binding site, which when occupied leads to time-
dependent inactivation of the enzyme. 
The tissue distribution and localization of the 3 classes of human GSH 
S-T in normal and tumour tissue was examined. Antibodies to representatives of 
the 3 classes were raised in rabbits, and radial immunodiffusion employed to 
quantitate their concentrations in the cytosol of 18 organs from 9 individuals. 
The data provide the first direct, quantitative evidence for the inter-individual 
and inter-organ variation suggested by earlier workers. The absence of the 
near-neutral GSH S-T in 5 of the 9 individuals studied confirms an earlier 
suggestion of a "null" allele for this transferase. Basic and acidic GSH S-T ( apart 
from in a single liver), were always present. Near-neutral GSH S-T, when 
present, were found in all tissues examined. The marked inter-organ and 
inter-individual variation observed in this study may explain individual and organ 
susceptibility to drugs, toxins and carcinogens. The immunohistochemical 
localization of the 3 classes of GSH S-T reveals important differences in their 
localization, and may provide insight into their functions in various organs and 
tissues. 
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The glutathione S-transferases (GSH S-T, EC 2.5.1.18) are a family of 
multifunctional enzymes that catalyse the reaction of glutathione with a variety of 
electrophilic xenobiotics (foreign compounds), including many mutagens and 
carcinogens (Boyland and Chasseaud, 1969). Many xenobiotics are toxic, 
lipid-soluble compounds and require conversion to non-toxic polar molecules in 
order to facilitate their excretion. One or more of 4 chemical mechanisms may 
be involved: oxidation, reduction, hydrolysis (Phase I reactions) and conjugation 
with endogenous substrates (Phase II reactions). The GSH S-T belong to the 
Phase II group of enzymes (Scott et al, 1988). 
The human cytosolic GSH S-T can be classified on the basis of their 
isoelectric points as basic, near-neutral and acidic enzymes (Mannervik, 1985a). 
Because of their important role in the biotransformation of xenobiotics, these 
enzymes have engendered a high level of interest and have stimulated ongoing 
research in many different fields. 
Early studies have shown that certain substrates are capable of binding 
covalently to rat GSH S-T resulting in their irreversible inhibition (Yamada and 
Kaplowitz, 1980; Reeve et al, 1981). 1-chloro-2,4-dinitrobenzene (CDNB), one 
of the most universal substrates for the transferases, reacts with a basic GSH 
S-T (transferase A) from rat liver to form a covalent complex in the absence of 
the substrate, GSH. However, little is known about covalent interactions of 
substrates with the human GSH S-T or about the nature and degree of any 
associated inhibition. As loss of activity of the human placental GSH S-T 
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resulting from incubation with CDNB is prevented by GSH (Vander Jagt et al, 
1981), a compound found in varying concentrations in different physiological and 
pathological conditions (Baars and Breiner, 1980), it was thought important to 
examine the binding of CDNB to the 3 classes of GSH S-T and to document any 
associated inhibition. 
Previous studies have suggested the existence of marked inter-organ 
and inter-individual variation of the 3 classes of GSH S-T in man (Warholm et al, 
1980; Sherman et al, 1983b; Board et al, 1981a). This finding has been claimed 
to explain individual and organ susceptibility to drugs, toxins and carcinogens. 
However, these earlier studies were based on indirect measurements of the GSH 
S-T or on direct measurement of a single GSH S-T. It was therefore decided to 
measure all 3 classes of GSH S-T in the same group of individuals in order to 
provide direct and quantitative data on the distribution of these enzymes in man. 
Similarly the immunohistochemical studies were prompted by the fact 
that there have been few comparative studies of the cellular localization of these 
various enzyme forms in normal and abnormal human tissues. 
With these considerations in view, this thesis describes the purification 
and characterization of the human liver basic and near-neutral GSH S-T as well 
as the basic and acidic lung forms. The binding of the substrate CDNB to the 3 
classes of human GSH S-T was investigated by kinetic and radiolabelling 
studies. Antibodies to the purified forms were raised in rabbits and utilized to 
quantitate immunologically the levels of these three classes of GSH S-T in a 
variety of organs from 9 individuals. In addition, a monoclonal antibody was 
raised to the acidic lung transferase. Finally, immunohistological localization of 





2.1 HISTORICAL BACKGROUND 
The glutathione S-transferases ( GSH S-T, EC 2.5.1.18) were first 
identified by Booth et al in 1961. The first GSH S-T to be purified was a basic 
protein, isolated from rat liver by 3 research groups who were independently 
investigating the binding of an azodye carcinogen (Ketterer et al, 1967), 
corticosteroid metabolites (Morey and Litwack, 1969) and organic anions (Levi 
et al, 1969) to proteins in rat hepatic cytosol. 
The realization that rat azocarcinogen-binding protein B, corticosteroid 
metabolite binder 1 and Y protein had similar physical and chemical 
characteristics, led to the exchange of antisera and the establishment of identity. 
In publishing the results of this joint study the authors suggested that the term 
ligandin be used for their protein since none of the previously used terms 
reflected the many ligands which it bound (Litwack et al, 1971). 
The possibility that ligandin might have catalytic activity was first 
suggested by Kaplowitz et al in 1973. They noted that much of the 
bromosulfophthalein (BSP) added to cytosol as a marker of the Y peak was 
converted to a glutathione (GSH) adduct. Their suggestion that ligandin 
possessed both binding and catalytic ability resulted in considerable controversy. 
This was resolved by Habig et al (1974a) who isolated rat liver ligandin and the 
rat liver glutathione S-transferases ( GSH S-T) independently and compared 
their physical properties, binding ability, catalytic activity, antigenicity and 
response to phenobarbital, and were able to demonstrate conclusively that 
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ligandin and GSH S-T B were the same protein. 
In 1976 Jakoby suggested that either the generic term ligandin or GSH S-T 
could be used to describe these multifunctional proteins (Sariff and 
Heidelberger, 1976). However the diversity of function plus important 
interspecies variations in the structure of the GSH S-T have resulted in the 
retention of a large and often confusing number of synonyms. In order to avoid 
such confusion the structure of these enzymes in the rat will be outlined briefly, 
although this review will concentrate primarily on the human GSH S-T. 
Early reports on the structure of rat liver ligandin suggested that it was a 
dimeric protein composed of identical subunits (Ketterer et al, 1975). However 
Bass et al (1977a) demonstrated that the Y fraction consisted of three subunits 
on discontinuous sodium dodecylsulphate polyacrylamide gel electrophoresis 
(SOS-PAGE) viz. Ya (Mr 22 000), Yb (Mr 23 500) and Y c (Mr 25 000), and that 
purified ligandin might indeed consist of two proteins viz. a homodimer Ya Ya 
and a heterodimer Ya Y c· Later Hayes et al (1979) suggested that the term 
ligandin should be reserved for the Ya Ya species while the Ya Y c species should 
be termed GSH S-T B. 
At the same time those workers studying the GSH S-T were engaged in 
characterizing and naming these proteins. At first the transferases were named 
according to their ability to catalyse various classes of substrates viz. 
alkyltransferase, aryltransferase, epoxidetransferase, arylalkyltransferase and 
alkenetransferase. Indeed it was only after Pabst et al (1973) purified the rat 
liver transferases to homogeneity that it was realized that rat liver contained 
several transferases of broad and overlapping substrate specificities. This led 
Habig to propose a new way of classifying the rat transferases (Habig, 1974b) in 
which letters were assigned to the transferases based on their reverse order of 
elution from a CM-cellulose ion exchanger viz. A ,B , C, D and E. An additional 
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transferase, viz. transferase AA, was later detected by Habig et al (1976) . This 
eluted at a salt concentration higher than that required for transferase A and was 
detected only after the introduction of a more sensitive assay using CDNB as 
substrate. 
The Yb band described by Bass et al (1977a) has been shown to comprise 
two components, viz. Yb and Yb' (Mannervik and Jensson, 1982). Thus 
transferases Yb Yb, Yb Yb' and Yb'Yb' correspond to transferases A, C, and D 
respectively. A minor component of the "Yb" band contains the subunits for 
transferase E. In 1982 Mannervik and J ensson suggested that each subunit be 
denoted by a letter of the alphabet. The confusion caused by the systems for 
naming ligandin and the GSH S-T led to a decision by the participants of a 
workshop on the GSH S-T in 1983 to introduce a numerical nomenclature 
(Jakoby et al, 1984) which would allow for the inclusion of new isoenzymes. It 
was based on the fact that the GSH S-T are dimers and reflected their different 
subunit composition by assigning a number to each subunit. To date transferases 
1-1 to 8-8 have been classified according to this nomenclature (see Table 2.1). 
It was also agreed that the identification of each protein species should be 
based on the name of the organism from which it was isolated rather than the 
tissue from which it was extracted. This system of classification has been 
extended to the mouse (Warholm et al, 1986) where an arbitrary system was 
previously used to identify the GSH S-T. The mouse enzymes are identified by 
both subunit numbers and a letter identifying the mouse strain from which the 
protein was isolated. 
The nomenclature has been further complicated by the use of letters of the 
Greek alphabet to describe the individual human transferases. 
Recently a species independent classification has been proposed 
(Mannervik et al, 1985). This system is based on similarities of the isozymes, 
Table 2.1 ALTERNATIVE NOMENCLATURE FOR THE
 RAT GSH S-TRANSFERASEsa 
Nomenclature Alternative Nome
nclature referencesb 
(1) (2) (3) (4) (5) (6) (7, 9) 
(8) (9) (10) (11) (12) (13) 
GSH S-T 1-1 Ligandin 
X B1 YaYa L2 
Ligandin n 





GSH S-T 5-5 
GSH S-T6-6 
GSH S-T 7_716,17 
GSH S-T g_gl7,18,19 
B 8 2 YaYc YaYb BL 
AA AA YcYc B2 
A II A ybyb A2 
C I C Yb Yb' AC 
O?C "D" Yb'Yb' C2 X 
E E 
MT YtYt 
a modified from Mannervik (1985a). 
b (1) Litwack et al (1971); (2) Jakoby et al (1976); (3) Askelof et al (1975); 
(4) Hayes et al (1981); 
(5) Scully and Mantle (1981) ; (6) Beale et al (1983); (7) Bass et al (1977
a) ; (8) Bhargava et al 
(1980); (9) Mannervik and Jensson (1982); (10) Friedberg et al (1983); (11
) Dierickx et al (1981); 
(12) Boyer and Kenney (1985); (13) Hayes (1984); (14) Sato et al (1984); (
15) Hayes (1986); (16) 
Meyer et al (1985); (17) Guthenberg et al (1985); (18) Robertson et al (19
85); (19) Jensson et al 
(1986). 
c GSH S-T D was never fully characterized by Jakoby and co-workers. 
The identification with 







which despite their species specific features, have certain characteristics in 
common. According to this system the GSH S-T are divided into three classes; 
Alpha, Mu and Pi, based on their enzymatic properties, amino-terminal amino 
acid sequences and immunological characteristics (see Tables 2.2, 2.3, 2.4). 
As with the rat, the early human GSH S-T studies were limited to the 
liver. In the first published report on human transferases, Kamisaka et al (1975) 
described the isolation of 5 basic transferases which they named O..to t in order 
of increasing pl ( > 7.8). Human liver GSH S-T were initially thought to be 
homodimeric, immunologically identical and to have minor variations in amino 
acid composition which were thought to be compatible with post-translational 
modification. 
An acidic GSH S-T was first described in 1978 by Marcus et al who 
reported the purification of a human erythrocyte GSH S-T ( p ) with a pl of 4.65, 
and which differed immunologically and in molecular weight from the human 
liver GSH S-T. In the following years acidic GSH S-T were purified from several 
human organs: placenta (1T) pl 4.8 - 4.65 (Guthenberg et al, 1979; Polidoro et al, 
1980); liver, a major form (w) with a pl of 4.6 and ( 'f ), a minor form with a pl 
of 5.4 (Awasthi et al, 1980); liver (Koskela and Valmet, 1980); lung (A ) eluting 
at pH 4.8 on chromatofocusing (Stockman et al, 1985). 
Considerable differences between the catalytic properties of the basic and 
acidic transferases have been found (see Section 2.3. Nomenclature of the 
Human GSH S-T). 
The first description of a near-neutral GSH S-T (J-l) was by Warholm et al 
in 1980 (pl 6 - 6.5). This transferase was found to be immunologically distinct 
from both the basic and the acidic GSH S-T and has a slightly higher Mr, It is 
only present in certain adults and this may explain why it was not detected by 




















AMINO-TERMINAL AMINO ACID SEQUENCES OF 
GSH S-TRANSFERASES 
Amino acid sequence 
(M)S GK P V L HY F NA R GR ME CIR W LL A A A 
PGKPVLHYFNGRGRMEPI 
P GK P V L(H)Y F 
(M)P GKPVLH YFD GR GRMEPI 
PMILG YWD IRGLAHAIRLLLE YT 
PMILG YWNVR GLTHPIRLL 
PMTLG YWDIR GLAHAIRLFLE YTDT 
PMILGYWNVR GLTHPIRMLLQYT 
PMILG Y XNVR GLXHPIRMLLE YXD X 
PMTLGYWNTRGLTHSIRLLLEYXDS 
PMILG YWD IR G LAHAIS LLL 
PPYTVVYFPVRGRCAALRMLLAD 
P P Y(T)I VY F P V 
PPYTIVYFPVVD G CEAM 
Residues within parenthesis indicate tentative assignments or initiator methionine. 
• Class alpha also comprises human transferase ~ - £, and mouse transferase MI. These 
proteins are amino-terminally blocked and are not listed owing to lack of sequence 
information. 
From: Mannervik et al (1985). 
Table 2.3 
CLASS-DISTINGUISHING SUBSTRATE SPECIFICITIES AND 




























Triphenyltin Bromosulf o- Hematin 
chloride phthalein 
0.3-30 2-200 0.05-2 
0.04-0.5 0.5-10 1-2 
>10 20-100 4-5 
Characteristically high specific activities and low IC50 values are given in bold face. 
Members of class alpha or mu have high activity with at least one of the two substrates 
indicated. No characteristic inhibitor for class pi has yet been identified. Members of class 
pi are distinguished from those of class alpha and mu by low sensitivity to both triphenyltin 
chloride and hematin. 
From: Mannervik et al (1985). 
Table 2.4 











































in mononuclear leucocytes is thought to be identical with the neutral hepatic 
form (Seidegard and Pero, 1985; Seidegard et al, 1987). Recently GSH S-T ~ 
(first described by Awasthi et al (1980) as an acidic GSH S-T) has been termed a 
neutral GSH S-T (Hussey et al, 1987b). 
A new GSH S-T (-& ) with an acidic pl has been isolated from human liver 
(Stockman and Hayes, 1987). It is composed of two subunits of identical Mr 
similar to the near-neutral GSH S-T µ, and has a pl of 4.6. This GSH S-T was 
present in only 1 out of 20 livers examined. 
In recent years 5-13 forms of GSH S-T have been purified from human 
liver (Soma et al, 1986; Vander Jagt et al, 1985). lsoenzymes have also been 
purified from a number of organs such as lung (Partridge et al, 1984), brain 
(Theodore et al, 1985), prostate (Tew et al, 1987) and kidney (Singh et al, 1987b; 
Tateoka et al, 1987). However, in platelets (Federici et al, 1985) and breast (De 
Ilia et al, 1986) only a single, acidic form has been purified. 
Over the years, many different classification systems have been used by 
many authors. In this thesis, the human enzymes have been referred to by Greek 
letters. When other nomenclatures are used, the Greek letter equivalents are 
given in parenthesis wherever possible. 
2.2 CLASSIFICATION OF THE GSH S-T 
In 1985 Mannervik et al demonstrated that the major cytosolic GSH S-T 
isoenzymes of rat, mouse and man shared structural and catalytic properties. 
This allowed them to propose a species-independent classification for the GSH 
S-T (Mannervik et al, 1985). Correlation of the data collected illustrated a clear 
division of the isoenzymes into 3 classes viz. Alpha, Mu and Pi (see Tables 2.2; 
2.3; 2.4). Each mammalian species studied was found to possess at least 
9 
one isoenzyme from each class. Since the similarities of isoenzymes within a 
given class were thought to reflect an evolutionary relationship it was suggested 
that the classification was generally applicable. 
Class ALPHA: 
Enzymes in this class exhibit high activity towards the substrate 
1-methyl-1-phenylethyl hydroperoxide (cumene hydroperoxide). Class alpha 
enzymes have low IC50 values for hematin and high IC50 values for cibacron 
blue. With the exception of rat subunit 2, which appears to have a high Mr, class 
alpha enzymes have subunits of intermediate size. 
Class MU: 
This class is characterized by high activity towards one or more of the 
substrates; trans-4-phenyl-3-buten-2-one, BSP or 1,2 dichloro-4-nitrobenzene. 
Class mu enzymes have high IC50 values for hematin and low values for cibacron 
blue. The enzymes have a low IC50 value (0.04 - 0.5 .uM) for triphenyltin 
chloride. Class mu subunits are larger than those of the other classes. 
Class PI: 
Class pi enzymes have high activity towards the substrate ethacrynic acid. 
Their IC50 values for hematin and cibacron blue are similar to class mu. 
However class pi enzymes differ from mu in that they exhibit high IC50 values 
( > 10 ,uM) for triphenyltin chloride. Class pi subunits are smaller than those of 
mu and alpha. 
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Immunologic studies in which antisera to 4 rat and 3 human transferases 
were tested against all available rat, human and mouse GSH S-T demonstrated 
cross-reactivity amongst the 3 species (see Table 2.4; Section 2.8.2). It is 
important to note that this cross-reactivity was limited to enzymes within each 
class and that cross-reactivity between classes did not occur even within the same 
species. 
N-terminal amino acid sequences demonstrated similarities within as well 
as between, classes. However, differences between enzymes from different 
species, but from within the same class, were smaller than the differences 
between the three classes of GSH S-T from a single mammalian species, 
suggesting that divergence of the three classes preceded the evolution of 
different mammalian species (see Table 2.2). 
The existence of additional classes has been suggested by the apparent 
lack of homology of the amino acid sequence of the rat liver microsomal GSH 
S-T with any of the other enzymes studied. This enzyme has a subunit Mr of 
14 000, is thought to be a trimer or tetramer, has a pl of 10.1 and has distinct 
enzyme activity. Using CDNB or cumene hydroperox:ide as substrates, it can be 
activated 15 and 10 fold respectively by treatment with sulfhydryl reagents such 
as N-!!thylmaleimide (Morgenstern et al, 1982; Morgenstern and DePierre, 1983). 
Thus based on protein sequencing, cDNA cloning and sequencing, and 
kinetic and immunological studies, it appears that the major forms of GSH S-T 
in rat, mouse and man fall into 4 gene families (Mantle et al, 1987). The 
cytosolic GSH S-T seem to be the product of 3 gene families, whereas the 
microsomal GSH S-T is genetically distinct (Hayes et al, 1987b). 
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2.3. NOMENCLATURE OF THE HUMAN GSH S-T 
The human GSH S-T are divided into three broad classes; the basic ( d..- t,) 
(pl > 7.5), the neutral or near-neutral ().J.) (pl 6 - 6.5), and the acidic (fr/ _f) (pl 
< 5.4) (Mannervik, 1985a). As yet no major functional differences apart from 
differences in substrate specificity have been noted between the isoenzymes of 
any of the three classes. 
2.3.1 THE BASIC GSH S-T 
The basic transferases, termed ct, 13, i , 5 and f in order of increasing pl, 
were first isolated from human liver by Kamisaka et al (1975). They were 
thought to be homodimers composed of subunits which were identical in size 
(Mr ± 51 000), varied slightly in charge, and had very similar amino acid 
analyses. The presence of heterodimers has since been described (Stockman et 
al, 1985; Singh et al, 1985; Soma et al, 1986) (see Table 2.5 which shows the 
enzyme forms purified by various workers, their subunit composition, when 
available, and attempts to relate them to the forms described by other workers). 
They all catalyse a similar spectrum of substrates differing slightly in 
specific activity. Basic GSH S-T have been identified in a wide variety of adult 
tissues (Sherman et al, 1983b). 
The basic transferases have high specific activity with the substrates 
cumene hydroperoxide (peroxidase activity) and delta 5-androstene-3,17-dione 
(isomerase activity) (Warholm et al, 1983) (see Table 2.6). 
They have been found to have comparatively low binding affinities for 
bilirubin (Kd = 18 - 110 uM) (Warholm et al, 1983) and they are strongly 
inhibited by tributyltin acetate (I50 = 0.1 uM) (Tahir et al, 1985) (see Table 2.7). 
Table 2.5 
PUTATIVE ALTERNATIVE NOMENCLATURE AND SUBUNIT TYPE 
FOR THEGSHS-T 
GSHS-T 





0 B2B2 Al I-VIII• B2B2 Y4Y4 II-II Ya 
d B1B2 II C2 B1B2 Y1Y4 I-II 
£ B1B1 I Cl B1B1 Y1Y1 I-I 
, 
•Grouping tentative as division based on apparent pl. 
(7,8) (9) 
AB Ha• 
(1) Kamisaka et al (1975); (2) Stockman et al (1985); (3) Soma et al (1985); (4) Sugimoto et al 
(1987) (5), Vander Jagt et al (1985); (6) Hussey et al (1986b); (7) Dao et al (1982, 1984), (8) 







$This enzyme may not be identical to f-
(4) (5) (6) (7) 
SUBUNIT TYPE 
(1) Warholm et al (1980,1983); (2) Soma et al (1986); (3) Sugimoto et al (1987); (4) Vander Jagt et 
al (1985); (5) Hussey et al (1986b); (6) Singh et al (1985); (7) Tu et al (1986). 
(6) (7) (8) (9,10) (11) 
ACIDIC SUBUNIT TYPE 
Liver 
f 1 
w(l) ?V ?Yf BC 
4' (1) IX - XIII• ?Yf: A'A' H/ 
&(2) Yb 2) . . . 
, 
Erythrocyte p (3) yf(12) cc 
Placenta ,r(4) yf(12) cc 
Lung t1 (5) yf(12) cc 
• Grouping tentative as division based on apparent pl. 
(1) Awasthi et al (1980); (2) Stockman and Hayes (1987); (3) Marcus et al (1978); (4) Guthenberg 
and Mannervik (1981); (5) Stockman et al (1985); (6) Soma et al (1986); (7) Vander Jagt et al 
(1985); (8) Hussey et al (1986b); (9) Dao et al (1982, 1984); (10) Singh et al (1985); (11) Tu et al 
(1986); (12) Hayes, et al (1987b). 
Table 2.6 
SUBSTRATE SPECIFICITIES OF HUMAN GSH S-TRANSFERASES 
Specific Activity (µmol.min-1.mg-1) 
Transferases 
Substrate Basic Near-neutral 
Acidic 
(o<.- l) ( ,u.) ('TT) 
1-Chloro-2,4-dinitrobenzene 64 187 105 
1,2-Dichloro-4-nitrobenzene 0.035-0.065 0.032 0.11 
Bromosulfophthalein 0-001-0.01 <0.002 <0.002 
Ethacrynic acid 0.017-0.044 0.081 0.86 
trans-4-Phenyl-3-buten-2-one 0.001-0.002 0.36 0.01 
1,2-Epoxy-3-(p-nitrophenoxy)- 0 0.11 0.37 
propane 
Styrene-7,8-oxide 0.02 2.6 0.07 
Benzo( a )pyrene-4,5-oxide 0.047 0.92 0.13 
Cumene hydroperoxide 10.6 0.63 0.03 
~5-Androstene-3,17-dione 8.0 0.12 0.01 
p-Nitrophenylacetate 0.18 0.22 0.19 
From: Mannervik (1985a). 
Table 2.7 
INHIBITION PARAMETERS, Isa VALUES (µM)a FOR THE THREE 
TYPES OF HUMAN GSH S-TRANSFERASES 
Isoenzyme 
Inhibitor Basic Near-neutral Acidic 
(o{- 8 ( ,u.) ('Tl) 
Cibacron blue 5 0.05 0.5 
Gossypol acetic acid 50 2 >100 
Tributyltin acetate 0.1 0.5 4 
Triethyltin bromide 10 5 6 
Triphenyltin chloride 0.25 0.5 >10 
Bromosulfophthalein 75 2 100 
Hematin 0.5 1 5 
S-hexylglutathione 3 10 20 
S-(p-Bromobenzyl)glutathione 4 1 4 
Indomethacin 100 4 100 
Rose Bengal 1 1 15 
a The 150 value is the concentration of inhibitor giving 50% inhibition of the·enzyme activity 
assayed at pH 6.5, 30°C, with 1 mM 1-chloro-2,4-dinitrobenzene and 1 mM GSH as substrates. 
From: Tahir et al (1985). 
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2.3.2 THE NEAR-NEUTRAL GSH S-T 
A near-neutral GSH S-T (f-) comprising 2 subunits of Mr 26 300 and a pl 
of 6.6 was first described by Warholm et al (1980; 1981b; 1983). This transferase 
is present in varying amounts in both males and females but was found only in 
60% of the adult livers studied (Warholm et al, 1980) and was not present in 
significant amounts in foetal liver (Warholm, 1983). The near-neutral GSH S-T 
has also been described in adult testis (Sherman et al, 1983b) and adrenal glands 
(Sherman et al, 1983b, Warholm, 1983). The existence of more than 1 
near-neutral form (termed J..l1 and J.l2) has subsequently been shown by Vander 
Jagt et al (1985). 
Particularily noteworthy of GSH S-T }l is the high specific activity with the 
substrates trans-4-phenyl-3-buten-2-one, benzo(a)pyrene-4,5-oxide, styrene-7,8-
oxide and trans-stilbene oxide (Warholm et al, 1983; Seidegard et al, 1987). 
Transferase _µ. has a high binding affinity for BSP (Kd = 1 µM) and for bilirubin 
(Kd ± 10).lM). 
Irreversible inactivation occurs with Hg2 +, N-ethylmaleimide, N-phenyl-
maleimide, 2,4,6,-trinitrobenzenesulphonate and 1-fluoro-2,4-dinitrobenzene. 
Strong ~bition of transferase JJ- occurs with cibacron blue (150 = 0.05 µM) 
(Tahir et al, 1985). 
Amino acid analyses show distinct differences from the basic transf erases 
(Warholm et al, 1983). 
2.3.3 THE ACIDIC GSH S-T 
The acidic GSH S-T are characterized by their low isoelectric point. They 
have been identified in a number of different adult organs e.g. 
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adrenal, ovary, lung, testis, kidney, spleen, placenta, brain, breast and thyroid 
(Sherman et al, 1983b; Koskelo et al, 1983; Dao et al, 1984; Polidoro et al, 1984; 
Theodore et al, 1985; Di Ilio et al, 1986; Del Boccio et al, 1987b). However, only 
certain individuals contain acidic GSH S-T in their livers (Sherman et al, 1983b, 
Hussey et al, 1986b ). 
In contrast to the liver, the acidic lung transferase was found to represent 
± 98% of the total GSH S-T activity of the lung towards the substrate CDNB 
(Partridge et al, 1984). The acidic lung GSH S-T is similar in many respects to 
the acidic liver GSH S-T but differs greatly from the hepatic basic transferases. 
The pl of the acidic lung transferase is 4.6 - 4.9 and the Mr 45 000 - 46 000 
(Koskelo. et al, 1981; Partridge et al, 1984). In a recent publication which 
described the use of anion exchange high performance liquid chromatography 
(HPLC) for protein purification, it was suggested that in addition to the major 
acidic form, two minor acidic lung isozymes exist (Singh et al, 1986). The 
existence of more than one acidic isozyme was also demonstrated in human heart 
and erythrocytes. 
Although the acidic form was found to represent such a high percentage of 
the total transferase activity of the lung it comprised only 72% of the GSH S-T 
protein of the lung (Partridge et al, 1984). It posesses activity towards a wide 
range of substrates but unlike the basic lung transferase does not exhibit 
peroxidase activity with either cumene hydroperoxide or H202 as substrates 
(Partridge et al, 1984). 
Dao et al (1984) found very close similarity between the acidic lung and 
placental GSH S-T. 
Using isoelectricfocusing Polidoro et al (1984) were able to demonstrate 
that brain GSH S-T activity in the human brain cortex could be resolved into a 
single peak in the acidic portion of the pH range. However, Theodore et al 
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(1985) purified three forms of GSH S-T from human brain viz. one basic (pl 8.3) 
and two acidic forms (pl 5.5 and 4.6). Although 20% of the total GSH S-T 
protein consisted of the basic transferase, this enzyme only contributed 
approximately 3% of the total enzyme activity towards CDNB. 
The substrate most characteristic for the acidic transferases is ethacrynic 
acid (Marcus et al, 1978; Guthenburg and Mannervik, 1981). The best inhibition 
has been noted with cibacron blue (150 = 0.5 JJM) (Tahir et al, 1985). 
Although this classification based on isoelectric point is commonly used, it 
has been suggested that it may be misleading, as division between the groups is 
unclear, particularly over the pl range of 5 - 7.3 (Hayes et al, 1987a). For 
example, an enzyme ( e) with an acidic pl ( 4.6) and subunit size identical to the 
near-neutral liver GSH S-T ( µ. ) has recently been described (Stockman and 
Hayes, 1987). In addition, misclassification may occur if chromatographic 
properties are used as at least one of the basic forms is strongly hydrophobic and 
may elute at a much lower pH than the pl value (Soma et al, 1986). It has been 
suggested that a more reliable grouping may be based on the migration of the 
GSH S-T subunits on SDS-PAGE (Hussey et al, 1986b). The three subunits 
separated by SDS-PAGE, termed Yb, Ya and Yf, generally correspond to the 
near-neutral, the basic and acidic groups respectively (Table 2.5) (see Section 
2.8.1.2). 
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2.4 TISSUE DISTRIBUTION OF THE HUMAN GSH S-T 
The GSH S-T are widely distributed throughout the plant (Frear and 
Swanson, 1970; Mozer, 1983) and animal kingdom with enzyme activity having 
been detected in 71 of 72 animal species/stages representing 9 phyla from 
aquatic and terrestrial animals (Stenersen et al, 1987). The cytosolic GSH S-T 
account for as much as 4% of cytosolic proteins in the liver and 1 % in the kidney 
and intestine (Hayes et al, 1987a). Radioimmunoassays (Tsuru et al, 1978, 1979; 
Sherman et al, 1983a; Hayes et al, 1983; Beckett and Hayes, 1984; Hussey et al, 
1986a, 1987a; Allan et al, 1987) and enzyme-linked immunosorbent assays 
(Hirano, 1984) have yielded new data on the tissue distribution of the GSH S-T, 
as well as their concentration in the plasma and tissues of normal subjects and in 
patients with a variety of clinical disorders. 
In humans the GSH S-T have been identified in a variety of organs. The 
highest concentrations are found in the liver and kidney (Baars et al, 1981; 
Sherman et al, 1983b). Relatively high levels have been found in the 
steroid-producing endocrine tissues, lungs and intestine but GSH S-T activity 
and immunoactivity have also been detected in the brain, erythrocytes, placenta, 
spleen, colon, pancreas, salivary gland, heart, muscle, prostate, bladder, thyroid 
and ileum of adults (Sherman et al, 1983b). In addition, GSH S-T activity has 
also been reported in semen of adults (Muktar et al, 1978) and foreskin from 2-4 
day old neonates (Muktar and Bresnick, 1976a). 
The isoenzyme patterns in human adult and foetal tissue differ markedly. 
The acidic form of GSH S-T occurs in all the human foetal organs investigated to 
date. In 1981, Warholm et al identified an acidic transferase in foetal liver which 
appeared to account for a significant proportion of total transferase activity 
(Warholm et al, 1981a). This is in contrast to the adult, where the contribution 
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of this enzyme form to the total transferase activity is small (from O - 5%) 
(Hussey et al, 1986b). In the foetus GSH S-T have been identified in the liver, 
lung, kidney, brain, intestine, adrenal, spleen, heart and diaphragm (Guthenberg 
et al, 1986; Pacifini et al, 1986; Faulder et al, 1987; Hirrel et al, 1987). 
The ability of different organs in the body to metabolize foreign 
compounds is of great importance. The liver sits astride the portal circulation 
and toxins absorbed by the intestine must pass through the hepatic sinusoids. 
The high GSH S-T activity in the liver together with the relatively high 
concentration of GSH suggests that the liver should be reasonably protected 
against these foreign compounds which undergo GSH S-T catalysed conjugation 
with GSH. However, in circumstances of GSH depletion it is possible that this 
defence mechanism will fail. 
Other organs with high GSH S-T levels are strategically placed at possible 
entry or exit sites of foreign compounds to the body e.g. intestine, lungs and skin. 
High GSH S-T levels are found in the steroid-producing tissue. A role for 
the GSH S-T as steroid hormone binding proteins has been described 
(Maruyama and Listowsky 1984; Homma et al, 1986). The GSH S-T are present 
in both the cytosol and the microsomes and thus may be involved in the transport 
or metabolism of steroids. In addition, they may protect against the undesired 
effects of these hormones (Homma et al, 1986). In the rat testis the GSH 
peroxidase activity of the GSH S-T is high (Eidne and Kirsch, 1982), and it is 
probable that the GSH S-T protect genetic material from both lipid peroxidation 
and electrophiles arising from mixed-function oxygenation of xenobiotics 
(Ketterer, 1986). As steroidogenic tissue is rich in the mixed function oxidases it 
is probable that this tissue would need the protection given by the GSH S-T and 
the GSH peroxidases (Ketterer, 1986). 
In the testis of man, ligandin (basic GSH S-T) is confined to the interstitial 
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cells where testosterone synthesis occurs (Campbell et al, 1980). In the 
undescended testis it is also present in the immature tubular cells (Campbell et 
al, 1980). It is attractive to speculate that the GSH S-T are playing a protective 
role in this tissue. The levels of GSH S-T decrease considerably with descent 
down the male genital tract. The epididymis has a reasonable amount of GSH 
S-T, however, low levels are present in the epididymal fluid and epididymal 
sperm (Ketterer, 1986). 
The main route of entry of most carcinogens is probably through the 
gastrointestinal tract. It is thus essential that a good detoxifying system exists in 
these tissues. In rats significant activity towards CDNB is found in the cytosol of 
interstitial villus and crypt cells. This activity is inducible by phenobarbital 
treatment. The specific activity of GSH S-T towards CDNB from mucosa! 
scrapings is highest in the duodenum and jejunum and lowest in the stomach 
(Pinkus et al, 1977). The lungs also provide a major entry route for carcinogens. 
Muktar and Bresnick (1976b) have demonstrated GSH S-T activity towards 
epoxide substrates in the lungs. 
In man several isoenzymes have been demonstrated, however, all forms of 
the enzyme are not present in every tissue. Evidence has been presented of wide 
inter-organ and inter-individual variation (Warholm et al, 1980; 1983; Muktar et 
al, 1981; Sherman et al, 1983b; Hussey et al, 1986b ). A comparative study of the 
liver GSH S-T from 8 individuals demonstrated the presence of the basic 
transferases in all individuals whereas the neutral and acidic forms were only 
detected in certain livers (Hussey et al, 1986b). It has been suggested that this 
wide inter-organ and inter-individual variation may explain individual 
susceptibility to drug toxicity (Sherman et al, 1983b; Warholm et al, 1983). 
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2.4.1 CELLULAR LOCALIZATION. 
In 1973, Bannikov et al studied the immunofluorescent cellular localization 
of rat liver azodye binding protein and were able to demonstrate 
immunofluorescence in the ovary, testis, liver, kidney and small intestine. 
These results were expanded by Fleischner et al (1977) who described the 
cellular localization of the GSH S-T in rat, hamster and man. Using the 
technique of direct immunofluorescence they were able to localize ligandin 
(basic GSH S-T) to the cytoplasm of hepatocytes, proximal renal tubular 
epithelial cells and epithelial cells of the proximal, mid and distal small intestine. 
Uniform fluorescent staining within the hepatic lobule was shown. Other tissues 
did not show specific staining for ligandin. 
Using the indirect immunoperoxidase (PAP) method of Taylor (1976) and 
a monospecific anti-human liver ligandin serum raised in rabbits, Campbell et al 
(1980) studied the distribution of ligandin in various human tissues. Ligandin 
was present in hepatocytes, in cells of the proximal convoluted tubule and the 
thick segment of Henle's loop in the kidney, in cells of the reticular layer of the 
adrenal cortex, in oxyntic cells of the stomach, in interstitial Leydig cells of the 
normal testis and in the fully developed Graafian follicle. Of interest was their 
finding that immature tubular cells of the undescended testis exhibited strong 
positive staining. Any form of Sertoli cell or interstitial cell hyperplasia from 
pathological testis or ovatestis also gave a strong positive reaction. The 
hepatocytes, the adrenal cortex and small intestinal villi of foetal tissue all gave 
strong positive reactions. 
Tillman (1984) used immunohistochemical methods to study the ligandin 
content of human ovaries at different stages of the menstrual cycle, during 
pregnancy and after the menopause, and found that ligandin was limited to those 
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cells actively producing steroids. 
Several studies have suggested that the transferases may prove useful 
markers for the detection of preneoplastic cells and neoplastic tissues. In rat 
chemical hepatocarcinogenesis, preneoplastic foci and hyperplastic nodules 
appear during the promotion stage of carcinogenesis, and they express specific 
preneoplastic marker enzymes (Sato et al, 1987). The rat placental tr~ferase 
GSH S-T P (transferase 7-7) has been identified as a marker for these 
preneoplastic lesions (see Section 2.10). Similarly, attempts have been made to 
stain (pre)neoplastic tissues immunohistologically in man. Using antibodies to 
human placental transferase 1T and the PAP technique, Kodate et al (1986) 
demonstrated that of 60 colonic carcinomas (including differentiated 
adenocarcinomas and undifferentiated carcinomas) 88% were positive for this 
GSH S-T. 47% of 23 adenomas of the colon were also positive. In normal 
colonic mucosa GSH S-T 1T' , when present, stained weakly. 
This same antibody was used to demonstrate high levels of GSH S-T rr in 
a variety of stomach carcinomas (Tsutsumi et al, 1987). As high levels of this 
transferase were also shown in the surface mucous cells and glandular cells of 
foetal stomach (18 weeks), the authors suggested that the phenotypic expression 
of GSH S-T Tt is oncofoetal in character, and may be useful for the detection of 
carcinomas of the stomach. 
Similarly, the findings of a study by Shiratori et al (1987) suggest that the 
placental transferase 1T may be a useful immunohistochemical marker for 
(pre )neoplasia of human uterine cervix. 
Hayes et al (1987) used antisera raised against the 3 classes of GSH S-T to 
study immunohistologically the expression of the 3 classes of GSH S-T in normal 
and diseased liver. In normal hepatocytes the basic GSH S-T were well 
expressed, whereas the concentration of the near-neutral GSH S-T was low in 
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both healthy and diseased hepatocytes. Strong staining of acidic GSH S-T in 
normal and malignant biliary epithelium was demonstrated. 
The expression of basic GSH S-T was markedly reduced in malignant 
hepatocytes. This reduction appeared to be a two step process, since adenomata 
demonstrated intermediary staining and a mosaic staining pattern was shown in 
at least one hepatocarcinoma. The strong positive nuclear staining for the basic 
GSH S-T seen in normal cells was markedly reduced in the nuclei of cells from 
hepatocellular carcinoma. 
Significantly increased acidic GSH S-T activity has been noted in human 
breast cancer cells (Batist et al, 1986), hepatic and lung tumours (Soma et al, 
1986; Di Ilio et al, 1988)) and kidney carcinoma (Di Ilio et al, 1987a). The 
increase in activity in the multidrug-resistant human breast cancer cells was 
associated with the appearance of a novel acidic transferase, which in contrast to 
other acidic transferases, had high organic hydroperoxide activity. 
In contrast to the above, a recent publication by Awasthi et al (1988) 
suggested that GSH S-T 1T or immunologically related isozymes might not be 
useful general markers for neoplastic states. Investigation of the expression of an 
isoenzyme (immunologically related to human Tl ) in 3 lung cancer cell lines 
showed a marked decrease in this enzyme in one of the cell lines, as shown by 
both enzyme activity and immunohistologically in tumours grown in nude mice 
from these lines. Futhermore, examination of the expression of GSH S-T 1T 
mRNA in human tumour and normal tissues suggested that unlike rat 
hepatocarcinogenesis this expression does not appear to correlate with 
neoplastic transformation in the liver. The authors suggested that the expression 
of the Class 'iT enzymes may differ in humans and rat (Kano et al, 1987). 
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2.4.2 SUBCELLULAR LOCALIZATION 
Subcellular localization of the GSH S-T has been studied in the rat, where 
93% of soluble enzyme activity is associated with the cytosol, and 7% with the 
mitochondrial matrix (Wahllander et al, 1979). However, as many of the GSH 
S-T enzyme substrates are lipophilic and are associated with the membranes of 
the cell rather than with the soluble fraction, the presence of membrane-bound 
GSH S-T would be advantageous in the inactivation of these substrates. A study 
by Friedberg et al (1979) showed that GSH S-T activity was highest in the 
membranes of the rough endoplasmic reticulum, microsomes and smooth 
endoplasmic reticulum and lower in the nuclei, nuclear envelope, golgi 
apparatus, plasma membrane and unbroken mitochondria. The microsomal 
enzyme has been further characterized (Morgenstern et al, 1980, 1982, 1984; 
Morgenstern and DePierre, 1983) and it appears to be at least partially exposed 
on the cytoplasmic surface of the endoplasmic reticulum. It is therefore feasible 
that these enzymes could come into contact with reactive metabolites generated 
by microsomal mono-oxygenases, and could inactivate them efficiently, thereby 
preventing lipid peroxidation. It appears that these microsomal enzymes may 
also be present in human liver (Hayes et al, 1987b). 
2.5. GENETIC EXPRESSION OF THE GSH S-T IN MAN. 
Kamisaka et al (1975), using the then standard techniques of ion exchange 
chromatography, gel exclusion chromatography and isoelectricfocusing to purify 
human liver GSH S-T, were able to identify 5 forms. These appeared to be 
homodimers and were similar in their molecular weight, amino acid composition, 
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substrate specificity and immunological characteristics. Based on their findings 
the authors suggested that the human liver GSH S-T were products of a single 
locus and that the multiple forms were the result of post-translational 
modifications of a single gene product. 
Board (1981a), using starch gel electrophoresis to separate the various 
human liver and erythrocyte GSH S-T, was able to examine GSH S-T forms 
excluded during the purification process used by Kamisaka et al. Board found a 
high degree of heterogeneity of the liver GSH S-T. He suggested that the 
strongly staining anodal and cathodal components were products of different loci 
and that the fast, weakly staining, anodal component might be the product of a 
third locus. On the basis of these findings Board postulated that there were at 
least three loci coding for the GSH S-T in man. He termed these GST1, GST2 
and GST3. 
At about the same time other workers in different centres using various 
techniques including affinity chromatography, detected the presence of the 
acidic placental (Guthenberg et al, 1979), acidic liver (Awasthi et al, 1980; 
Koskelo and Valmet, 1980) and the near-neutral liver transferase (Warholm et 
al, 1980). The use of different techniques and nomenclature has led to some 
confusion. In liver it seems that Board's GST2 isoenzymes correspond with the 
five basic transferases c:1-.- [ (Kamisaka et al, 1975) and one of the GST1 
isoenzymes with the near-neutral transferase ().l) (Warholm et al, 1980; 1983). 
The GST3 isoenzyme is weakly expressed in the liver, but appears to resemble 
the acidic transferase w (Awasthi et al, 1980) and the erythrocyte transferase (p) 
(Marcus et al, 1978). 
Board found that the three loci were all expressed in the liver. The GST3 
product is only weakly expressed and he proposed that the GSH S-T in human 
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liver are predominantly the products of two polymorphic autosomal loci viz. 
GST1 and GST2. 
He also suggested that two alleles are present at the GST2 locus and that 
there were 3 common alleles including a null allele at the GST1 locus. He 
proposed that the GST1 and GST2 loci possibly resulted from gene duplication 
and were highly polymorphic and suggested that this high degree of 
polymorphism and heterozygosity at these loci may explain the multiple forms 
described by Kamisaka et al (1975). Board suggested that in some individuals a 
common null allele exists at the GST1 locus and that this null allele may result 
from gene deletion thus preventing product formation. The total level of liver 
GSH S-T activity is significantly lower in individuals homozygous for the null 
allele (Board, 1981b). 
The suggestion that the GSH S-T are the products of three autosomal loci 
was supported by a study of the tissue distribution and genetic variation of the 
GST1, GST2 and GST3 isoenzymes (Strange et al, 1984). Using starch gel 
electrophoresis they found the GSH S-T isoenzymes in human tissue resolved 
into three groups viz. those with fast anodal mobility (GST3), those with slower 
anodal mobility (GSTi) and those which migrate towards the cathode (GST2). 
Four phenotypes were exhibited by the GST1 isoenzyme including a 
common "null" phenotype resulting from different combinations of three 
autosomal alleles GST1 •1, GST1 •2 and GST1 •o of frequency 0.13, 0.23 and 0.64 
(Strange et al, 1984). By examining various tissues from the same subject, 
Strange et al demonstrated that the GST1 phenotype was a constant individual 
characteristic. In certain tissues (liver, adrenal, kidney and stomach) relatively 
high levels of the GST1 locus were expressed whereas in foetal human liver, red 
cells, lymphocytes, platelets and cultured fibroblasts no GST1 activity was found. 
In contrast to this, the GST3 locus was expressed with relatively strong 
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components in all the adult tissues examined with the exception of adult liver. 
The pattern of expression of the GST3 is very different in adult and foetal liver. 
The relationship between the GST2 isoenzymes remains unclear and 
contradictory evidence has been presented. Strange et al found that in human 
liver cytosol variation of the GST2 isoenzyme pattern also occured on starch gels 
and usually demonstrated one of three different electrophoretic patterns. They 
proposed that the locus is not genetically polymorphic, that the most cathodal 
GST2 isoenzyme is the primary form and that the other relatively more anodal 
isozymes are the result of secondary post-synthetic modification. This was 
confirmed by Laisney et al (1984) and by Board and Webb (1987). The latter 
authors isolated a cDNA clone containing the entire amino acid coding sequence 
of a human GST2 subunit, and suggested from their results that the additional 
cross-hybridization clones are transcripts of the same gene. 
A publication by Stockman et al (1985) demonstrated the presence in liver 
of a basic hybrid enzyme composed of two monomers which the authors termed 
B1 and B2 (see Section 2.8.1.2). They suggested that these were two allelic 
products of the GST2 locus which were immunologically distinct and had 
different isoelectric points. In a recent publication by Stockman et al (1987), 
peptide mapping experiments supported the suggestion that the B1 and B2 
subunits are structurally distinct and that they are genetically separate, but share 
significant sequence homology (possibly more than 90% ). Rhoads et al (1987) 
have provided additional evidence suggesting the presence of more than one 
gene locus. Thus the theory of more than one gene product cannot be ruled out. 
Strange et al found that the GST2 isoenzyme was present in many tissues 
including foetal liver but was not detectable in erythrocytes, platelets, cultured 
fibroblasts or lymphocytoid cells. 
Board (1981a) suggested that the GSH S-T expressed in erythrocytes is the 
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product of a single locus viz. GST3. However a paper published by Strange et al 
(1983) in which they examined the electrophoretic mobility of erythrocyte GSH 
S-T on starch gels, concluded that 2 enzyme forms do exist. In the foetus, 
erythrocytes from cord blood also demonstrated two anodal bands. The authors 
proposed that these 2 isoenzymes reflect a post-synthetic modification of one 
gene product. 
Laisney et al (1984) suggested that the erythrocyte transferase differs from 
the GST3 isoenzyme and is the product of a separate locus, GSTe, Using 
electrophoresis they found that GST e was the most thermolabile and the fastest 
of the different GSH S-T analyzed, and was found only in erythrocyte cells. 
In addition, 2 further loci were proposed by Laisney and his group viz. 
GST4 and GST5 (1983; 1984). GST4 is found in muscle tissue and is thought to 
be a dimeric protein which forms a heterodimeric band with GST1 (interlocus 
hybrid isoenzymes). On electrophoresis GST4 migrated between GST1 and 
GST3. GST5 is found in brain homogenates in significant amounts but is also 
present in the lung. It has been suggested that an isozyme (GST5), purified by 
Suzuki et al (1987) and as yet found only in brain, may be a post-translational 
modified product of GST1. In addition, Suzuki et al (1987) purified an acidic 
isozyme GST6 (present in many tissues) composed of 2 dissimilar subunits. As 
no cross-reaction of this isozyme occured with GST1, GST2 or GST3, they 
proposed that it may represent an additional locus. 
Utilizing the techniques of starch gel electrophoresis and 
chromatofocusing, Strange et al (1985) studied the developmental aspects of the 
3 loci of the human transferases in liver, spleen, kidney, myocardium, diaphragm 
and adrenal. Four developmental stages were used viz. 10-20 weeks, 21-30 weeks 
and 31-42 weeks of gestation and term infants who died at 2-67 weeks 
post-natally. Although the expression of loci altered during development no 
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specifically foetal isozymes were found at any stage. 
In liver, spleen and kidney the GST1 was not usually expressed before 30 
weeks of gestation. Thereafter levels rose steadily until late infancy when adult 
levels were reached. In adrenal, however, the increase was slower and this locus 
was weakly expressed until after birth. These findings suggest that induction of 
the enzyme occurs, but whether or not this is in response to exposure to 
xenobiotics acting as inducers, is not known (Warholm et al, 1983). 
In all the groups studied the GST2 isoenzymes were consistently expressed 
m liver and adrenal but weakly expressed in spleen, cardiac muscle and 
diaphragm. In the kidney, the enzyme was only detected 1 year after birth. 
The GST3 isoenzymes were also expressed in all 4 groups. In the liver the 
expression of the GST3 isoenzymes decreased after 30 weeks of gestation. This 
decrease was not seen in the other tissues studied and it did not appear to be a 
negative response to increased expression of GST1. 
The electrophoretic patterns of the GST3 isoenzymes became more 
complex after 30 weeks of gestation with the appearance of 2 new isozymes. A 
weak isozyme moving more rapidly than the erythrocyte enzyme was identified in 
all tissue types studied. The second isozyme identified moved more slowly than 
the major GST3 enzyme - this mobility was similar to that of the GST4/GST1 
hybrid isoenzyme proposed by Laisney et al, (1984). It was often expressed in 
diaphragm muscle, sometimes in heart and kidney, but was not consistently 
found in other tissues of the same individuals. Strange et al (1985) suggested 
that these more complex enzyme patterns may arise from post-synthetic 
modification of a parent enzyme. 
Further studies by the same group on the ontogeny of the human GSH S-T 
(utilizing chromatofocusing and ion exchange chromatography) indicated that 
the B1 and B2 subunits in liver cytosol are present at 21 weeks gestation. 
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Although there were great changes in the expression of the GSH S-T, no 
developmental trends in total activity were noted (Faulder et al, 1987). Similarly 
with the isoenzymes present in the heart and diaphragm no developmental 
expression was found (Hirrel et al, 1987). 
The development of GSH S-T and GSH peroxidase in human lung has 
been studied (Fryer et al, 1986). The GSH peroxidase activity remains relatively 
constant between 13 weeks gestation and 84 weeks post-natally. Fryer and 
colleagues suggested that this peroxidase activity found in foetal lung cytosol 
resulted mainly from the selenoenzyme as after chromatofocusing of the cytosols 
only small amounts of peroxidase activity was associated with the basic 
transferase. In contrast, the GSH S-T activities during the 1st and 2nd trimester 
showed a decrease and the levels remained low until a year after birth. In 
chromatofocusing experiments on foetal lung cytosol they showed that the acidic 
GSH S-T accounted for most of the activity and that there is a marked decline in 
these levels during gestation. Between 10 - 30 weeks gestation reorganisation of 
structure and differentiation of lung cells occurs. During this time the levels of 
the GSH S-T decrease. A similar fall in liver acidic GSH S-T level occurs 
(Strange et al, 1985). As both liver and lung are derived from endoderm, Fryer 
et al suggested that other tissues derived from the same source may show a 
similar fall in acidic GSH S-T level. 
A comparative study of GSH S-T activity in human foetal and adult 
erythrocytes failed to reveal significant differences and suggested that a single 
form of this enzyme is present throughout foetal and post-natal life (Strange et 
al, 1980). 
From these starch gel electrophoresis studies it seems that the basic, 
near-neutral and acidic GSH S-T in human foetal, neonatal and infant tissue and 
adult tissue are similar. Immunological similarities and similarities in 
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sensitivity to inhibitors have been shown between the basic and acidic GSH S-T 
with their corresponding foetal forms (Guthenberg et al, 1986). These findings 
suggest that no specific foetal isoenzymes exist - at least not after the first 
trimester (Faulder et al, 1987). However, using the substrate styrene-7,8-oxide, 
the foetal liver GSH S-T were shown to have a greater activity than the adult 
forms (particularly the basic forms), suggesting that perhaps there is a foetal 
enzyme similar, but not identical, to the adult form. A novel enzyme Y c Y fetus 
(pl ± 8.65) with high GSH peroxidase II activity has been isolated from rat 
foetal liver (Scott et al, 1986; Scott and Kirsch, 1987). 
Chromosome localization studies (Laisney et al, 1983; 1984) revealed that 
the GSH S-T located on chromosome 11 is GST3 and not GST1 as suggested by 
Silberstein and Shows (1982). This has been confirmed by Suzuki and Board 
(1984). 
2.6 SEX DIFFERENCES IN THE GSH S-T 
Investigations have shown that differences between male and female exist 
in the hepatic GSH S-T activity towards certain substrates (Kaplowitz et al, 1975; 
Fujita et al, 1985). The implications of this are not known. 
It is possible that these differences are related to the sex hormones. It has 
been suggested that in the rat liver these differences are due to a hypothalamic 
inhibiting factor in the male (present after puberty) which acts on the pituitary 
preventing the secretion of a pituitary inhibiting factor which mature females 
secrete autonomously. This suggests that liver GSH S-T may be under 
hypothalamic-hypophyseal-gonadal regulation (Lamartiniere, 1981). The 
changes of ligandin levels during development in the ovary, testis and adrenal of 
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the rat paralleled changes in the circulating levels of testosterone and 
progesterone (Eidne et al, 1984). 
The levels of GSH S-T B (transferase 1-1 and 1-2) in adult rat liver 
supernatant was lower in males (3.3% of total protein) than in females ( 4.5% of 
total protein). However, hypophysectomy of the females abolished this 
difference (Hales and Niems, 1976). 
No sex difference in enzyme activities towards 1-chloro-2,4-dinitrobenzene 
(CDNB) or 3,4-dichloronitrobenzene (DCNB) was noted in rats before 5 weeks 
of age (Igarashi et al, 1987). No difference in GSH S-T microsomal activity was 
found between male and female at any age (Igarashi et al, 1987). In 7 week old 
rats, the activity of the cytosolic GSH S-T towards DCNB is higher in males than 
females. With the substrate CDNB no significant differences were noted. 
Analysis of the subunit composition of GSH S-T purified by GSH affinity 
chromatography showed a significant difference between the 2 sexes. Females 
have more Ya (subunit 1) and Y c (subunit 2) than YbfYb' (subunits 3 and 4). In 
contrast, in males the YbfYb' are the most abundant followed by Ya and Y c 
subunits (Igarashi et al, 1985). Likewise in mice the levels of the Ya subunit in 
females are marginally higher than those in males (McLellan and Hayes, 1987). 
The hepatic cytosolic GSH peroxidase activity towards H202 and cumene 
hydroperoxide is higher in females than males. However separation of the 
cytosolic peroxidases into peroxidase I and II, showed that these differences are 
mainly due to GSH peroxidase I and to a lesser extent to GSH peroxidase II 
activity (Igarashi et al, 1985). 
In mice cytosolic hepatic GSH S-T activities (especially towards CDNB) 
were significantly higher in males than females. In addition, the level of form II 
(1 of the 3 forms of mouse hepatic GSH S-T) was much higher in males. This 
difference could be abolished by castration. With the administration of 
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testosterone to adult females, the levels were raised to those of males (Hatayama 
et al, 1986). 
The Y f GSH S-T subunit is significantly higher in male than female mouse 
hepatic cytosol (as evidenced by SOS-PAGE, immunoblotting and hydroxy-
apatite HPLC) (McLellan and Hayes , 1987). 
2.7 AGE-RELATED DIFFERENCES IN THE GSH S-T 
Age associated differences in the GSH S-T activities occur in both male 
and female rats. Hepatic cytosolic GSH S-T activities towards the substrate 
CDNB increase progressively up to 7 weeks of age and thereafter remain 
constant or gradually decline (Igarashi et al, 1987). 
When the effects of aging on the cytosolic GSH S-T activities in liver and 
lung from both sexes were investigated using a variety of substrates (Spearman 
and Liebman, 1984), evidence was presented of changes related to age which 
were substrate, tissue and sex specific. The levels of transferase E (transferase 
5-5) in both liver and lung cytosol were lowest in senescent males. As some 
epoxides e.g. 1,2-epoxy-3-(-p-nitrophenoxy)propane (EPNP) are mainly meta-
bolized by this enzyme, it would seem that the toxic effects of these epoxides may 
increase with age. 
GSH S-T activities towards trans-4-phenyl-3-buten-2-one and DCNB m 
hepatic cytosol from male rats (1.5 - 28 months) were found to increase from 6 -
14 months and then gradually decline till 28 months when these values were at 
their lowest. In females these age associated differences were much smaller. No 
marked age associated differences were found towards the substrate CDNB 
(Fujita et al, 1985). 
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2.8. PHYSICOCHEMICAL CHARACTERIZATION 
The soluble GSH S-T are climeric proteins composed of 2 non-covalently 
associated subunits. Multiple forms of these enzymes occur and they can be 
distinguished on the basis of their isoelectric point, subunit Mr, immunogenicity, 
amino acid composition, substrate specificities, and sensitivity to different 
inhibitors. 
2.8.1. STRUCTURAL PROPERTIES 
2.8.1.1 CHARGE 
The human GSH S-T have been divided into three classes on the basis of 
their isoelectric points (Table 2.8). 
Many of the purification procedures commonly used for the GSH S-T, e.g. 
isoelectric focusing, chromatofocusing and ion exchange chromatography are 
based on the differences in pl values of the three classes of enzymes. 
2.8.1.2 SUBUNIT COMPOSITION 
During the early investigations of Kamisaka et al (1975) SOS-PAGE of the 
liver GSH S-T demonstrated climeric proteins of apparently identical subunits 
(Mr 25 000). The near-neutral form first described by Warholm et al (1981b; 
1983) was also found to consist of 2 apparently identical subunits (Mr 26 300) 
Table 2.8 
ISO ELECTRIC POINTS OF THE HUMAN GSH S-T IN VARIO US TISSUES 
Basic GSH S-T 
Tissue Liver Erythrocyte Lung 
pl 7.8- 8.9a 
Near-neutral GSH S-T 
Tissue Liver 
pl 
Acidic GSH S-T 
Tissue Liver Erythrocyte Lung 
pl 4.5, 5.4; 4.6g 4.6h 
a Kamisaka et al (1975) 
b Awasthi and Singh (1984) 
c Partridge et al (1984) 
d Singh et al (1987b) 
e Warholm et al (1983) 
f Awasthi et al (1980) 
g Stockman and Hayes (1987) 
h Marcus et al (1978) 
i Guthenberg et al (1979) 





Kidney Placenta Breast 
4.7, 4.9d 4.61 4.61 
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and the acidic forms which are present in trace amounts in liver (Awasthi et al, 
1980; Koskelo and Val.met, 1980; Warholm et al, 1980 and Sherman et al, 1983b), 
were similarly described as dimers of apparently identical subunits, which have 
been reported to have Mr values ranging from 22 500 to 23 500 (Awasthi et al, 
1980; Marcus et al, 1978 and Warholm et al, 1983). Thus each class seemed to 
consist of homodimers of distinct subunits of different molecular weight, amino 
acid composition and substrate specificity. 
More recently, however, several conflicting reports have been published as 
regards the subunit composition of the human GSH S-T. For example the basic 
liver transferases have been described as heterodimers composed of 2 subunits 
of different size (Singh et al, 1985; Awasthi and Singh, 1985), whereas others 
have described 2 distinct "basic" homodimers which are structurally distinct from 
the acidic subunits (Stockman et al, 1985; Soma et al, 1986; Sugimoto et al, 1987) 
(see Table 2.5). 
Dao et al (1982, 1984) suggested that the multiple forms of GSH S-T in 
human liver arise from the binary combinations of 3 different size subunits of Mr 
26 500, 24 500 and 22 500. Dimers of the 2 higher Mr subunits ( designated A 
and B) formed the basic enzymes, while a heterodimer of subunits B (Mr 24 500) 
and C (Mr 22 500) formed the acidic liver enzyme (w) described by Awasthi et 
al (1980). Using this nomenclature, the subunit composition of both the acidic 
placental and lung enzymes would be designated CC. These A, B and C type 
subunits are distinct from one another, differing in amino acid composition, 
substrate specificities, and immunogenicity (Dao et al, 1984; Theodore et al, 
1985). A fourth immunologically distinct subunit in human liver, A', was 
described by the same group in 1985 (Singh et al, 1985). In addition, Theodore 
et al (1985) showed that the human brain GSH S-T could be divided into similar 
subunits and presented evidence of heterogeneity. 
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The above findings are contrary to those of other researchers (Stockman 
et al, 1985; Hussey et al, 1986b; Soma et al, 1986; Sugimoto et al, 1987) who 
observed: 
1) homodimeric basic transferases as well as heterodimeric forms and 
2) no hybridization between basic and acidic subunits. 
Stockman et al (1985) used OEAE-sephadex chromatography to separate 
2 immunologically distinct subunits (B1 and B2) both having an Mr of 26 000 
which can form homo and heterodimers viz. B1B1 (t- ), B1B2 ( & ) and B2B2 
(probably c ). 
Soma et al (1986) purified 5 human liver GSH S-T, all apparently 
homogenous in size as shown by SOS-PAGE, and similarly described homo and 
heterodimers of two immunologically distinct subunits (Y 1 and Y 4) which 
seemed to correspond to the the B1 and B2 subunits described by Stockman et al 
(1985), as did the subunits I and II of Sugimoto et al (1987). 
Hussey and colleagues (1986b) attempted to classify the different subunits 
into 3 broad groups viz. the "basic type" (subunits of Mr 26 000), the "neutral 
type" (subunits of Mr 26 700) and the "acidic type" (subunits of Mr 24 800). 
These subunits were termed Ya, Yb and Y f respectively. They found the pl 
range quoted for the 3 groups was not clear-cut and they thus suggested that the 
transferases might be better classified according to their mobility on SOS-PAGE. 
In 1985 Vander Jagt et al isolated 13 forms of GSH S-T which were 
further characterized by Tu et al (1986). The 13 enzyme forms were composed 
of subunits in 2 electrophoretic mobility groups viz. Mr 26 000 (Ha) and Mr 
27 500 (Hb). There appeared to be no group corresponding to the rat Y c 
enzymes. 
The confusion caused by the naming of the different subunits suggests that 
34 
the introduction of a numerical classification system as suggested in the rat GSH 
S-T may be prudent and that further investigations are necessary to clarify the 
subunit strucure of the GSH S-T. 
2.8.1.3 AMINO ACID COMPOSITION 
The amino acid compositions of the various human GSH S-T are listed in 
Table 2.9. 
Comparisons of total amino acid compositions and N-terminal sequence 
analyses of 3 different forms of human GSH S-T were made by Alin et al (1985) . 
The acidic 1Y and near neutral }1 have free ~-amino groups whereas the basic 
(o<. - E, ) have a blocked c,:-amino group. Although the N-terminal amino acid 
sequence of Tr and f are different, they have 35% sequence homology in the 
N-terminal regions, having a one residue shift in starting position. 
Amino acid composition analyses showed significant differences in the 3 
forms. The acidic form 'TT had the highest valine level whereas phenylalanine was 
highest in the near-neutral transferase and isoleucine highest in the basic forms, 
suggesting that it is unlikely that the proteins are derived from a common 
precursor by limited proteolysis. Alin et al concluded from these studies that the 
3 types of enzymes are the products of 3 distinct genes, a finding in agreement 
with the genetic studies of Strange et al (1984). Despite these amino acid 
differences, there are areas of close structural relationship between certain 
subunits, e.g. the acidic ~ and near-neutral enzyme of the human liver have 
complete identity in the first twenty three amino acids of the N-terminal region 
(Singh et al, 1987a). Comparisons between the amino acid sequences of enzymes 
from different tissues show that similarities exist, for example, the placental and 
Table 2.9 
AMINO ACID COMPOSITIONS OF HUMAN
 GSH S-T 
Human Transferase 
Basica Basicb Near-neutralC Acid
icd Acidice Acidicb Acidicf 
Acidici; Acidich 
c~- l) ( 0) ( µ) ( !fl) lung (?) ('TT) 
breast thyroid 
Mr 51000 47000 
53000 53000 47000 45000
 46000 46000 46 000 
Amino Acid 
Asx 37.6 14.5 
50.4 47.8 39.7 45.3 
42.1 45.0 45.6 
Thr 8.5 30.0 
13.4 16.4 17.1 19.8 
18.4 18.2 19.8 
Ser 25.0 8.1 
21.4 20.4 23.4 25.8 
20.2 24.9 22.8 
Glx 51.9 54.6 
49.9 50.8 52.8 54.7 
49.2 56.0 51.8 
Pro 24.3 18.3 
20.2 17.8 25.3 26.3 
23.6 24.2 25.1 
Gly 22.2 65.8 
30.0 40.6 47.8 47.5 
37.4 42.2 38.9 
Ala 31.5 20.0 22
.8 39.4 27.2 35.0 
32.0 32.0 30.7 
Cys 2.0 9.
2 
8.0 8.2 7.8 
Val 19.3 12.2 U.6
 35.6 23.2 26.2 
28.1 20.6 23.4 
Mel 14.9 3.4 
12.4 11.2 2.9 3.0 
4.8 5.0 4.8 
Ile 29.8 4.9 27
.0 33.4 11.7 10.0 
13.5 13.7 13.9 
Leu 57.7 52.9 55.6 
50.8 61.9 60.5 62.4 
56.2 62.8 
Tyr 20.6 54.4 24
.0 19.2 24.7 20.8 24
.0 24.3 24.3 
Phe 19.9 3.0 26.0 
43.0 15.4 15.5 13.8 
14.1 15.8 
His 5.8 4.2 11.0 
9.8 7.2 5.2 3.9 
4.9 3.8 
Lys 47.4 7.6 40.0 
33.0 24.5 23.1 24.2 26
.5 24.1 
Trp 3.2 6.8 
n.d. 3.4 
Arg 23.3 16.0 19.8 
22.4 17.9 17.0 15.9 17
.1 16.1 
a from Warholm el al (1983) 
b from Awasthi and Singh (1984) 
c from Warholm el al (1983) 
d from Singh et al (1987a) 
e from Panridge et al (1984) 
f from Guthenberg and Mannervik (1981) 
g from Di Ilia et al (1986) 
h from Del Boccio et al {1987b) . 
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acidic lung transferases have identical N-terminal sequences (Dao et al, 1984). 
Evidence suggests that the transferases have been retained with relatively 
minor alterations through evolution. Examination of the nucleotide sequences of 
pGTH2 (cDNA of a human Ha subunit found in the 13 liver forms described by 
Vander Jagt et al, 1985) and DNA of rat and corn showed significant homology 
(Rhoads et al, 1987). Similarly, when the amino acid sequences of various 
transferases from different animals are compared, areas of homology are 
identified. Great similarities exist between the novel basic human skin GSH S-T 
(pl 9.9) and rat GSH S-T 2-2 (Del Bo~io et al, 1987a). The N-terminal 
structure of this novel GSH S-T is identical with that of rat 2-2 and differs in 
three positions from rat GSH S-T 1-1. 29 - 39% identity was found in the 
N-terminal region of the human lung acidic and placental enzymes and the rat 
liver enzymes described by Frey et al, 1983 (Dao et al, 1984) Fig. 2.1 shows a 
comparison of the human placental GSH S-T N-terminal sequence with those 
reported by Frey et al (1983) for rat liver GSH S-T. Mouse MIi and placental 
transferase (1T) have very similar amino terminal sequences (Table 2.2). 
Homology has also been demonstrated between the N-terminal amino acid 
sequence of human near-neutral transferase and that of mouse transferases 
GT-8.7 and GT-9.3 (Pearson et al, 1983), mouse MIii (Mannervik et al, 1985) 
and rat transferases 3-3 and 4-4 (Mannervik et al, 1985; Frey et al, 1983). 
Similarly 77 and 84 % residue identity between GSH S-T ~ and GSH S-T A 
(3-3) and X (4-4) were shown respectively (Singh et al, 1987a). 
Rat liver enzyme A 
Rat liver enzyme X 
Rat liver enzyme B 
Human placental 
Predicted conformation .....__ /3-Sheet------- ~.8-Turn--....,•• .. ----c,(-Hel ix--..... • 
Residues identities are boxed in. Abbreviation: N.D., not determined. 
Fig.2.1 Cofll)arison of human placental GSH S-transferase N-terminal sequence 
with sequences reported for rat liver GSH S-transferases by Frey et 
a 1 (1983). 
From: Dao et al (1984). 
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2.8.2. IMMUNOLOGICAL STUDIES 
Monospecific polyclonal and more recently monoclonal antibodies have 
been of great use in clarifying the antigenic characteristics of the human GSH 
S-T. In this regard "Western" and "dot blotting" have proved to be invaluable 
(Towbin et al, 1979; Hawkes et al, 1982). 
Some uncertainty exists about the immunological relationships of the 3 
classes of human transferases and conflicting reports have appeared in the 
literature. Thus the basic and acidic transferases have been reported both as 
being immunologically distinct (Partridge et al, 1984, Dao et al, 1984; Awasthi 
and Singh, 1984; Mannervik et al, 1985; Guthenberg et al, 1986; Hussey et al, 
1986b) and as being immunologically related (Awasthi et al, 1980; Singh et al, 
1985). Lack of cross-reactivity amongst the classes of human GSH S-T with both 
native and unfolded protein has been reported (Vander Jagt and Garcia, 1987). 
Initially the 5 basic GSH S-T identified by Kamisaka et al (1975) were 
thought to be immunologically identical (Fleischner et al, 1976). However, new 
techniques of purification have resulted in the preparation of basic GSH S-T 
species with dissimilar antigenic properties. The B1 and B2 subunits purified by 
Stockman et al (1985), the Y 1 and Y 4 of Soma et al (1986) and the I and II 
subunits of Sugimoto et al (1987) are immunologically distinct, although they may 
share some antigenic sites (Soma et al, 1986). 
There is also uncertainty over the immunological relationship between the 
neutral GSH S-T and the other 2 classes of transferases. Lack of cross-reactivity 
between the near-neutral liver form ( µ.) with the other classes of GSH S-T has 
been reported (Warholm et al (1983); Soma et al (1986); Vander Jagt and 
colleagues (1985)). In contrast a neutral liver form (pl 6.8) (as well as an acidic 
form, pl 4.5) described by Singh et al (1985) was shown to cross-react with a 
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mixture of the basic forms (see Table 2.10). The near-neutral liver enzyme (~) 
appears to be immunologically related to the recently described GSH S-T 8 (pl 
4.6) (Stockman and Hayes, 1987) and to lj/ (pl 5.5) (Hussey et al, 1987a). 
Cross-reactivity between the same class of transferases isolated from 
different tissues has been demonstrated in several studies. The acidic forms of 
lung and placenta cross-react with the acidic form of human liver (Dao et al, 
1984) and the acidic erythrocyte enzyme (Partridge et al, 1984). 
Similarly, cross-reactivity is found between the GSH S-T of different 
species (Mannervik et al, 1985; Warholm et al, 1986). Antibodies raised against 
the human basic transferases described by Kamisaka et al (1975) did not react 
with any of the rat GSH S-T, although they showed reactivity with rhesus monkey 
preparations (Fleischner et al, 1976). More recently, however, results disputing 
these findings do show cross-reactivity between rat and human enzymes (Soma et 
al, 1986; Tu et al, 1986; Mannervik et al, 1985; Del Boccio et al, 1987a). 
From the above it appears clear that inter-species cross-reactivity certainly 
exists, however, cross-reactivity amongst the different classes of human GSH S-T 
remains unclear. 
2.8.3. CATALYTIC PROPERTIES. 
The GSH S-T catalyse the conjugation of the nucleophile GSH with a wide 
variety of electrophilic compounds. These compounds, providing they have 
sufficiently reactive electrophilic centres and are able to bind to the substrate 
binding site of the enzyme, are subjected to nucleophilic attack by bound GSH. 
For a compound to be a substrate for the GSH S-T it must have a hydrophobic 
region which promotes binding and an electrophilic domain which may be a 
TABLE2.10 
IMMUNOLOGICAL CHARACTERIZATION OF HUMAN LIVER GSH S-T 
Purified by Singh et al (1985) 
Cross-reactivities of the antibodies 
With the human liver GSH S-T 
Antibodies raised against: Cationic* Neutral Anionic Anionic 
(pl 8.9) (pl 6.8) (pl 5.5) (pl 4.5) 
Human placental anionic GSH S-T (CC) + 
Human lung anionic GSH S-T (CC) + 
Human liver cationic GSH S-T (AB) + + + 
Antibodies specific to B subunits + + + 
of cationic human liver GSH S-T 
Antibodies specific to A subunits + 
of cationic human liver GSH S-T 
*Immunological properties of other cationic forms were found to be similar. 
From: Singh et al (1985). 
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carbon, nitrogen, sulphur or oxygen atom (Habig, 1983). Examples of the wide 
range of substrates and the substrate specificities of the GSH S-T are shown in 
Fig. 2.2 and Table 2.6 respectively. 
Glutathione is the common substrate for all the GSH S-T catalysed 
reactions. This tripeptide (Fig. 2.3) is widely distributed in nature and is usually 
at high concentration (between 1 - 10 mM depending on the tissue) within the 
cell (Habig, 1983, Ketterer et al, 1986). Conjugation of GSH with the second 
substrate forms the first step of the mercapturic acid pathway (see Fig. 2.4). The 
conjugates may then undergo transpeptidation with the loss of the (f-glutamyl 
group followed by removal of the glycine and N-acetylation of the cysteine 
moiety. The end product ( a mercapturic acid) is usually non-toxic and water 
soluble and is readily excreted. 
Reactions with endogenous substrates may also occur (Habig, 1983). 
Examples of these reactions catalysed by the GSH S-T are given below. 
The most well studied reactions catalysed by the GSH S-T are those 
involving electrophilic carbon. These reactions include: 
(1) conjugation with a wide variety of compounds (Fig. 2.5 a-d) 
(2) isomerization (Fig. 2.5 e) 
(3) thiolysis (Fig. 2.5 f) 
In the conversion of delta5-androstene-3,17-dione to delta4-androstene-
3,17-dione (Fig. 2.5 e) no intermediate conjugate has been found. GSH is 
required in this reaction but is not consumed (Benson et al, 1977). 
Other reactions catalysed by the GSH S-T include those with: 
(1) electrophilic nitrogen 
(2) electrophilic sulphur 
(3) electrophilic oxygen 
• 
Fig. 2.2 
2 3 II 7 
CH~ 
10 11 
Substrates for the glutathione S-transferases. Leaving sites, and sites of 
addition are indicated by circles and arrows, respectively. 
1 1,2-dichloro-4-nitrobenzene 
2 1-chloro-2,4-dinitrobenzene 
3 p-nitrobenzyl chloride 
4 4-nitropyridine-N-oxide 
5 1,2-epoxy-3-(p-nitrophenoxy )propane 
6 1,2-napthalene oxide 
7 iodomethane 
8 1-menaphthyl sulphate 
9 trans-4-phenyl-3-buten-2-one 
10 p-nitrophenethyl bromide 
11 bromosulf ophthalein 
From: J akoby et al (1976) 
Fig. 2.3 Structural formula of Glutathione (GSH). 




















Fig.2.4 Metabolic Pathway for the Biosynthesis of Mercapturic Acids 
R.X represents an electrophilic compound. The initial step is catalysed by the 
glutathione S-transferases. 
Cl SG 
¢t' ¢t' GSH + + HCI (a) 
N02 N~ 
SG 
I 6CHitH, or 0 0 (b) 
GSH + I I 
SG 
I 
Qc\T"' ¢1:°"' 0 (c) GSH + I I 
N02 N02 








0 ¢ II (f) GSH + GSCCHJ + 
N02 N0 2 
Fig. 2.5 The reactions between GSH and (a) 1.2-dichloro-4-nitrobenzene (an aryl 
substrate) (b) trans-4-phenyl-3-buten-2-one (an alpha, beta unsaturated ketone); 
(c) 1,2-epoxy-3-(p-nitrophenoxy)propane (an epoxide) (d) iodomethane (an alkyl 
substrate). 
( e) shows the conversion of delta5-androstene-3,17-dione to delta4-andro-
stene-3,17-dione and (f) the conversion of p-Nitrophenylacetate to p-nitrophenol 
and the acylated thiol. 
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The first 2 reactions involve organic nitrate esters and thiocyanates, 
resulting in the release of HN02 and HCN, respectively (Keen et al, 1976). 
The reaction of GSH with organic hydroperoxides is an example of a 
reaction with electrophilic oxygen as substrate (Mannervik, 1985b) (see Section 
2.8.3.1). 
There have been several reports of GSH catalysed reactions with 
endogenous compounds. 
The conjugation of prostaglandin A 1 and GSH has been shown to be 
catalysed by the GSH S-T in both human and rat liver (Cagen, 1975). 
15-Ketoprostaglandins also form conjugates with GSH, but in the presence of 
prostaglandin A1 this reaction is inhibited (Chaudhari et al, 1978). 
Another group of possible substrates are the epoxides formed from 
various compounds. The 2 major biotransformational pathways for the epoxides 
are: 
1) hydration to the diol, and 
2) conjugation with GSH (catalysed by the GSH S-T). 
Endogenous compounds may form these epoxides. Differences in specific 
activity with a given epoxide are noted in the various isoenzymes of the human 
GSH S-T, for example, the neutral transferase (.U.) has a high specific activity 
with benzo(a) pyrene-4,5-oxide. This may be of particular significance as only 
60 % of the population have this isoenzyme (Warholm et al, 1983). 
Investigations have shown that the GSH S-T may play a role in leukotriene 
synthesis. The leukotrienes are a family of biologically active compounds formed 
from arachidonic acid via a 5-lipoxygenase. Conjugation of the epoxide 
derivative of arachidonic acid, leukotriene A4, is catalysed by both the purified 
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soluble as well as the microsomal hepatic GSH S-T (Bach et al, 1984b). The 
human basic, near-neutral and acidic forms are all able to catalyse the formation 
of leukotriene C4 from GSH and leukotriene A4, with the highest activity being 
shown by the near-neutral enzyme (Soderstrom et al, 1985). The GSH S-T 
involved in leukotriene C4 biosynthesis in rat basophilic leukaemia cells occurs 
only in the microsomes and is distinct from the rat microsomal form (Bach et al, 
1984a). 
Mutagenic 4-hydroxyalk-2-enals are toxic products of lipid peroxidation 
and alkaloid metabolism. These compounds serve as substrates for the GSH S-T 
with rat GSH S-T 8-8, 1-1 and 4-4, and human GSH S-T µ. having high activity 
with these substrates, suggesting that these isoenzymes may have evolved to 
detoxify 4-hydroxyalk-2-enals (Danielson et al, 1987a, b). 
Three further groups of compounds that may act as endogenous substrates 
are aralkyl sulphate esters (Gillham, 1971), quinones (Morgenstern et al, 1981) 
and peroxides (Meyer and Ketterer, 1982; Tan et al, 1984). 
It thus seems likely that not only do the GSH S-T play a role in the 
metabolism of xenobiotics but that they may also play an important role in the 
biotransformation of endogenous substrates. 
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2.8.3.1 GSH PEROXIDASE ACTIVITY 
Reactive 02 species are generated during normal cellular metabolism and 
may be enhanced by xenobiotics. These oxygen species may initiate lipid 
peroxidation by the abstraction of a hydrogen atom from an unsaturated 
phospholipid (Ketterer et al, 1986). Lipid hydroperoxides can be decomposed 
by metal catalysed reactions to reactive alkoxy, peroxy and hydroxy radicals 
which promote spontaneous lipid peroxidation (Reddy et al, 1981). Thus 
initiation of lipid peroxidation commences a chain reaction which, if 
uncontrolled by defence mechanisms may lead to extensive damage of the 
surrounding molecules (Feher et al, 1987). Targets for lipid peroxidation are the 
subcellular membranes rich in unsaturated fatty acids. In addition to localized 
damage, toxic products such as 4-hydroxyalkenals and aldehydes can migrate far 
from their site of production, even to other cells and tissues causing damage at 
these distant loci (Slater, 1984). 
GSH peroxidase I and the selenium-independent GSH peroxidase IT 
enzymes play a role in preventing peroxidation of polyunsaturated membrane 
fatty acids induced by reactive oxygen species. They prevent propagation of a 
radical chain reaction which ultimately leads to lipid peroxidation. 
The selenium-independent GSH peroxidases differ from the 
selenium-dependent forms in that: 
1) they are not selenoproteins 
2) they are unable to catalyse the reduction of H202 (Lawrence and Burk, 
1976) 
3) their peroxidase activity is not inhibited by cyanide, and 
4) they show zero order dependence on GSH (Prohaska and Ganther, 1976). 
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Evidence indicating the existence of a second GSH peroxidase species was 
provided by Lawrence and Burk (1976) using cumene hydroperoxide as 
substrate. The enzymes responsible for selenium-independent GSH peroxidase 
activity are the GSH S-T and were first identified as such by Prohaska and 
Ganther (1977). 
In most animals the contribution of the GSH peroxidase I to total activity 
is large, e.g. human breast and lung tissue where the contribution is close to 
100 % (Di Ilio et al 1985, 1987b ). However, in guinea pig liver this enzyme is 
either absent or the contribution is minimal, and in human liver and rat testis the 
contribution of the GSH peroxidase II is particularly high (Lawrence et al, 1978, 
Lawrence and Burk, 1978). There also appears to be inter-species variation in 
substrate specificities of the enzymes e.g. human liver GSH peroxidase II activity 
is only exhibited with cumene hydroperoxide as substrate. In contrast, the rat 
liver GSH S-T have GSH peroxidase activity with both cumene hydroperoxide 
and tert-butylhydroperoxide as substrates (Lawrence et al, 1978). In the human 
the highest GSH S-T peroxidase II activity is expressed by the 5 basic GSH S-T, 
with smaller amounts of activity expressed by the near-neutral transferase 
(Warholm et al, 1983). The acidic transferases wand tµ (Awasthi et al, 1980), as 
well as the acidic enzymes from the lung (Partridge et al, 1984) and placenta 
(Polidoro et al, 1982) have been found to have no peroxidase II activity. 
Mechanism of Peroxidase Activity 
GSH S-T B (transferases 1-1 and 1-2) and AA (transferase 2-2) were 
purified by Prohaska in 1980 in order to investigate the mechanism for their 
apparent GSH peroxidase activity (GSSG formation). 
He suggested that the nucleophilic attack by GS- on hydroperoxide results 
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in the formation of a reactive intermediate GSOH (the sulfenic acid of 
glutathione ). 
GSH + ROOH = GSOH + ROH 
The sulfenic acid reacts nonenzymatically with GSH resulting in the production 
of GSSG. 
GSOH + GSH ~ GSSG + H20 
The non enzymatic oxidation of GSH by H202 also results in the formation of 
the intermediate GSOH. 
GSH - reduced glutathione 
GSSG - oxidised glutathione 
ROOH - any of a wide variety of hydroperoxides. 
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2.8.3.2 KINETIC MECHANISM OF THE GSH S-T 
The kinetic mechanism of the GSH S-T has been examined by workers 
from different laboratories. Fortunately most of the kinetic studies have been 
done on rat transferase A (transferase 3-3), a homodimer which eliminates 
possible complications from having 2 non-identical subunits. One of the first 
mechanisms proposed was a ping-pong mechanism in which the first product 
leaves the enzyme-substrate complex before the second substrate is added (Pabst 
et al, 1974) (see right hand wing of Fig. 2.6). This was the case at GSH 
concentrations of less than 0.01 mM. However, at a high concentration of GSH 
( > 0.15 mM) kinetic analysis indicated an ordered sequential mechanism where 
GSH is added first followed by the second substrate (see left wing). 
The proposal of a random two-substrate mechanism resulted from studies 
by Askelof et al (1975), in which they investigated the steady-state kinetics of the 
2 forms of rat liver GSH S-aryltransferase (thought to correspond to transferase 
A (3-3) and C (3-4)) using GSH and 3,4-dichloro-1-nitrobenzene as substrates. 
The kinetics did not follow Michaelis-Menten kinetics when the concentration of 
either substrate was varied at a fixed concentration of second substrate, and it 
was suggested that a random two-substrate mechanism could explain these 
non-linearities. Studies by Mannervik's group (Jakobson et al, 1977) on the 
steady-state kinetics of rat liver GSH S-T A (transferase 3-3) using the same 
substrates led to the proposal of a steady-state random sequential mechanism. 
Further evidence supporting this was presented by Mangold and Abdel-Monem 
(1980, 1983) who used the same GSH S-T and the substrates GSH, 
phenethylchloride and phenethylbromide. The reaction was found to proceed 
with a high degree of stereoselectivity, and it resulted in an inversion of 




1' G C 4 3 G 
single double , (EGY::ce~E ~ace~: 
a 
(EC) (EA) 
Schematic representation of catalysis by glutathione S-transferase A (3-3). The 
reaction proceeds counterclockwise from E, the free enzyme, in each case. The 
left hand wing represents the ordered sequential mechanism, and the right hand 
wing the "ping-pong" mechanism. G = glutathione; A = the electrophilic 
substrate; a = the leaving group and C = the glutathione conjugate. Under 
physiological conditions, the single displacement pathway is followed, whereas 
at low concentrations of GSH, the double displacement pathway applies. 
From: Pabst et al (1974). 
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mechanism which is in agreement with a sequential reaction. Ridgewell and 
Abdel-Monem (1987) studied the GSH S-T catalysed conjugation of alkyl halides 
in vitro. Their data also supported the proposal of a single displacement 
mechanism, with product inhibition at low GSH concentrations. 
The actual function of the GSH S-T in the enzyme reaction has been 
debated as they are known to bind to many ligands, whether they are substrates 
or not. One theory is that the transferases act primarily by enhancing the 
nucleophilicity of the thiol function of enzyme-bound GSH thus facilitating its 
attack on the electrophilic centre of the second substrate (Keen et al, 1976). It is 
possible that the active site promotes ionisation of the thiol moiety of GSH by 
lowering its pKa (pKa 9.2), thus increasing its nucleophilicity and facilitating its 
interaction with the electrophilic substrate which is also bound to the enzyme. 
Currently it is thought that the GSH S-T act merely by bringing the GSH and the 
electrophilic substrate in close proximity to one another (Boyer, 1985). Although 
the GSH S-T are not very selective in their binding to the second substrate, their 
requirement for an active thiol first substrate is highly specific (Keen and Jakoby, 
1978). To date, GSH, homoglutathione (Habig et al, 1974b) and 
gamma-glutamylcysteine (Sugimoto et al, 1985) are the only compounds known 
to bind to the site. 
It has been suggested that 2 binding sites exist viz. the GSH binding site 
and the substrate binding site, which lie adjacent to each other. In 1978 
Mannervik proposed that the GSH-binding cavity be called the G-site and that 
the second substrate binding site be called the H-site (Mannervik et al, 1978). 
Various different functional groups of the enzyme have been identified as 
being important for catalytic activity: Studies with rat GSH S-T have suggested 
that thio~ amino and guanidino might be of importance although partial thiol 
modification could be obtained without loss of enzyme activity. Carne 
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et al (1979) studied the binding and catalytic activities of ligandin after 
modification of its thiol groups. Modification of 3 thiol groups resulted in a 
decrease in both enzymic and binding activities although the number of binding 
sites was unaffected. However, modification of only 1 or 2 of the thiol groups 
had little effect on enzymic activity. The authors suggested that there is a thiol 
group in the common hydrophobic-ligand and substrate-binding site of ligandin. 
Charged groups such as guanidino (Schasteen et al, 1983) and amino 
groups (Inoue et al, 1981) have been suggested at the GSH binding site. 
Schasteen et al, using the arginine specific chemical modifying agent, 
phenylglyoxal, showed that opthalmic acid (a GSH analog) and dithiothreitol 
protected the enzyme from phenylglyoxal inactivation whereas no protection was 
afforded by the oxidised form of GSH or 2 GSH methylesters. This suggests that 
the arginyl residues on the GSH S-T may function as anionic recognition sites for 
GSH. 
The 'lJ -glutamlycysteinylglycineamide and 't -glutamylcysteinylglycine-
1-methyl esters of GSH were not effective in eluting GSH S-T bound to an 
cx-aminoalkylsepharose derivative of GSH suggesting that the free carboxyl 
groups of the glycyl moiety of GSH may be important for the binding of the 
transferases (Inoue et al, 1981). 
Inhibition studies with diethylpyrocarbonate (a compound that prefer-
entially modifies histidyl residues) and human liver transf erase iµ suggest that 
histidine may be involved at the active site, and as GSH protected against this 
loss of activity, it is likely that the residue is situated at, or close to, the G-site 
(Awasthi et al, 1987). 
Studies carried out by Keen and Jakoby (1978) led to the proposal that the 
transferases interact specifically with GSH and bind any of a wide variety of 
second substrates at an adjacent hydrophobic locus. Evidence supporting a 
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hydrophobic subsite resulted from inhibition studies on rat liver transferases A 
(3-3) and C (3-4) utilizing S-substituted GSH derivatives (from methyl to n-octyl) 
(Askelof et al, 1975). Comparing S-alkyl and S-arylkyl derivatives, the authors 
showed that the strongest inhibitors were the S-alkyl compounds with the longest 
carbon chains, suggesting that hydrophobicity of the S-substituent rather than 
aromatic character, is required for efficient binding. 
An active site situated between the 2 subunits was suggested by Grover in 
1977 (Danielson and Mannervik, 1985) (see model II Fig. 2.7). Thus different 
combinations of subunits would result in the different substrate specificities 
found for the various isoenzymes. However, this hypothesis appeared to be 
disproved by the inhibition studies of Yalcin (1983) who showed that the 
inhibition effects on a subunit are independent of the nature of the neighbouring 
subunit. 
The results of Danielson and Mannervik (1985) also do not agree with 
Grover's hypothesis. They determined the kinetic parameter Keat/Km using 
CDNB , 4-hydroxyalk-2-enals, ethacrynic acid and trans-4-phenylbut-3-en-2-one 
as substrate for the rat isoenzymes 1-1, 1-2, 2-2, 3-3, 3-4 and 4-4. They showed 
that the Keat/Km values for the heterodimers could be predicted from the values 
of the corresponding homodimers. Furthermore the kinetic properties of the 
subunits were found to be additive. These results suggested that the subunits are 
kinetically independent, and that each polypeptide chain contains the necessary 
structure for a complete active site including the G-site and the H-site (see 
model I Fig. 2.7). However, the subunits are both responsible for maintaining 
the correct folding of the polypeptide chains and therefore a catalytically active 
conformation. Mannervik (1985a) suggested that the substrate specificity of the 
various transferases could be explained if it is assumed that the scissile ( easily 
split) bond of the electrophilic substrate has fairly strong stereochemical 
II 
Fig. 2.7 Alternative models of the topology for the 2 active sites of a dimeric glutathione 
S-transferase molecule. Model I shows a complete active site in each subunit 
which includes a subsite for GSH (G-site) and a subsite for the hydrophobic 
electrophilic substrate (H-site). Model II shows the substrate binding cavities 
localized so that both subunits contribute to the active site structure. 
From: Danielson and Mannervik (1985). 
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requirements in binding relative to the sulphur atom of GSH anchored in the 
G-site, and to the catalytic groups of the protein. Rat subunit 4 (which appears 
to be homologous with subunit 3) has very little activity with BSP in transferase 
3-4 or transferase 4-4 despite the fact that it appears to bind to the compounds 
with similar binding stoichiometry and Kcl as subunit 3. This suggests that the 
binding orientation is not adequate for catalysis. Mannervik therefore suggested 
that the theory proposed by Keen et al (1976), that the transferases act by 
increasing the nucleophilicity of the thiol group of GSH, is too simple. 
2.8.4 BINDING PROPERTIES 
2.8.4.1 Covalent Binding 
The GSH S-T can bind covalently with a variety of compounds, many of 
which are carcinogens. The enzymes may thus play an important role in their 
detoxication. In certain cases, e.g. CDNB, an irreversible marked reduction in 
the enzymatic function occurs after covalent binding and thus it was suggested 
that the reaction of the GSH S-T with highly reactive electrophiles appears to be 
a form of "suicide" (Jakoby and Keen, 1977). However, as the covalent binding 
of carcinogenic metabolites to DNA may be a critical event in tumorigenesis 
(Reeve et al, 1981) it is attractive to suggest that it is in the organism's interest 
that vital cell components such as DNA are protected at the loss of expendable 
protein (Jakoby and Keen, 1977). 
In contrast to this, with other compounds e.g. bromobenzene (Aniya et al, 
1988) and paracetamol (Wendel and Cikryt, 1981) the GSH S-T retain their 
activity, suggesting that these compounds bind covalently to the non-substrate 
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ligand binding site and not the catalytic site. 
Many of the substrates of the GSH S-T are strong alkylating agents and 
some of these can bind covalently to the enzyme, e.g. CDNB (Pabst et al, 1974) 
and ethacrynic acid (Yamada and Kaplowitz, 1980). 
Ethacrynic acid is interesting in that it is a unique example of a compound 
binding covalently to the GSH S-T without undergoing prior oxidative 
metabolism. Yamada and Kaplowitz (1980) showed that 13.5% of the ethacrynic 
acid bound to liver cytosol GSH S-T, bound covalently. 
The first GSH S-T to be purified was isolated as a binding protein viz. 
aminoazodye carcinogen binding protein (Ketterer et al, 1967). Initial 
investigations suggested that the aminoazodye carcinogen bound to the cysteinyl 
residues of the GSH S-T (Ketterer and Christodoulides, 1969nO). In further 
studies, digests of GSH S-T 1-1 (YaYa), or 1-2 (YaYc), extracted from 
aminoazodye treated rats gave peptides thought to be Asp and a 
carcinogen-amino acid adduct or Asp, Ala plus a carcinogen-amino adduct. 
Amino acid analysis after oxidation of the carcinogen amino acid adduct 
suggested that the nucleophilic residue involved was either methionine or 
cysteine. Study of the primary sequence of subunit one showed a tripeptide 
sequence Asp Met Ala in the C-terminal region suggesting that binding is 
probably through a methionine residue (Ketterer, 1986). 
Further examples of compounds that bind covalently to the GSH S-T are 
the oxidation products of 3-methylcholanthrene (3-MC) and benzo (a) pyrene 
(Arias et al, 1979; Reeve et al, 1981). Preferential covalent binding of the 
activated metabolites of azodye and 3-methylcholanthrene (3-MC) to the higher 
molecular weight subunit of ligandin was shown by Arias et al (1979). In 
addition, the study provided evidence supporting the view that the GSH S-T bind 
to the activated metabolites of the carcinogen rather than to the carcinogen 
itself. 
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Approximately 10 % of the aqueous metabolites of benzo (a) pyrene 
bound covalently to rat liver cytosolic proteins. After partial purification the 
metabolite bound covalently to 4 cytosolic fractions, all having GSH S-T activity 
(Reeve et al, 1981). As this covalent binding results in a marked decrease in 
activity, it has been suggested that enzyme-catalysed conjugation with GSH is 
inhibited and in this way the carcinogen effectively inhibits its own detoxication. 
Coles et al (1983) have studied the covalent binding of three ultimate 
carcinogens, + (anti) benzo(a)pyrene-7,8-diol-9,10 oxide (BPDE), N-sulphonyl-
oxy-N-acetyl-2-aminofluorene (AAF-N-sulphate) and aflatoxin B1-2,3-oxide 
(AFB1-oxide) to transferase B (1-2). In the absence of GSH, AAF-N-sulphate 
and AFB1-oxide reacted with both the Ya (subunit 1) and Ye (subunit 2) 
subunits, whereas BPDE bound to the Ya subunit (subunit 1). In the presence of 
GSH, binding of BPDE was almost completely prevented whereas this 
prevention was only partial with the other two carcinogens. This finding may 
well explain why AFB1 and AAF are strong hepatocarcinogens in the rat and BP 
is not (Coles et al, 1983). 
The reactive intermediates of xenobiotic metabolism can also bind 
covalently to the microsomal GSH S-T (Morgenstern and De Pierre, 1987). In 
contrast to the cytosolic GSH S-T where covalent binding results in either no loss 
(Wendel and Cikryt, 1981), or loss of activity (Reeve et al, 1981), activation of 
the microsomal enzyme may occur. Injection of carbon tetrachloride, 
1, 2-dibromomethane (Botti et al, 1982) or phorone (Musukava and Iwata, 1986) 
into rats resulted in a very rapid and marked increase in GSH S-T activity of 
hepatic microsomes towards CDNB (a period too short for induction to have 
occurred). 
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2.8.4.2 Non-Covalent Binding 
In addition to their catalytic function, the GSH S-T bind a variety of 
compounds which they do not metabolize (Listowski et al, 1976; Ketley et al, 
1975; Boyer et al, 1984; Homma et al, 1986; Takikawa et al, 1986a, b) These 
ligands include certain organic anionic dyes, bile salts and bile acids, antibiotics, 
certain porphyrins and their derivatives and certain steroid hormones and their 
metabolites. Most of these ligands have dissociation constants which are less 
than 10 micromolar (Boyer, 1985). 
Originally the ability to bind these compounds was attributed to the so 
called "ligandins". However, it is now known that all the GSH S-T are able to 
bind these non-substrate ligands and function as ligandins (Ketley et al, 1975). 
It is thought that the GSH S-T serve as intracellular binding proteins on a 
broad scale in much the same way as albumin does extracellularly (Tipping et al, 
1976). In the hepatocyte where the concentration of the GSH S-T is high, the 
enzymes may play a role in the storage of bilirubin and other ligands. It has been 
suggested (Boyer, 1985) that the transferases could enhance the uptake of 
ligands by: 
a) increasing the rate of influx of ligands into the cell, 
b) decreasing the rate of efflux of ligands into plasma, and . 
c) increasing the rate of movement of ligand through cytosol by enhancing 
the excretion of products formed either from reactions in the endoplasmic 
reticulum or by the transferases themselves . 
An interesting example of non-substrate binding is that of bilirubin, the 
catabolic product of haem metabolism. The GSH S-T influence the net uptake 
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of this compound by regulating efflux from the cell into the plasma (Wolkoff et 
al, 1979b). Bilirubin is bound to albumin in the circulation (at neutral pH it is 
essentially insoluble in aqueous solution). It is thought that intracellularly the 
GSH S-T allow the bilirubin to remain in solution before conjugation and 
excretion (Jakoby, 1978). It has been suggested that the GSH S-T may play an 
important role in intracellular transport viz. in movement of insoluble xenobiotics 
from the plasma membrane to other membranes in the cell (Boyer, 1985). 
In addition, the GSH S-T play a role in organic anion transport by the 
kidney (Kirsch et al, 1975). It thus appears that the GSH S-T play an important 
role in both intracellular transport and storage. 
The tightness of ligand binding depends on both the nature of the ligand 
as well as the specific transferase involved (Ketley et al, 1975). For instance 
indocyanine green (ICG) binds strongly to rat liver transferase A (3-3), B (1-1 
and 1-2) and C (3-4) and weakly to transferase AA (2-2). In contrast to this, 
haematin binds strongly to all 4 of the above transferases. 
Takikawa et al (1986b) studied organic anion binding (bilirubin, BSP and 
ICG) by human hepatic transferases. Two basic, an acidic and a neutral form 
were studied and all 3 forms were found to have comparable binding properties. 
In contrast, previous studies on the rat hepatic GSH S-T have identified two 
binding classes (Sugiyama et al, 1984), one with a high affinity for organic anions 
(those having the Ya subunit) (subunit 1) termed the ligandins and 1 with a low 
affinity (YbfYb' subunits) (subunits 3 and 4). With the human transferases the 
binding affinity for bilirubin and BSP was much lower than that found for rat 
ligandin, whereas with ICG and haematin high affinity binding was found with 
both the human transferases and rat ligandin. 
The relationship between the different binding sites of the GSH S-T is not 
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well understood. Initial inhibition studies by Ketley et al (1975) on rat GSH S-T 
B (transferase 1-1 and 1-2) suggested that the non-substrate ligand binding site 
and the catalytic site were similar as the inhibition of GSH S-T B by various 
non-substrate ligands such as bilirubin was found to be competitive. However, 
other studies have suggested that the two sites are independent as bilirubin 
binding occurs at 2 sites, a primary high affinity site and a secondary lower 
affinity site (Bhargava et al, 1978). Catalytic activity was unaffected by 
concentrations of bilirubin which saturated the primary high affinity binding site. 
This theory was supported by Vander Jagt et al (1982) who suggested that 
bilirubin has a unique binding site which is distinct from the transferase catalytic 
site. 
Sugiyama et al (1984) have presented evidence for a common high affinity 
binding site on GSH S-T B for the bile acid lithocholic acid and bilirubin. 
Extensive studies on bilirubin binding have been carried out by Vander 
Jagt's group (Simons and Vander Jagt, 1980). In 1980 they published a paper in 
which they studied the effects of bilirubin binding on the catalytic activity of 
human liver ligandin (basic transferases). They found the effects were complex 
and pH dependent. Ligandin can exist in 1 of 2 kinetically stable conformational 
states both of which bind bilirubin, but only 1 of which retains transferase 
activity. The conformational state produced is dependent on the order of 
addition of bilirubin and glutathione to the ligandin. 
At pH 6.5 it was found that the incubation of bilirubin and ligandin in the 
absence of GSH produced a form which was devoid of enzyme activity. In the 
presence of GSH, 66 % of the catalytic activity was retained despite the fact that 
bilirubin was still bound to the enzyme. Simons and V ander J agt proposed that 
although bilirubin binds rapidly in the presence or absence of GSH, 
conformational changes occur in the absence of GSH, which prevent enzyme 
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activity. They suggested that the main effect of GSH is to lessen the 
co-operativity of binding and increase the composite dissociation constant. 
However, at pH 7.4, 66 % of the ligandin activity was retained in the 
presence or absence of GSH and the time required for adoption of this 
conformer was found to be much shorter. Once the low activity conformational 
state had been obtained by incubation of bilirubin with ligandin at pH 6.5, raising 
the pH to 7.4 did not result in a return of activity in the presence of bilirubin. 
Thus, in the hepatocyte any physiological state which causes an increase in the 
flux of bilirubin under conditions where GSH levels are depleted, may result in a 
ligandin conformational state which is devoid of activity. Susceptibility to 
mutagens and carcinogens may thus be increased. However, it appears that this 
phenomenon will occur only if associated with a drop in intracellular pH. 
In further studies the inhibition of a human basic GSH S-T by a variety of 
ligands was investigated. Bromocresol green, biliverdin and sulfobromophthalein 
showed strict competitive inhibition, whereas the binding with haematin 
appeared to be non-competitive. No order of addition dependence was found. 
Thus it appears that bilirubin binding is fundamentally different from the binding 
of other ligands and that the binding of bilirubin to liver transferases occurs at a 
unique site which is distinct from the catalytic site. Although bilirubin, like other 
ligands, also binds to a non-specific secondary site which is part of the 
transferase catalytic site (Vander Jagt et al, 1982). 
Further investigations by these workers found that "foreign" proteins such 
as albumin, haemoglobin and aldolase are able to regulate the conformational 
states of the GSH S-T in the liver thus counteracting the inhibition by bilirubin 
(Vander Jagt et al, 1983). Studies performed on both human basic transferase 
and rat transferases A and B demonstrated that in the absence of bilirubin, the 
"foreign" protein had no effect on transferase activity, implying active enzyme 
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conformation. In the presence of bilirubin, the first step in the reaction involved 
the binding of bilirubin to the transferase. If "foreign" protein was present, it 
was found to compete with free bilirubin for the bilirubin-transferase complex 
and enzyme activity was retained. However, if conversion to the inactive 
conformer had already occurred, addition of "foreign" protein had no effect. 
Synthetic polypeptides such as polylysine and polyglutamate were also able to 
regulate the conformational states of the basic human liver transferase whereas 
this was not the case with individual amino acids. 
Vander Jagt et al suggested that this represented a type of enzymic 
memory involving protein-protein interactions which arises from the fact that 
various conformations of the human transferases are stable. The conformation 
produced has activity, which is a reflection of the prior sequence of events viz. 
the interaction of bilirubin, the transferase and the foreign protein. Therefore 
kinetic rather than thermodynamic control seems to determine the 
conformational states of the human basic liver transferases. The same behaviour 
was noted in a study of bilirubin binding to 13 forms of GSH S-T isolated from 
human liver (Vander Jagt et al, 1985). 
Boyer (1986) used an enol ester derivative of bilirubin 
(bilirubin-Woodwards reagent-K) to covalently label the non-substrate ligand 
binding site on rat liver cytosol Ya Y c (transferase 1-2) and Ya Ya (transferase 
1-1). He found that a linear relationship existed between the amount of 
bilirubin-Woodwards reagent-K added and the labelling achieved, up to a ratio 
of 2:1 (bilirubin-Woodwards reagent-K:YaYc) with a maximum of 0.87 mol 
bound per mol of enzyme (binding occuring at a single site). However, at a 
higher ratio the binding appeared to take place at a second site. With both 
transferases the label blocked the non-substrate binding site, but not the catalytic 
) 
site. Using autoradiography, an equal distribution of the label between the 
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subunits ofrat transferase Ya Y c (transferase 1-2) was demonstrated. Boyer thus 
suggested that both these subunits are involved in the formation of the bilirubin 
binding site rather than the binding site being situated on a specific subunit. 
2.9 ENZYME INHIBITION 
The GSH S-T are known to be inhibited by a number of compounds which 
they do not metabolize. For example, non-substrate ligands such as cephalothin, 
indocyanin green (Ketley et al, 1975), steroid sulphates (Ohl and Litwack, 1977), 
certain radiographic contrast media (Goldstein and Arias, 1976) and organotin 
compounds (Henry and Byington, 1976), are all known inhibitors. 
Inhibition characteristics for the human GSH S-T with various inhibitors 
are listed in Table 2.7. 
Non-substrate ligands can be either competitive or non-competitive 
inhibitors of the transferase catalysed conjugation. Competitive inhibitors bind 
to the same active site as the substrates e.g. bilirubin binds to the transferases 
competitively when CDNB is used as substrate (Ketley et al, 1975). 
In 1961 Booth et al reported inhibition of the GSH S-T by their own 
substrates. Reports by other workers have also been cited in the literature 
(Pabst et al, 1974; Vander Jagt et al, 1982). 
Inhibition of the GSH S-T by non-substrate ligands has been studied in 
both rat and man (Boyer et al, 1984; Boyer and Vessey, 1987). Boyer et al 
(1984) studied the inhibition effect on rat transferase Ya Ya (transferase 1-1), 
transferase Ya Y c (transferase 1-2) and transferase Y c Y c (transferase 2-2), by 
the non-substrate ligands indocyanin green, biliverdin and bile acids, over the pH 
range 6.0 · 8.0. At pH 6.0, with transferases Ya Y c (transferase 1-2) 
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and Y c Y c (transferase 2-2) saturating concentrations of these non-substrate 
ligands resulted in total loss of activity. At a higher pH value (pH 8.0) this 
inhibition was not observed and between these values intermediate degrees of 
inhibition were observed. In contrast, transferase Ya Ya (transferase 1-1) was 
inhibited by at least 80% at all pH values. This suggests that those enzymes 
containing the Y c subunit (subunit 2) are able to act simultaneously as both 
catalytic enzymes and binding proteins at the higher pH values. 
The effects of the addition of GSH to the system were also studied. Using 
indocyanin green it was found that by increasing the concentration of GSH from 
0.2 to 5.0 mM, the inhibition was decreased from 100% to 76% (pH of 
incubation mixture 6.0). At a high pH this effect was much less marked. 
The mechanism by which the pH of the assay buffer modified the 
inhibition of certain transferases by these non-substrate ligands is not completely 
understood. It appears that the lack of inhibition at the higher pH values is 
probably not due to failure of the enzyme to bind the non-substrate ligand as a 
quenching of protein fluorescence by both indocyanin green and biliverdin 
occured at both pH 6.0 and 8.0. Boyer has suggested that the effects of pH on 
enzyme inhibition of the transferases containing the Y c subunit (subunit 2) may 
be a r~sult of changes in the non-substrate ligands, as bile acids may lose their 
charge and self associate at a low pH. Thus the state of ionization of the bile 
acid may affect its ability to act as an inhibitor. 
The buffer pH may influence the conformation of the enzyme-inhibitor 
complex. This pH-dependent variation in inhibition may demonstrate a change 
in the ratio of active to inactive conformers. The inactive conformers could be 
converted to active conformers by increasing the pH. Thus, depending on the 
conformation formed after binding to non-substrate ligands, the enzyme may 
remain catalytically active and function as both enzyme and binding protein. 
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Further investigation of this inhibition by non-substrate ligands was 
extended to a human basic transferase (Boyer and Vessey, 1987). Although 
inhibition of the basic GSH S-T by indocyanin green was independent of pH, 
similar effects to those in the rat were noted with the inhibitors bilirubin, 
biliverdin and chenodeoxycholic acid. The inhibition was pH dependent with far 
less inhibition at high pH values. A significant difference between human basic 
and 2 rat basic enzymes (Ya Y c and Y c Y c) was found, namely, at physiological 
pH values (7.0) the human transferase was completely inhibited by saturating 
concentrations of the non-substrate ligand, whereas the 2 basic rat enzymes 
studied retained significant catalytic activity at this pH despite saturating 
concentrations of non-substrate ligand. 
Boyer suggested that these non-substrate ligands were binding at a 
different site (not directly at the active site) resulting in a conformational 
change. It appears that it is the response of the enzyme to the binding of the 
ligand at the non-substrate ligand site(s) that is pH dependent. 
As the intracellular pH of hepatocytes is about 7 (Arieff et al, 1980) this 
could be of physiological significance. A build up of non-substrate ligands is 
often associated with conditions that cause cholestasis (Griem et al, 1972; Boyer 
and Vessey, 1987) and will thus probably inhibit GSH S-T activity. Under 
certain conditions, e.g. fasting, this could be coupled with a decrease in the levels 
of intracellular GSH thus increasing the degree of inhibition. It thus appears 
that the human liver may be particularly vulnerable to dangerous toxins during 
cholestasis. Although there are other classes of human · GSH S-T it is of 
importance that the high GSH peroxidase II activity of the human GSH S-T is 
associated with the basic enzymes. 
Inhibition studies using the phenoxyacid herbicides 2,4-dichloro-
phenoxyacetate(2,4-D) and 2,4,5-trichlorophenoxyacetate (2,4,5-T) have been 
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carried out on all the known enzymes of human liver (Singh and Awasthi, 1985). 
2,4,5-T was found to be a competitive and more potent inhibitor than 2,4-D. 
Thus exposure to certain drugs or electrophilic xenobiotics may cause a reversal 
of this inhibition. In contrast, the inhibitory effects of 2,4-D were found to be 
non-competitive for all the human isoenzymes with the exception of 1 of the 
acidic liver transferases (pl of 5.5). Thus the effects of 2,4-D may be more 
harmful to humans exposed to xenobiotics which are detoxified by the GSH S-T. 
GSH peroxidase II activity was also inhibited by both 2,4,5-T and 2,4-D. Thus 
exposure to these herbicides could result in impairment of conjugating, and GSH 
peroxidase II activity of the GSH S-T. 
In the rat the Y c subunit (subunit 2) was found to be activated by both 
2,4-D and 2,4,5-T. No such activation was noted for the human transferase. In 
the rat this activation does not appear to be limited to those forms having the Y c 
subunit (subunit 2). Ethylene dibromide (EDB), the widely used industrial 
solvent and fumigant which is both toxic and carcinogenic, when preincubated 
with a mixture of rat hepatic cytosol GSH S-T at 25°C resulted in a decrease in 
activity towards CDNB and DCNB (Ivanetich et al, 1984). The EDB decreased 
the activity of forms A (transferase 3-3) and C (transferase 3-4) containing the 
Yb and the Yb' subunits (subunits 3 and 4) whereas the other forms investigated 
viz. AA (transferase 2-2) and B (transferases 1-1 and 1-2) showed no decrease in 
activity suggesting that EDB may interact only with those isoenzymes containing 
the Yb and the Yb' subunits (subunits 3 and 4). The precarcinogen is thus 
trapped and the ability of transferase A and C to further activate these 
compounds is reduced. This inhibition appears to be irreversible as 
lyophilisation or gel filtration failed to produce a return of activity. 
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2.10 ENZYME INDUCTION 
In an effort to survive most organisms are able to adjust to changes in their 
environment. The level of proteins in the various organs of the animal body are 
influenced by physiological, ontogenic and exogenous factors. Therefore the 
normal development of the foetus to adulthood, dietary changes, and exposure to 
various atmospheric pollutants for example, can result in either induction or 
suppression of these proteins, which may in turn lead to the development of 
various disease states. However, enzyme induction is not limited to animals, e.g. 
in corn a GSH S-T isoenzyme ( designated GSH S-T II) is induced by treatment 
with certain chemicals used as antidotes to herbicides. This isoenzyme form is 
not expressed in untreated corn where only a single isoenzyme GSH S-T I is 
expressed (Mozer, 1983). 
Inducers of the mixed function oxidases may be divided into 3 groups: 
1) Those which induce the cytochrome P-450 enzymes e.g. phenobarbital and 
some polychlorobiphenyls which produce an increase in a number of 
microsomal and cytosolic enzymatic reactions. 
2) Those which induce the cytochrome P-448 group of enzymes e.g. 
3-methylcholanthrene (3-MC) and benzo-(a)pyrene. 
3) Induction of the mixed function oxidases has been reported for certain 
steroids e.g. pregnenolone 16-carbonitrile. 
Inducers of the GSH S-T are found within all 3 groups. 
Induction of GSH S-T in humans is difficult to study. The isoenzyme 
pattern in the human foetus is very different from the adult, (see Section 2.5). 
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Some of these differences may well be accounted for by induction. However, 
extensive research has been conducted in this field using animals. 
Various inducers of drug metabolism such as phenobarbital, 3-MC and 
trans-stilbene oxide produce increased levels of cytosolic GSH S-T in various 
organs of the rat. Marked differences in the effects of induction on various 
organs has been described. Phenobarbital administration caused a significant 
increase in hepatic ligandin when measured immunologically. In extrahepatic 
tissue, e.g. kidney and intestinal mucosa, this increase was less marked and 
absent in the testis (Bass et al, 1977b ). Further studies using phenobarbital 
showed significant increases in the GSH S-T activity in the liver and the intestine, 
whereas 3-methylcholanthrene (3-MC) induced the GSH S-T in the liver only 
(DePierre et al, 1984). Trans-stilbene oxide induced the GSH S-T activity in 
liver, kidney and adrenal (DePierre et al, 1984). The increase in Vmax after 
drug induction is not accompanied by a change in Km, suggesting that no 
alteration of the substrate affinity for enzymes occurs as a result of the 
xenobiotics (Kaplowitz et al, 1975). 
Glutathione S-epoxide transferase activity m mouse lung cytosol was 
unchanged after either 3-MC or phenobarbital administration whereas some 
increase in activity in the liver was noted after phenobarbital treatment (Muktar 
and Bresnick, 1976b). 
In rat hyperplastic nodule bearing livers, the placental transferase P 
(transferase 7-7) normally only found in significant amounts in the pancreas and 
kidney, is markedly induced (Kitahara et al, 1984; Satoh et al, 1985). Unlike the 
other GSH S-T, this form of enzyme was not inducible in normal tissue by drugs 
and carcinogens. Its presence in preneoplastic foci and hyperplastic nodules 
may thus serve as a marker for these states in the rat. This may be similar to the 
situation in drug-resistant human breast cancer cells where a novel acidic 
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transferase with high peroxidase activity is also over-expressed (Batist et al, 
1986). Likewise, the over-expression of an acidic GSH S-T present in human 
melanoma cells and solid tumor has been reported (Mannervik et al, 1987). 
These authors suggested that this GSH S-T may contribute to the drug resistance 
characteristic of malignant melanoma. Pickett et al (1987) demonstrated that in 
the rat, administration of phenobarbital and 3-MC may cause transcriptional 
activation of GSH S-T, resulting in accumulation of Ya (subunit 1) and YbfYb' 
(subunits 3 and 4) mRNAs and an accumulation of these subunits. Preneoplastic 
hepatic nodules have elevated levels of certain phase II drug metabolizing 
enzymes. This over-expression may explain the resistance to cytotoxic and 
antineoplastic agents. By increasing the rate of formation of drug-GSH 
conjugates the GSH S-T may reduce the sensitivity of neoplastic cells to the 
action of chemotherapeutic drugs (Shea et al, 1988). 
It appears that the various GSH S-T subunits m rat cytosol are 
differentially induced. This induction is either limited to a single subunit as in 
induction by 3-MC viz. transferase 1-1 (Kitahara et al, 1983; Igarashi et al, 1987) 
or more than one, as with phenobarbital (Bass et al, 1977a; Kitahara et al, 1983; 
Igarashi et al, 1987). 
In rat liver, transferase 1-1 is the enzyme most effectively induced by 
inducers such as phenobarbital, 3-MC and trans-stilbene oxide (Mannervik, 
1985a). Butylated hydroxytoluene (BHT) induces all the subunits in the rat liver 
with the Ya subunit (subunit 1) being maximally induced (Awasthi et al, 1984). 
Sex differences in induction responses have been documented (see Section 
2.6). In adult rats, the increase in rat liver cytosolic GSH S-T activity towards the 
substrate CDNB after phenobarbital treatment was greater in males than 
females. In contrast the reverse was true after 3-MC administration. 
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2.11 PURIFICATION OF THE HUMAN GSH S-T 
Initial purification of human GSH S-T was performed on liver by 
Kamisaka et al (1975) and was based on the then conventional procedures 
described for the isolation of the GSH S-T in the rat (Habig et al, 1974a). The 
procedure used is shown schematically in Fig. 2.8. After initial DEAE-cellulose 
chromatography, CM-cellulose chromatography was followed by repeated 
chromatography with hydroxyapatite. Gel filtration and preparative 
isoelectricfocusing were used in the final steps. This procedure resulted in the 
purification of 5 basic GSH S-T viz. c:;.. , ~, l , cS and f: . 
Awasthi et al (1980) fractionated the human liver transferases into basic 
and acidic forms using ammonium sulphate precipitation. The acidic forms were 
concentrated in the 65% saturated (NH4)2S04 fraction whereas the basic forms 
were found in the 80% saturated fraction. The different transferases in these 
fractions were further purified by ion exchange chromatography (DE-52), 
Sephadex G-200 gel filtration, affinity chromatography using GSH bound to 
epoxy-activated Sepharose and isoelectric focusing. 
The initial purification of the near-neutral GSH S-T in human liver 
(Warholm et al, 1981b) employed a combination of DEAE-cellulose, hexyl-
glutathione affinity and hydroxyapatite chromatography. 
The development of the use of affinity chromatography in the preparation 
of the GSH S-T has proved invaluable and nowadays is the method of central 
importance in the purification of the soluble GSH S-T. This method utilizes the 
organic anion binding capacity of the GSH S-T in contrast to ion exchange and 
molecular sieving chromatography which rely on protein charge and size. 
Ligands with a high affinity for the GSH S-T are coupled to a matrix enabling the 
GSH S-T to be selectively isolated from other contaminants. Further isoenzyme 
10 000 g supernatant 
+ (NI4)2S04 precipitation 
1 Dissolved precipitate 
CM-cellulose pH 6.7 
1 Eluted with a KC! gradient 
4 peaks (I, II, III, IV) each 
subjected to hydroxyapatite chromatography l Eluted with potassium P04 gradient 
Fraction I showed 2 peaks and was divided 
into IA andIB 
i 
Hydroxyapatite chromatography 
j Eluted with potassium P04 gradient 
Sephadex G-75 
+ Preparative electrofocusing 
+ 5 basic GSH S-T viz. c1., ?, , ~ , iS and f,. 
Fig. 2.8 Schematic representation of the initial purification scheme for the 5 basic GSH 
S-T (Kamisaka et al, 1975). 
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separation is often achieved by employing chromatofocusing, isoelectric focusing 
or hydroxyapatite chromatography. 
Initial workers immobilized the phthalein dye, sulphobromphthalein, on 
agarose and used this as the affinity ligand (Clark et al, 1977; Grahnen and 
Sjoholm, 1977; Wolkoff et al, 1979a). However, due to the very tight binding of 
certain transferases to sulphobromphthalein, difficulty in eluting the protein from 
the ligand may occur. It is necessary therefore to use a ligand which provides a 
compromise between good binding and easy elution. 
To date the most popular matrices used are either GSH coupled directly 
to epoxy-activated Sepharose (Simons and Vander Jagt, 1977) or immobilized 
S-hexylglutathione (Guthenberg and Mannervik, 1979). In the method of Simons 
and Vander Jagt the coupling is via the sulphur atom whereas with 
hexylglutathione the coupling is via the d...-amino group of the glutamyl residue. 
These two methods result in similar binding capacities for the GSH S-T. Two 
important points are that: 
1. certain of the GSH S-T do not bind to S-hexylglutathione sepharose under 
standard conditions e.g. rat GSH S-T 5-5 does not bind and transferase 
1-1 is less tightly bound than the other major rat GSH S-T (Mannervik, 
1985a); and 
2. the hexylglutathione column also binds glyoxylase I (Aronsson and 
Mannervik, 1977; Aronsson et al, 1979; Mannervik et al, 1982) whereas the 
GSH column does not (Simons and Vander Jagt, 1977). 
It is worth noting that the GSH affinity column may alter the behaviour of 
the GSH S-T on subsequent cation exchange chromatography. This was 
demonstrated by Ramage and Nimmo (1983) whilst purifying the hepatic 
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GSH S-T of the rainbow trout. The apparent pl values of these enzymes were 
lowered when eluted from the GSH affinity column by reduced glutathione at 
pH 8.85. 
A number of other affinity matrices have been used in the purification of 
the GSH S-T. These include; 
1) S-carbamidomethyl glutathione linked to Sepharose CL-4B via lysyl or 
aliphatic diamine spacers (Inoue et al, 1981). 
2) cholic acid (used to isolate two bile acid binding proteins, one of which 
was a transferase) (Pattinson, 1981). 
3) orange A agarose (Asoaka, 1984). 
Hydrophobic interaction chromatography was used by Meuwissen and 
Zeegers (1981) to purify the transferases from rat liver cytosol. :!'he transferase 
activity was absorbed on to phenylsepharose at pH 7 and eluted with 20% 
ethanol. 
Isoelectricfocusing, although time consuming, has been used by various 
workers in the purification of the GSH S-T isoenzymes (Kamisaka et al, 1975; 
Awasthi et al 1980; Koskela, 1983; Singh et al, 1985; Theodore et al, 1985; Del 
Boccio et al, 1987a). 
The development of chromatofocusing by Sluyterman and Elgersma (1978) 
has proved a useful tool in the purification of the transferases and has shortened 
the purification time. It has been used by several workers in the purification of 
the human transferases (Koskela, 1983; Koskela and Icen, 1984; Vander Jagt et 
al, 1985; Soma et al, 1986, Sugimoto et al, 1987) 
The isoelectric points obtained by chromatofocusing ( estimated from 
eluting pH), and isoelectricfocusing are not directly comparable. In 
66 
chromatofocusing the pH at which a transferase is eluted seems to depend on 
the pH gradient used (Koskelo, 1983; Sugimoto et al, 1987). 
With the advent of high performance liquid chromatography (HPLC) and 
fast protein liquid chromatography (FPLC) even more rapid purification is now 
possible. Radulovic and Kulkarni (1985) described a two step purification of 
human placental transferase using affinity chromatography followed by HPLC. 
Rapid resolution on the HPLC was obtained in less than twenty minutes, 
separating one major and two minor forms with complete recovery of enzyme 
activity. Thus rapid separation, high resolution and good yields have recently 
made these purification techniques popular (Hussey et al, 1986b; Takeoka et al, 
1987; Ostlund Farrants et al, 1987). 
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PART II: EXPERIMENTAL 
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Chapter3 
PURIFICATION OF BASIC AND NEAR-NEUTRAL GSH S-T FROM HUMAN 
LIVER AND BASIC AND ACIDIC GSH S-T FROM HUMAN LUNG. 
3.1 INTRODUCTION 
Most studies on the human GSH S-T have been limited to the 
description of a single transferase. Lack of simultaneously collected data on the 
other forms has often resulted in difficulties in the interpretation of such data. 
In order to provide comparative information on the 3 major classes of human 
GSH S-T the basic, near-neutral and acidic GSH S-T were purified. The 
procedures used for the purification and characterization of the human basic and 
near-neutral liver, and the basic and acidic lung GSH S-T are described in this 
chapter. 
3.2 MATERIALS AND METHODS 
3.2.1 Chemicals 
Unless otherwise stated all chemicals used were of analytical grade 
(see Appendix A). 
3.2.2 Assay of GSH S-T activity 
All purification procedures were monitored using an Isco UA-5 
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Absorbance Detector. Fractions containing protein were assessed for GSH S-T 
activity using CDNB as substrate, according to the standard procedure of Habig 
et al (1974b) (See Appendix B method VIII). 
3.2.3 Preparation of human liver basic and near-neutral GSH S-T 
Preparation of Cytosol 
All purification steps were performed at 4°C. Human liver and lung 
were obtained at autopsy from apparently healthy motor vehicle accident 
victims. The tissue was obtained within 12 h of death and was stored at -70°C if 
not used immediately. 
100 g of liver, cut into small pieces, was placed in sufficient buffer 
(0.2 mM dithioerythritol, 0.057 mM phenylmethyl-sulphonyl fluoride, 55 units/ml 
aprotinin, 0.01 M Tris/HCl, pH 7.8) to make a 30% homogenate. Following 
initial homogenization using an Ultra-turrax homogenizer (Janke and Kunkel 
KG) for 3 min (20 second bursts, with a 20 second rest period), further 
homogenization was carried out using a motorized Potter-Elvejham glass-teflon 
homogenizer. 
The homogenate was centrifuged at 35 000 g for 1 h in a Sorval (model 
RC 5) superspeed centrifuge. The supernatant layer was removed, care being 
taken not to disturb the lipid layer, and recentrifuged at 105 000 g for 2 h in a 
Beckman L5-65 ultracentrifuge. 
Affinity chromatography 
After filtration through Whatman no. 1 filter paper, a 50 ml aliquot of 
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the cytosol was applied to a S-hexylglutathione affinity column (1 x 10 cm) 
equilibrated with 0.2 mM dithioerythritol, 0.01 M Tris/HCl pH 7.8, at a flow rate 
of 17.5 m1/h as described by Guthenberg and Mannervik (1979) (full details of 
the methodology are given in Appendix B method V). This was followed by 300 
ml of equilibration buffer. 3.5 ml fractions were collected on an Isco Retriever 
111 fraction collector and the absorbance of the eluate was monitored at 280 nm 
on an lsco UA 5 absorbance/fluorescence monitor. Once the absorbance at 280 
nm had returned to zero, the column was washed with equilibrating buffer 
containing 0.2 M NaCl to remove non-specifically bound protein, after which the 
GSH S-T were eluted with 5 mM S-hexylglutathione in the same buffer. 
Fractions showing activity towards CDNB (Habig et al, 1974b) were pooled, 
concentrated, and dialysed against 0.2 mM dithioerythritoV0.025 M ethanol-
amine/HCl, pH 9.5. 
Chromatofocusing 
The dialysate was applied to a PBE 94 polybuffer exchanger (0.9 x 30 
cm), previously equilibrated with 0.2 mM dithioerythritol, 0.025 M ethanol-
amine/HCl, pH 9.5 at a flow rate of 37 m1/h (See Appendix B method VII for 
details). 2.5 ml fractions were collected and those fractions showing absorbance 
at 280 nm were assayed for activity with CDNB. 400 ml of a 10% solution of 
polybuffer 96, pH 6.0 were used for the elution. Basic fractions eluting at a pH 
> 7.8 were pooled (fraction A) and concentrated. These fractions consisted of a 
mixture of the basic liver GSH S-T. Fractions eluting at pH 7.8 were also 
pooled (fraction B) and concentrated and found to consist of the near-neutral 
GSH S-T with some contamination by basic GSH S-T. 
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Removal of Polybuffer 
(See Appendix B method IV for full methodology). 
Molecular sieve chromatography was employed to remove the 
p_olybuffer from the transferases. Fractions A and B (see above) were applied 
individually to a Sephadex G-75 column (1.5 x 100 cm) in 0.2 mM dithio-
erythrito~ 0.05 M phosphate buffer, pH 7.4. Elution was performed with the 
same buffer and a pump-driven, upward flow system. Flow was 37 m.1/h and 
samples of 3.1 ml were collected. The eluate was monitored as previously 
described. Those fractions exhibiting activity towards CDNB were pooled and 
concentrated. 
Immunoaffinity chromatography 
Attempts to separate the basic GSH S-T, which co-eluted from the 
chromatofocusing column, by hydroxyapatite chromatography proved 
unsuccessful ( data not shown). Thus immunoaffinity chromatography was 
applied to effect this removal. Following Sephadex G-75 chromatography, the 
near-neutral transferase fractions were pooled, concentrated, and subjected to 
immunoaffinity chromatography to remove the basic transferase co-eluting with 
the near-neutral transferases. 
Rabbit anti-human basic transferase IgG was prepared according to 
the method of Hebert et al (1973) and coupled to Affi-Gel 10 in a coupling 
buffer of 0.1 M NaHC03, pH 8.5 (see Appendix B methods III F and G for 
details). The fraction containing the transf erases was placed in a 50 ml 
centrifuge tube and rolled with the gel for 4 h. The near-neutral transferases 
were separated from the the gel by filtration through a sintered glass funnel. 
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3.2.4 Preparation of human lung basic and acidic GSH S-T 
The purification procedure followed was based on that of Partridge et 
al (1984). However, as this method proved time consuming, the initial 
ammonium sulphate step was eliminated from the procedure and 
DEAE-cellulose chromatography replaced the isoelectric focusing step. 
Preparation of cytosol 
350 g of lung (well rinsed in homogenization buffer to remove as much 
blood as possible) was homogenized in 0.2 mM dithioerythritol, 0.057 M 
phenylmethyl-sulphonyl fluoride, 55 units/ml aprotinin, 0.01 M Tris/HCl, pH 7.2 
to make a 50% homogenate. Difficulty was experienced in the homogenization 
of the lung. In spite of the use of the Ultra-Turrax to disrupt the tough 
connective tissue, clumps of connective tissue remained, requiring removal by 
filtration before further homogenization with the glass-teflon homogenizer. 
After homogenization, the pH of the homogenate was readjusted to 
pH 7.2 with NaOH and centrifuged at 37 000 g for 2 h. The supernatant was 
filtered through Whatman no.1 filter paper and subjected to S-hexylglutathione 
affinity chromatography as described for the liver enzyme preparation (flow rate 
17 ml/h). 
DE-52 ion exchange chromatography 
The active fraction which eluted from the affinity column was dialysed 
overnight against 2 x 5 litres of 0.2 mM dithioerythritol, 0.01 M imidazole/HCI, 
pH 7.0, and applied to a DE-52 ion exchange column equilibrated with the same 
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buffer (flow rate 47 ml/h, 3.9 ml fractions collected) (see Appendix B method 
VI). The basic transferases eluted in the void volume. Those fractions exhibiting 
activity towards the substrate CDNB were pooled and concentrated. 
The column was then developed with a 12 h linear salt gradient of O -
0.2 M NaCl in a total volume of 564 ml of buffer to elute the acidic transferase. 
This yielded two peaks of activity, the first and major peak containing virtually all 
of the transferase activity towards CDNB (elution volume 462 ml). This peak was 
pooled and concentrated. 
Immunoaffinity chromatography 
Where possible, acidic transferases were prepared from tissues lacking 
the near-neutral transferases. When tissue from an individual containing the 
near-neutral transferases was used for enzyme purification, immunoaffinity 
chromatography was used to remove traces of the near-neutral transferases 
co-eluting with the acidic transferase (anti-near-neutral transferase coupled to 
Affi-Gel 10 as described in Appendix B method IIIG). 
3.2.5 Characterization of the human GSH S-T 
The purity of the GSH S-T was established by their electrophoretic 
homogeneity on SDS-P AGE and their specific activity with various substrates. 
Specific activity was expressed as units of activity/mg protein. Activity towards 
the substrates CDNB, DCNB, trans-4-phenyl-3-buten-2-one and ethacrynic acid 
was measured according to the standard method of Habig et al (1974b) and 
towards cumene hydroperoxide as described by Prohaska and Ganther (1977). 
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All enzyme assays were performed at 25°C. Protein concentrations were 
determined by the method of Lowry et al (1951) standardized to human serum 
albumin (see Appendix B method XVa for details). 
3.2.5.1 Determination of molecular weight 
The subunit composition of the GSH S-T was determined by PAGE in 0.15% 
SDS on vertical slab gels (Laemmli, 1970). The system comprised a 3.6% 
stacking gel in 0.125 M Tris/HCl buffer, pH 6.8 and a 7.5 - 17.5% gradient gel in 
0.35 M Tris/HCI pH 8.8. The samples were run in a reduced state and the gels 
were stained in Coomassie Brilliant Blue R. A standard calibration curve was 
constructed from the protein markers and the unknown molecular weight 
determined from the curve (see Appendix B method I). 
3.2.5.2 Determination of isoelectric point 
Flat bed isoelectric focusing was carried out using 5% polyacrylamide 
gel Ampholine PAGplates (LKB, Bromma, Sweden), pH 3.5 - 9.5 or pH 4 - 5. 
For the pH range 3.5 - 9.5, the gels were fixed and then stained with Coomassie 
Brilliant Blue R. A pH gradient profile was constructed from the pl markers 
and the enzyme pl determined from the profile. For the pH range 4 - 5 a series 
of segments from the middle of the gel was removed and after elution in 0.01 M 
KCl, the pH of the solutions was measured and a pH profile constructed (see 
Appendix B method XIV). 
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3.2.5.3 Kinetic properties 
GSH S-T activity was measured by following the conjugation of GSH 
with CDNB at 340 nm (see Appendix B method VIII). Concentrations of CDNB 
and GSH were varied independently in the range of 0.1 - 1.0 mM CDNB for the 
basic, near-neutral liver and the acidic lung transferases whereas the range 0.05 
- 1.0 mM was used for the basic lung transferases. The range of 0.06 - 1.0 mM 
GSH was used for the the basic and the near-neutral liver transferases whereas 
0.05 - 1.0 mM and 0.03 - 1 mM were used for the acidic and basic lung 
transferases respectively. 
Kinetic data was fitted directly to the hyperbolic form of the 
Michaelis-Menten equation by an iterative non-linear least squares fitting 
procedure. Initial estimates of the parameters were estimated by double 
reciprocal substrate-velocity (Lineweaver-Burk) plots. 
3.2.5.4 Amino acid analysis. 
0.5 mg of protein was hydrolysed in 6 N HCl for 24 h at 110°C. The 
hydrolysate was analysed on a Beckman model 12 M amino acid analyser. The 
traces were manually integrated and the results expressed as residues per mole 
( details described in Appendix B method II). 
3.2.5.5 Immunological properties 
Antisera to each of the 3 classes of transferases were raised in rabbits 
as described by Kirsch et al (1975). Specificity and cross reactivity of the 3 
antisera were assessed using immunodiffusion and Western blotting (see 
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Purification of basic and near-neutral liver GSH S-T from 105 000 g supernatant 
of human liver: 
(A) chromatography of human liver cytosol on hexylglutathione affinity 
column. Unbound material was eluted in the first peak. Bound material 
was eluted with 0.005 M hexylglutathione. 
(B) Separation of the basic and near-neutral GSH S-T by chromatofocusing. 
Hexylglutathione bound material was eluted with a pH gradient, pH 9 .5 -
6.0. 
Fractions pooled at each stage of the purification are indicated by horizontal 
bars. GSH S-T activity was assayed with CDNB as substrate and expressed as 
.umoVmin/ml (-). 
Table 3.1 
SUMMARY OF THE PURIFICATION OF THE HUMAN BASIC AND NEAR-
NEUTRAL GSH S-TRANSFERASES FROM HUMAN LIVER 
Purification step Vol. Protein Activity Specific % Yield Total Activity 
Activity 
ml mg/ml umol/min/ml • umol/min/mg µmol/min* 
Liver Cytosol 50 35.5 35.9 1.02 100 1795 
Affinity 
Chromatography 8.8 2.99 157.3 52.6 77.1 1384 
Basic GSH S-T post 11.8 0.97 53.35 55.0 35.1 630 
PBE 94 + G-75 
neutral GSH S-T 9.5 0.535 35.62 66.58 18.3 338 
post PBE 94 + G-75 
neutral GSH S-T 9.2 0.321 24.39 76.0 12.5 224 
post Affi-Gel. 
*GSH S-T activity was measured with CDNB according to Habig et al (1974b). 
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Fig. 3.2 SDS-Polyacrylamide gel electrophoresis of basic and near-neutral liver GSH S-T 
purified as described in section 3.2.3. Post hexylglutathione affinity fraction 
(lane 1); basic liver GSH S-T (lane 2); pooled post chromatofocusing fraction 
eluting at pH 7.8 (lane 3); near-neutral liver GSH S-T (lane 4) and molecular 
weight markers (lane 5). 
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3.3. RESULTS AND DISCUSSION 
3.3.1 Purification of basic and near-neutral liver GSH S-T 
Table 3.1 summarizes the purification and resultant yield of the liver 
basic and near-neutral GSH S-T. The elution profiles for the affinity and 
chromatofocusing steps are shown in Fig. 3.1. 
In the S-hexylglutathione column the bulk of the activity bound to the 
column during the application whilst the remainder passed through in the 
breakthrough peak together with the other proteins. This purification step 
resulted in a 77% yield and a 52 fold purification. 
Chromatofocusing yielded 2 peaks eluting at a pH > 7.8. These peaks 
were pooled and following concentration and Sephadex G-75 chromatography, 
the single active peak which eluted comprised pure basic transferases as shown 
on SOS-PAGE (Fig. 3.2). This was followed by a small inactive peak of 
polybuffer. The% yield after the Sephadex G-75 step was 35% and there was a 
54 fold purification. The near-neutral transferases eluted from the 
chromatofocusing column as a single peak at pH 7.8 and, after concentrating, 
polybuffer removal was effected by Sephadex G-75 chromatography as described 
above, resulting in an 18% yield. After the final immunoaffinity step the yield 
was 13% with a 75 fold purification. The yield of basic GSH S-T compared 
favourably with that of Warholm et al (1981b) viz. 35% and 44% respectively. 
However, the % yield of near-neutral GSH S-T was somewhat lower viz. 13% 
and 26% respectively. Similarly, the specific activity of the basic GSH S-T with 
the substrate CDNB agreed reasonably with the results of Warholm et al (1983) 
viz, 55 and 64 umoVmin/mg whereas the near-neutral GSH S-T specific activity 
was also comparatively lower (78 and 187 .umoVmin/mg). 
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3.3.2 Purification of basic and acidic lung GSH S-T 
A typical purification procedure for the basic and acidic lung 
transferases is summarized in Table 3.2. The affinity step resulted in a 29% yield 
and a 442 fold purification. Fig. 3.3 illustrates a typical elution profile from a 
DE-52 ion exchange column. The % yield following the affinity step is in 
excellent agreement with that of Partridge et al (1984). The 80% saturated 
(NH4)2S04 step prior to the affinity column included in the purification 
procedure by this group appears unnecessary as it did not increase the specific 
activity. 
In this study ion-exchange chromatography followed the affinity step as 
opposed to isoelectric focusing used by Partridge et al. The acidic transferases 
which were purified by these 2 techniques had very similar % yields viz. 12.8% 
and 13%. In contrast, the % yield of the basic transferases in this study was 3 
fold higher viz. 0.6% and 0.2%. The specific activity for the acidic lung GSH S-T 
with the substrate CDNB was identical to that obtained by Partridge et al (1984) 
viz. 44 .nmoVm.in/mg (see Table 3.4). However the specific activity of the basic 
GSH S-T was 11 fold higher viz. 23 and 2.12 .nmoVm.in/mg. 
Comparison of Tables 3.1 and 3.2 demonstrates that the yield for the 
affinity step was far higher for the liver enzymes than for lung viz. 77% for the 
former and 29% for the latter. A possible contributing factor to this lower yield 
is that during the lung purification the affinity column was subjected to an 
overnight NaCl wash due to the large volume of cytosol initially applied to the 
column, possibly resulting in slow leaching of transferase from the column. 
Table 3.2 
SUMMARY OF THE PURIFICATION OF THE BASIC AND ACIDIC 
GSH S-TRANSFERASES FROM HUMAN LUNG 
Purification step Vol. Protein Activity Specific % Yield Total Activity 
Activity 
µmoVmin"' ml mg/ml umoVmin/ml umoVmin/mg 
" 
Lung cytosol 400 52.6 4.53 0.086 100 1812 
Post affinity 
chromatography 26.2 0.532 20.21 38.0 29.2 530 
Post DE52 
Acidic lung GSH S-T 11 0.53 21.13 40.0 12.8 232 
Basic lung GSH S-T 8 0.060 1.40 23.3 0.62 11.2 


















































Fig. 3.3 Resolution of basic and acidic lung GSH S-T by DEAE - cellulose 
chromatography. The basic GSH S-T eluted in the void volume. The acidic GSH 
S-T was eluted by a O - 0.2 M linear NaCl gradient. 
Fractions pooled are indicated by horizontal bars. GSH S-T activity was 
measured with CDNB as substrate and expressed as µmoVmin/ml (-). 
' 
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3.3.3 Characterization of Human GSH S-T 
3.3.3.1 Determination of molecular weight 
SOS-PAGE under denaturing conditions revealed the existence of a 
single band of protein for all 4 purified GSH S-T (Fig. 3.2; 3.4). The subunit 
molecular weights as determined by SOS-PAGE are in close agreement with 
previously published values (Table 3.3). 
3.3.3.2 Determination of isoelectric point 
The isoelectric points of the transferases, as determined by flat bed 
isoelectric focusing are listed in Table 3.3. Similar isoelectric points for the 
acidic lung GSH S-T were obtained using both broad and narrow pH range 
gels. These pl values are in close agreement with those described by others. Flat 
bed isoelectric focusing (Fig. 3.5; 3.6; 3.8) confirms the existence of several 
isomers in both liver and lung basic preparations and shows that 2 forms of 
near-neutral transferase are present in the preparations studied. This is in 
agreement with the findings of Vander Jagt et al (1985). A single acidic form 
was shown (Fig. 3.7). , However, in certain purifications isoelectric focusing 
revealed 2 minor bands on either side of the main acidic GSH S-T presumably 
corresponding to the minor acidic GSH S-T described by Singh et al (1986) (Fig. 
3.8). 
3.3.3.3 Kinetic properties 
The specific activities for the purified enzymes are listed in Table 3.4. 
Comparative data by others is also shown. 







Fig. 3.4 SDS-polyacrylamide gel electrophoresis of basic and acidic lung GSH S-T 
purified as described in section 3.2.4. Lane 1 contains lung cytosol; lane 2, post 
hexylglutathione affinity fraction; lane 3, basic lung GSH S-T; lane 4, acidic lung 
GSH S-T and lane 5 molecular weight markers. 
Table 3.3 
PHYSICAL PROPERTIES OF THE HUMAN LIVER AND LUNG GSH S-T 









a Data according to Kamisaka et al (1975) 
b Data according to Warholm et al (1983) 
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Fig. 3.5 Analytical thin layer isoelectric focusing of basic liver GSH S-T (lane 2). pl 
markers are shown in lane 1. 
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Fig. 3.6 Analytical thin layer gel isoelectric focusing of near-neutral liver GSH S-T 
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Fig. 3.7 (A) Analytical thin layer gel isoelectric focusing of acidic lung GSH S-T (pH 
range 4 - 5). 
(B) pH profile constructed by measuring the pH of the gel at the positions 
indicated on the right hand side of A (see Appendix B, method XIV) . 
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Fig. 3.8 Analytical thin layer isoelectric focusing of acidic lung GSH S-T (lanes 1 and 4), 
and basic lung GSH S-T (lane 3). pl markers are shown in lane 2. 
Table 3.4 
SUBSTRATE SPECIFICITIES OF THE HUMAN LIVER AND LUNG GSH S-Ta 
Substrate specific activity (JJD10Vm.in/mg) 
Substrate Transferases 
Basic Liver Neutral Liver 
CDNB 55 64b 78 187b 
DCNB 0.04 0.035- 0.02 0.03b 
0.065d 
ethacrynic 0.24 0.017- 0.082 0.081b 
acid 0.044d 
tPBQl 0.001 0.001- 0.46 0.36b 
Cumene.OQH2 8.0 0.23 0.63b 
n.d. not detected 
a data are means from several purifications 
b Data according to Warholm et al (1983) 
c Data according to Partridge et al (1984) 







Abbreviations used ltPBO, trans-4-phenyl-3-buten-2-one 








While there is considerable overlap of substrate specificity, e.g. all 4 
transferases catalyse the conjugation of CDNB, each group appears to favour 
certain substrates. The basic transferases have a high specific activity with the 
substrate cumene hydroperoxide whereas the near-neutral transferases have 
high activity with the substrate trans-4-phenyl-3-buten-2-one. The acidic GSH 
S-T exhibits high specific activity with the substrate ethacrynic acid. Although 
many of the specific activities obtained in this study agree well with the literature, 
there are some notable differences: 
1) The near-neutral transferases have a lower specific activity with CDNB 
and cumene hydroperoxide than previously reported (Warholm et al, 
1983). 
2) The basic lung transferases have an 11 fold higher specific activity with 
CDNB than documented by Partridge et al (1984). 
3) The acidic lung transferase has approximately a 10 fold higher specific 
activity with the substrate ethacrynic acid than reported by Partridge et 
al (1984). A specific activity of 0.227 J1II10I/m.in/mg was obtained with 
the basic lung transferase for this substrate whereas it was not 
detectable in the study of Partridge et al (1984). 
4) In this study the specific activity for the acidic lung transferase with 
DCNB was approximately 6 fold lower than that reported by Partridges' 
group. 
This is probably explained by the different column purification 
techniques and the different buffers used for homogenization. In addition, the 
kinetic measurements of Warholm et al (1983) were performed at 30°C. 
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Fig. 3.9 Double reciprocal plot of reaction velocity (v) and substrate concentration [S] 
(1-chloro-2,4-dinitrobenzene) for the acidic lung GSH S-T Initial estimates from 
the plot of the parameters K' m and K' cat were used in the Gauss-Newton iterative 
non-linear curve fitting procedure. 
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estimates of kinetic parameters. The apparent Km and Keat values for the 
purified transferases are listed in Table 3.5. Comparative data, when available, is 
also shown. 
3.3.3.4 Amino acid analysis 
The amino acid compositions of the human GSH S-T are listed in 
Table 3.6. Values are expressed as number of residues per mole determined 
after hydrolysis in 6 N HCl at 110°C for 24 h. As the method of hydrolysis used 
destroys tryptophan, this amino acid was not detected. In addition, the amino 
acid composition of the basic liver, the near-neutral liver and the acidic lung 
transferases obtained by others are listed for comparative purposes (Warholm et 
al, 1983; Partridge et al, 1984). The results obtained in this study are in 
reasonable agreement with these values. 
3.3.3.5 Immunological properties 
The human basic and near-neutral transferases, when placed in 
adjacent wells to liver cytosol, revealed single lines of identity when subjected to 
immunocliffusion against antibodies raised to the human basic and near-neutral 
transferases respectively (see Figs. 3.10 and 3.11). Similar results were obtained 
for the antiserum raised to the acidic lung transferases when tested for 
immuno-identity against pure antigen and lung cytosol (Fig. 3.12). 
Western blotting, using the 3 antisera, demonstrated that each 
antiserum was specific for its antigen (Figs. 3.13 and 3.14). This finding is in 
agreement with those of Sherman et al (1983b) and Partridge et al (1984), but 
differs from that of Awasthi et al (1980). 
Table 3.5 
KINETIC CONSTANTS OF THE GSH S-T FOR CDNB AND GSHC 
Basic Liver Neutral Liver 
CDNB K'cat 2071±142 2802±226 (11600a) 
min-1 





GSHK'm 0.34±0.04 0.09 ± 0.008 (0.16a) 
(mM) 
a Data according to Warholm et al, 1983 
b Data according to Partridge et al, 1984 
Acidic Lung Basic Lung 
3248±224 (865h) 3124±342 (73b) 
0.55±0.08 (0.68b) 1.66±.25 (0.52b) 
2236±57 (1319b) 1360±48 
0.11±0.009 (0.32b) 0.083 ± 0.0096 
c Kinetic data was fitted directly to the non-linear form of the Michaelis-Menten equation by an 
iterative non-linear least squares curve fitting procedure using the Gauss-Newton method. Initial 
estimates of the parameters were from lineweaver-Burk plots. Iteration was continued until 
successive estimates of Km differed by < 10-5%. Standard deviation in Km and Keat were 
obtained directly from the principal diagonal elements of the variance/covariance matrix. 
Concentrations of CDNB and GSH were varied independently in the range of 0.1 - 1.0 mM CDNB 
for the basic, and near-neutral liver transferases as well as the acidic lung transferase whereas 0.05 -
1.0 mM was used for the basic lung transferase. The range 0.06 - 1 mM GSH was used for the basic 
and the near-neutral liver transferase whereas 0.05 - 1.0 mM and 0.03 - 1 mM were used for the 
acidic and basic lung transferases respectively. Results are expressed ± standard deviation. 
Table3.6 
AMINO ACID COMPOSITIONS OF THE HUMAN LIVER AND LUNG GSH S-T 
Transferase 
Basic Liver Neutral liver Acidic lung Basic lung 
Mr 52000 51 oooa 54000 53 ooooa 47000 45 ooob 49000 
Amino 
Acid 
Asx 29.1 37.6 41.8 50.4 36.1 39.7 6.1 
Thr 8.9 8.5 13.6 13.4 19.1 17.1 11.7 
Ser 29.7 25.0 27.2 21.4 28.4 23.4 29.9 
Glx 58.9 51.9 54.0 49.9 60.9 52.8 51.7 
Pro 27.9 24.3 29.4 20.0 28.8 25.3 21.7 
Gly 25.8 22.2 28.2 30.0 49.7 47.8 27.4 
Ala 37.2 31.5 25.1 22.8 38.8 27.2 36.7 
Val 17.8 19.3 9.8 12.6 19.8 23.2 17.1 
Cys 1.0 2.0 4.6 9.2 1.8 1.3 
Meth 16.8 14.9 17.8 12.4 1.9 2.9 14.8 
Ileu 28.6 29.8 20.7 27.0 11.4 11.7 20.2 
Leu 61.9 57.7 61.5 55.6 73.3 61.9 60.9 
Tyr 21.1 20.6 27.2 24.0 23.9 24.7 19.2 
Phe 21.9 19.9 19.9 26.0 16.12 15.4 19.2 
Lys 49.4 47.4 45.6 40.0 26.6 24.5 45.0 
Hist 6.1 5.8 5.8 11.0 3.20 7.2 4.9 
Arg 24.5 23.8 20.2 19.8 16.97 17.9 24.7 
a Data according to Warholm et al (1983) 
b Data according to Partridge et al (1984) 





Fig. 3.10 Immunodiffusion in agar gel demonstrating the reactivity of rabbit anti-human 
basic GSH S-T (central well) with cytosol (wells 1 and 3), basic GSH S-T (well 2), 
near-neutral GSH S-T (well 4) and acidic GSH S-T (well 5). Well 6 contains no 




Fig. 3.11 Immunodiffusion in agar gel demonstrating the reactivity of rabbit anti-human 
near-neutral GSH S-T (central well) with cytosol (wells 1 and 3), near-neutral 
GSH S-T (well 2), basic GSH S-T (well 4) and acidic GSH S-T (well 5). Well 6 
contains no antigen. Precipitates are stained with amido black. 
Fig. 3.12 Immunodiffusion in agar gel demonstrating the reactivity of rabbit anti-human 
acidic GSH S-T (central well) with cytosol (wells 1 and 3), acidic GSH S-T (well 
2), basic GSH S-T (well 4) and near-neutral GSH S-T (well 5). Well 6 contains 
no antigen. Precipitates are stained with amido black. 
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Fig. 3.13 (A) SDS-polyacrylamide gradient gel (7.5 - 17.5%) showing in lane 1, acidic 
lung GSH S-T; lane 2, near-neutral GSH S-T and lane 3, basic GSH S-T. 
(B, C) "Western blots" of the polyacrylamide gel shown in "A" incubated with 
antibody to the basic GSH S-T, and normal rabbit serum, respectively. 
A. 8. 
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Fig. 3.14 (A) 
(B, C, and D) 
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D. 
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SDS-polyacrylamide gradient gel (7.5% - 17.5% showing in 
lane 1, near-neutral liver GSH S-T; lane 2, acidic lung GSH 
S-T and lane 3, basic liver GSH S-T. 
"Western blots" of the polyacrylamide gel shown in A, 
incubated with normal rabbit serum, rabbit antibody to the 




In conclusion, the purification procedures described in this chapter 
yielded pure basic and near-neutral liver GSH S-T and basic and acidic lung 
forms. Based on physicochemical and immunological characterization, these 
enzymes are apparently identical to those described in the literature (Kamisaka 
et al, 1975; Warholm et al, 1981b,1983; Partridge et al, 1984). 
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Chapter4 
SITE-DIRECTED INACTIVATION OF HUMAN LUNG ACIDIC GLUTA-
THIONE S-TRANSFERASE BY 1-CHLOR0-2.4-DINITROBENZENE 
IN THE ABSENCE OF GLUTATHIONE 
4.1. INTRODUCTION 
As previously discussed, the GSH S-T are a family of multifunctional 
proteins which play an important role in the metabolism of xenobiotics. Three 
classes of human GSH S-T exist: basic (pl >7.5), near-neutral (pl ±6.5) and 
acidic (pl < 5.5) (Mannervik, 1985a). Although these enzymes have many 
overlapping substrate specificities, each class appears to favour certain substrates 
(Warholm et al, 1983) enabling the GSH S-T to metabolize a broad spectrum of 
xenobiotics. The different substrate specificities of the three classes suggest 
distinct roles for each class in the detoxication of xenobiotics. 
Amongst other functions, these enzymes are able to detoxify 
electrophiles by conjugation with glutathione (GSH). Nucleophilic groups on 
the transferase can covalently bind reactive electrophiles (Jakoby, 1978; Jakoby 
and Habig, 1980). In elucidating the kinetic mechanism for the basic transferase 
(transferase A) from rat liver, Pabst et al (1974) demonstrated that in the 
absence of GSH the electrophile CDNB ( one of the best substrates for the 
transferases) bound to the enzyme but that not all of this binding was reversible 
and it was suggested that this reagent can alkylate the enzyme irreversibly. 
Covalent binding of the substrates to rodent liver GSH S-T, with no or partial 
loss of activity has also been reported for ethacrynic acid (Yamada and 
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Kaplowitz, 1980), benzo(a)pyrene metabolites (Reeve et al, 1981), bromo-
benzene (Monks et al, 1984; Aniya et al, 1988), and paracetamol (Wendel and 
Cikryt, 1981). 
However, little is known about the covalent interaction of substrates 
with the human GSH S-T, or about the nature and degree of any associated 
inhibition. Loss of activity of the human placental GSH S-T in the presence of 
CDNB has been shown. GSH and S-methylglutathione protected against this 
loss of activity (Vander Jagt et al, 1981). Thus the situation may arise where the 
enzyme may be irreversibly inhibited in a glutathione deficient environment. In 
this chapter the binding of CDNB to the 3 classes of GSH S-T has been studied. 
CDNB binds covalently to all 3 classes of transferase. However, only the acidic 
lung GSH S-T is rapidly inactivated in the absence of the co-substrate GSH. 
4.2 MATERIALS AND METHODS 
4.2.1 Chemicals 
All chemicals used were of the highest 'grade available (see Appendix 
A). 
4.2.2 Enzyme Assay 
Enzyme activity towards the substrate CDNB was determined at 25°C 
by the method of Habig et al (1974b). Enzyme (0.05 ml) was added to 2.95 ml 
O.lM potassium phosphate (pH 6.5) containing 1 mM CDNB and 1 mM GSH. 
Initial rates were determined from continuous monitoring of absorbance at 340 
nm over 1 min in a Unicam SP 1700 spectrophotometer. The stock solution of 
84 
GSH was prepared in degassed, distilled water and the stock solution of CDNB 
was protected from light. Although this substrate is an inhibitor under the 
conditions to be described, it was chosen to monitor residual activity due to its 
high specific activity (Partridge et al, 1984). 
Protein concentration was determined using the method of Bradford 
(1976) with human albumin as standard. 
4.2.3 Kinetic and Binding Studies 
4.2.3.1 CDNB Incubation 
The incubation mixture to study the effects of CDNB on the human 
transferases was prepared as follows: CDNB in 95% ethanol (0 - 1.2 mM final 
concentration) was vortex mixed for 1 min into 0.04 M Tris/HCl, pH 8.2 after 
which 0.156 units GSH S-T were added. The total reaction volume was 0.5 ml. 
The ethanol concentration was maintained constant (1.9%) in all experiments, in 
control. experiments an equivalent volume of ethanol replaced the ethanolic 
solution of CDNB. 
Enzyme was incubated with CDNB alone, or with CDNB and one of 
the following: GSH (1.2 mM), S-methylglutathione (1.2 mM); or albumin (8 
mg/ml). The pH of the stock solutions of GSH and S-methylglutathione was 
adjusted to pH 7.0 before addition to the incubation mixture (full details of the 
method are described in Appendix B method X). After incubation in a shaking 
water bath (70 cycles/min) for 3 - 15 min, transferase activity was measured by 
adding 0.05 ml of the incubation mixture to the standard assay solution as 
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described above. All experiments were performed m quadruplicate. Assay 
variability was less than 10%. 
The inactivation of the acidic lung transferase by CDNB (0.15 mM) 
was investigated as a function of pH. At pH values of 6.5 and 7.5, 0.04 M 
phosphate buffer was used for the incubation mixture and at pH 8.2, 0.04 M 
Tris/HCl was used. 
Results were expressed as % CDNB activity remaining (mean ± 
S.D). Statistical analyses were performed with the Student's t test for unpaired 
data. 
4.2.3.2 Ethacrynic acid Incubation 
The incubation mixture to study the effects of ethacrynic acid on the 
GSH S-T was prepared as for the CDNB incubation described above (see 
Section 4.2.3.1). 
Enzyme was incubated with ethacrynic acid alone (0.12 mM) or with 
ethacrynic acid and GSH (1.2 mM) under the conditions described above. 
4.2.3.3 Binding of [14CJ-CDNB to GSH S-T 
In all cases Beta emission of the [14C]-CDNB was quantitated in 10 ml 
Instagel scintillation fluid in a Packard Tri-carb 4640 Beta counter. 
A) Human acidic lung transferase (1.2 .uM) was incubated with 0.6 mM 
[14C]-CDNB for 15 min at 25°C. After application of the incubation mixture to a 
Sephadex G-75 column (0.7 x 28 cm) equilibrated with 0.04 M Tris/HCl pH 8.2 
(full details are described in Appendix B method XI) the protein-bound 
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radiolabelled fractions were pooled. A small aliquot was subjected to 
SDS-PAGE (see Appendix B method XIII) and the remainder divided into 3 
equal parts, each treated as below before re-application to a Sephadex G-75 
column. One was incubated with GSH (1 mM) for 15 min at 25°C (Pabst et al, 
1974), a second part was incubated with guanidine HCl (6 M) for 1 h at 25°C 
(Boyer and Vessey, 1983) and the third incubated with unlabelled CDNB 
(1 mM) for 15 min at 25°C. 
B) In a further set of experiments human acidic lung transferase, basic 
and near-neutral liver transferases (1.2 l!M) were incubated with [14C]-CDNB 
(0.6 mM) in the presence or absence of GSH (1.2 mM). These incubation 
mixtures were not applied to a Sephadex G-75 column to separate bound from 
free radiolabelled CDNB but instead were subjected directly to trichloroacetic 
acid (TCA) precipitation using an equal volume of 20% trichloroacetic acid (see 
Appendix B method XII). After centrifugation at 105 000 g, the pellet was 
washed twice with 20% trichloroacetic acid. The precipitate was redissolved in 
0.1 N NaOH. Aliquots were counted in Instagel in the Beta counter and the 
protein concentration estimated in order that the number of moles of substrate 
bound per mole of protein might be determined. 
C) Lastly, for the acidic lung and basic liver GSH S-T the TCA 
precipitates were, in a separate experiment, dissolved in formic acid, and 
subjected to cyanogen bromide cleavage (Samuels et al, 1983). The resulting 
peptides were analysed on a Waters HPLC using a C18 uBondapak reverse 
phase column developed with a 5 - 75% acetonitrile gradient in 0.1 % 
trifluoroacetic acid. Peaks were collected, pooled and analysed for radioactivity 
and amino acid composition. The latter experiment was conducted in 




4.3.1 Effect of CDNB incubation on human GSH -S-T 
Incubation of CDNB (0.6 mM) with human acidic lung transferase 
resulted in a time-dependent inactivation with < 5% activity remaining after 15 
min (Fig. 4.1). The replacement of CDNB with an equivalent volume of ethanol 
(the solvent for CDNB) did not result in a significant loss of activity (p > 0.1). 
Since the inhibitor was present in 88 fold molar excess over the enzyme, 
pseudo-first order conditions were assumed to apply (Dixon and Webb, 1979) 
and the pseudo-first order rate constant (kobs) for the inactivation was kobs = 
0.32 min-1, as determined from a plot of In A vs time, A = % activity remaining 
(Fig. 4.1, inset) . No significant inhibition was noted when the human basic lung, 
basic liver and near-neutral GSH S-T were incubated under identical conditions, 
(p > 0.1) (Table 4.1). 
The degree of inactivation of the acidic GSH S-T after 15 mm 
incubation was saturable with respect to the concentration of CDNB (Fig. 4.2). 
A Hanes-Woolf plot of the data gave a Ki of 0.14 mM for CDNB (Fig. 4.2, 
inset). Gel filtration of the inactivated enzyme did not restore enzymatic activity. 
The presence of either 1.2 mM GSH or 1.2 mM S-methylglutathione in 
the incubation mixture protected against inactivation (see Tables 4.2 and 4.3). In 
contrast, the addition of albumin did not protect (see Table 4.4). Of interest is 
the fact that incubation with either GSH, S-methylglutathione or albumin alone 
(without CDNB) resulted in a small activation of the enzyme relative to the 
control. 
When the inactivation of the acidic lung transferase by CDNB was 
\ 
investigated as a function of pH, the extent of inactivation was found to be 
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Fig. 4.1 Time dependent reduction in activity of human acidic lung GSH S-T during 
incubation with CDNB (0.6 mM) in 0.04 M Tris/HCI, pH 8.2 at 25°C (O); 
compared with control incubation with ethanol (D) ( ethanol was required to 
solubilize CDNB). Initial rates were determined in 0.1 M sodium phosphate, pH 
6.5 containing 1 mM CDNB and 1 mM GSH. 
Inset, lo %A vs time. 
TABLE4.1 






% CDNB activity remaining at 15 minC 
CONTROLb 1.2 mM CDNB 
91.8 ± 8.5 (8)d 
88.8 ± 5.6 (6) 
85.1 ± 8.5 (8) 
93.8 ± 3.0 (5) 
0 (8) 
85.9 ± 8.9 (6) 
80.8 ± 8.5 (8) 
93.2 ± 9.7 (5) 
aThe human GSH S-T were incubated with CDNB (1.2 mM) for 15 min at 25°C in 
0.04 M Tris/HCl, pH 8.2, containing 1.9% ethanol. After incubation, initial rates were 
determined in 0.1 M sodium phosphate buffer, pH 6.5 containing 1 mM CDNB and 1 
mMGSH. 
bcontrols were incubated in buffer containing ethanol. Ethanol reduced GSH S-T 
activity by up to 15%. 
CValues expressed as mean ± S.D., statistical analyses were performed with the 
student's t test for unpaired data. 
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Fig. 4.2 Inhibition of human acidic lung GSH S-T by CDNB. Human acidic GSH S-T was 
incubated with varying concentrations of CDNB for 15 min in 0.04 M Tris/HCl, 
pH 8.2 at 25°C. Initial rates were determined as described in the legend to Fig. 4.1. 
Inset, Single reciprocal plot of CDNBN vs CDNB, where V = % loss of activity 
per 15 min incubation. Intersection with the x-axis gives -1/Ki. 
Table 4.2 
THE EFFECT ON HUMAN ACIDIC LUNG GSH S-T ACTIVITY OF INCUBATION 
WITH CDNB IN THE PRESENCE of GSH (1.2 mM)a 
ethanolc 
ethanol + GSH 
CDNB 
CDNB + GSH 
% CDNB Activity Remainingb 
85.2 ± 4.5 
101.0 ± 7.0 
0 





aThe acidic lung GSH S-T was incubated with CDNB (0.6 mM) in the presence/absence of GSH 
(1.2 mM) for 15 min at 25°C in 0.04 M Tris/HCI, pH 8.2, containing 1.9% ethanol. After 
incubation, initial rates were determined in 0.1 M sodium phosphate buffer, pH 6.5, containing 1 
mM CDNB and 1 mM GSH. 
bResults are expressed as mean ± S.D. 
ccontrol was incubated in buff er containing ethanol. 
dNumber of activity determinations at time points O and 15 min. 
Table 4.3 
EFFECT ON HUMAN ACIDIC LUNG GSH S-T ACTIVITY OF INCUBATION 
WITH CDNB IN THE PRESENCE OF S-METHYLGLUTATHIONE (1.2 mM)a 
ethanolC 
ethanol + S-methylGSH 
CDNB 
CDNB + S-methylGSH 
% CDNB Activity remainingb 
89.6 ± 3.8 
101.4 ± 6.0 
8.9 ± 2.8 





aThe acidic lung GSH S-T was incubated with CDNB (0.6 mM) in the presence/absence of 
S-methylglutathione for 15 min at 25°C in 0.04 M Tris/HCI, pH 8.2, containing 1.9% ethanol. 
After incubation, initial rates were determined in 0.1 M sodium phosphate buffer, pH 6.5, 
containing 1 mM CDNB and 1 mM GSH. 
bResults are expressed as mean ± S.D. 
CControl was incubated in buff er containing ethanol. 
dNumber of activity determinations at time points O and 15 min. 
Table 4.4 
EFFECT ON HUMAN LUNG ACIDIC GSH S-T ACTIVITY OF INCUBATION 
WITH CDNB IN THE PRESENCE OF ALBUMIN (8mg/ml)a 
ethanolb 
ethanol + albumin 
CDNB 
CDNB + albumin 
% CDNB Activity remainingC 
85 2 ± 4.5 







aThe human lung acidic GSH S-T was incubated with CDNB in the presence/absence of 
albumin (8mg/m.1) for 15 min at 25°C in 0.04 M Tris/HCI, pH 8.2, containing 1.9% ethanol. 
After incubation, initial rates were determined in 0.1 M sodium phosphate buffer, pH 6.5, 
containing 1 mM CDNB and 1 mM GSH. 
bcontrol was incubated in buffer containing ethanol. 
CValues are expressed as mean ± S.D. 





EFFECT OF pH ON HUMAN ACIDIC LUNG GSH S-T ACTIVITY OF 
INCUBATION WITH CDNB (0.15 mM) FOR 15 MIN AT 25°ca 
6.5 7.5 8.2 
% Activity remb (n) % Activity remc (n) % Activity rem 
73.0 ± 1.6 (3) 85.0 ± 8.0 (4) 100.0 ± 4.4 
28.5 ± 2.4 (4) 40.6 ± 4.0 (4) 48.1 ± 3.0 




aThe human acidic lung GSH S-T was incubated with CDNB (0.15 mM) for 15 min at 25°C. 0.04 M 
Tris/HCl was used as incubation buffer at pH 8.2 and 0.04 M phosphate buffer at pH 6.5 and 7.5. 
bResults are expressed as mean ± S.D. 
CAbbreviation used: rem, remaining. 
(n) = number of activity estimations at time points O and 15 min. 
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4.3.2 Effect of Ethacrynic Acid Incubation on Human GSH S-T 
Incubation of ethacrynic acid (O.U mM) with human lung acidic GSH 
S-T resulted in a significant inactivation of the enzyme (p < 0.0005). Addition 
of GSH to the incubation mixture protected against this inactivation (see Table 
4.6). 
4.3.3 Binding of [14CJ-CDNB to GSH S-T 
A) Incubation of acidic lung transferase (1.2 .uM) with 0.6 mM 
[14C]-CDNB for 15 min at 25°C followed by separation of bound from free 
substrate by Sephadex G-75 chromatography resulted in 11 mol CDNB bound 
per mol of enzyme (Fig. 4.3 A). Treatment of the radiolabelled eluate with 6 M 
guanidine HCl or 1.2 mM GSH and rechromatography reduced the binding of 
CDNB to 2.9 and 4.3 moVmol protein, respectively (Fig. 4.3 B and C). In 
contrast, treatment of the radiolabelled eluate with 1 mM CDNB did not 
significantly decrease binding (Fig. 4.3 D). 
SDS-P AGE of the initial protein bound radioactive fraction which 
eluted from the Sephadex G-75 (in which 11 mol CDNB bound per mol of 
protein) showed that 43% of the radioactivity remained associated with the 
protein. 
B) Incubation of the 3 classes of human GSH S-T, aoidic, near-neutral 
and basic (all 1.2 .uM), with 0.6 mM [14C]-CDNB for 15 min at 25°C followed by 
TCA precipitation resulted in 3.5, 4.0 and 1.7 mol CDNB bound /mol protein, 
respectively; addition of 1.2 mM GSH to the incubation mixture decreased these 
values to 1.4, 2.6 and 0.9 moVmol enzyme, respectively. 
C) After incubation of the acidic lung and basic liver GSH S-T (1.2 pM) 
Table4.6 
EFFECT ON HUMAN ACIDIC LUNG GSH S-T ACTIVITY OF INCUBATION 
WITH ETHACRYNIC ACID (0.12 mM) IN THE PRESENCE/ABSENCE OF GsHa 
% CDNB Activity RemainingC 
ethanolb 
ethanol + GSH 
ethacrynic acid (0.12 mM) 
ethacrynic acid + GSH (1.2mM) 
91.3 ± 7.0 
105.4 ± 2.4 






aThe human acidic lung GSH S-T was incubated with ethacrynic acid (0.12 mM) in the 
presence/absence of GSH for 15 min at 25°C in 0.04 M Tris/HCl, pH 8.2. After incubation 
initial rates were determined in 0.1 M phosphate buffer, pH 6.5, containing 1 mM CDNB and 
lmMGSH. 
bcontrol was incubated in ethanol alone. 
CValues are expressed as mean ± S.D. 

















































0 10 20 30 40 50 
Fraction Number 
Fig. 4.3 Binding of [14C]-CDNB to human acidic lung GSH S-T. 
(A) Sephadex G-75 elution profile of human acidic lung transferase (1.2 µM) 
incubated at 25°C for 15 min with 0.6 mM [14C]-CDNB in 0.04 M Tris/HCI, pH 8.2 
(primary incubation); sample was applied and eluted in the incubation buffer. 
The peak fraction from A was pooled, divided into 3 fractions, treated with 6 M 
guanidine HCl (B), 1 mM GSH (C), or 1 mM CDNB (D), and then 
rechromatographed as above. 
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with 0.6 mM [14C]-CDNB, with or without 1.2 mM GSH, for 15 min at 25°C, the 
enzymes were cleaved with cyanogen bromide and subjected to HPLC. Both 
enzymes gave chromatograms with 10 peaks each (Fig 4.4). In the presence of 
GSH, only "peak 7" was radiolabelled in both cases. In the absence of GSH 
"peak 4" was additionally labelled in both enzymes, while only with the acidic 
GSH S-T was a third fragment, "peak 5" labelled (Fig. 4.4). Peaks 4, 5, and 7 
contained peptides as evidenced by their amino acid compositions (Table 4.7). 
4.4 DISCUSSION 
Covalent binding of reactive electrophiles to the GSH S-T is thought to 
constitute a second line of defence by these enzymes in the detoxication of 
potentially harmful compounds (Jakoby and Habig, 1980; Aniya et al, 1988). 
Since many of the substrates of the GSH S-T are vigorous alkylating agents, it is 
reasonable to assume that they may react directly with a nucleophilic group on 
an amino acid residue in the enzyme (Jakoby and Habig, 1980). Little is known 
about the mechanism of this process, the mode of inhibition, or even whether the 
alkylation is generally a random or directed event. 
This study has demonstrated that of the 3 major classes of human 
transferases, only the acidic lung GSH S-T is inactivated by CDNB, and that this 
inhibition only occurs in the absence of the co-substrate GSH. The inactivation 
is time-dependent and exhibits pseudo-first order kinetics, with a Kobs of 0.32 
min-1 at 0.6 mM CDNB. The inhibition is saturable with respect to the CDNB 
concentration suggesting that the inactivation is occurring from prebound CDNB 
(Walsh 1979) and not via a bimolecular reaction, as indicated by the scheme: 
Ki K 
E + CDNB ~ E.CDNB - E-CDNB 
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Fig. 4.4 HPLC elution profiles of trichloroacetic acid precipitates, after cyanogen bromide 
cleavage, of 1.2 .uM acidic lung GSH S-T(A) and 1.2 .uM basic liver GSH S-T(B), 
after incubation with 0.6 mM [14C]-CDNB in the presence E--) or absence(-) of 
GSH (1.2 mM) for 15 min at 25°C. A 5% - 75% acetonitrile gradient containing 
0.1 % trifluoroacetic acid was applied. The absorbance was monitored at 220 nm. 
Fractions were collected using a fraction collector equipped with peak detection 
system, pooled and analysed for radioactivity. Bar graphs · indicate 
peak-associated radioactivity (after adjustments to total volume and blank 
subtraction) in the presence (1::::1) and absence (a ) of GSH; < 500 cpm/peak was 
considered as background. 
Table4.7 
AMINO ACID COMPOSITTON OF RADIOACTIVE PEPTIDE FRACTIONS ELUTED 

































































This scheme would suggest that the CDNB is binding to a specific site on 
the enzyme prior to the chemical step resulting in covalent linkage. The 
apparent overall dissociation constant for this process was 0.14 mM, indicating 
low affinity binding. Since the inactivating capacity of CDNB is abolished by the 
second substrate it would appear that the latter may bind to a specific site 
rendering it inaccessible to CDNB or may cause conformational changes in the 
enzyme resulting in diminished CDNB binding. 
Over the pH range studied the hydrogen 10n concentration was not 
apparently involved in the inactivation process. However, one cannot comment 
on the ionization state of the nucleophilic group of the enzyme which may be 
involved in the inactivation, as the pH range studied does not extend significantly 
beyond the pKa of the possible residues. 
Radiolabelled binding studies indicate that CDNB bound covalently to all 3 
classes of human transferase. In the case of the acidic lung GSH S-T, incubation 
with [14C]-CDNB and denaturation of the protein resulted in approximately 3 
mol CDNB bound per mol enzyme after treatment with 6 M guanidine HCl or 
TCA precipitation. TCA precipitations of the incubates of the other 2 classes of 
human transferases, the basic and the near-neutral GSH S-T, gave values of 1.7 
and 4.0 mol CDNB/mol enzyme, respectively. In all cases the presence of GSH 
in the ·incubation mixture decreased the amount of covalently bound CDNB to 
1.4, 2.6, and 0.9 moVmol of the acidic, near-neutral and basic GSH S-T, 
respectively. These values suggest that GSH reduced the binding of CDNB by 
approximately 1 moVmol enzyme for the basic and near-neutral GSH S-T, and by 
2 moVmol for the acidic GSH S-T. This conclusion is supported by additional 
information obtained for two of the three human GSH S-T studied: Of the 
HPLC peptide fractions generated by cyanogen bromide cleavage of the acidic 
and basic GSH S-T after incubation with [14C]-CDNB and TCA 
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precipitation, one was radiolabelled in both cases when this incubation occurred 
in the presence of GSH, while in its absence one additional peak was labelled in 
the basic GSH S-T and two additional peaks in the acidic GSH S-T. One of 
these two additional peptide fractions is likely to contain the specific inhibitory 
site which is probably at or near the GSH binding site. Site-directed covalent 
binding of substrates to the transferases was recently proposed by Aniya et al 
(1988), who found that bromobenzene metabolites selectively bind to specific 
subunits of rat liver transferases without affecting catalytic activity. 
The rapid, irreversible inactivation of human acidic GSH S-T by the 
substrate CDNB (which was also observed in a preliminary study with ethacrynic 
acid) is difficult to reconcile with a physiological function, particularily since 
GSH S-T-mediated detoxication by covalent binding is not accompanied by a 
total loss of catalytic activity in the other classes of human GSH S-T. The 
inhibition of the acidic GSH S-T by CDNB is unlikely to occur under normal 
conditions in vivo since the 1 - 10 mM GSH present physiologically (Jakoby and 
Habig, 1980) would confer protection. However, in the event of a severe 
electrophilic challenge, tissue concentration of GSH may fall by more than one 
order of magnitude (Sugiyama and Kaplowitz, 1984), thus exposing the human 




GLUTATHIONE S-TRANSFERASE DISTRIBUTION 
AND CONCENTRATION IN HUMAN ORGANS 
5.1 INTRODUCTION 
Several studies have suggested wide inter-individual and inter-organ 
variations in the concentration of the 3 classes of transferases (Warholm et al, 
1980; Board, 1981a; Sherman et al, 1983b; Laisney et al, 1984; Strange et al, 1984; 
Faulder et al, 1987). These studies have been qualitative, however, based on 
starch gel electrophoresis (Board, 1981a; Strange et al, 1984; Laisney et al, 1984) 
or semi-quantitative, relying on separation of tissue cytosol by isoelectric 
focusing or chromatofocusing and subsequent measurement of enzyme activity, 
and in one case immunoactivity, in fractions thought to represent each class of 
transferases (Warholm et al, 1980; Sherman et al, 1983b; Faulder et al, 1987). 
Despite these limitations, the findings that certain livers lack acidic 
transferases (Warholm et al, 1980; Sherman et al, 1983b) and that a proportion 
of the population has no near-neutral GSH S-T (Warholm et al, 1980; Board, 
1981b), suggested that simultaneous immunoquantitation of all 3 classes of GSH 
S-T in the various organs of a single group of individuals might reveal important 
differences in their distribution and concentration. 
5.2 MATERIALS AND METHODS 
5.2.1 Chemicals 
All chemicals used were of the highest grade available (see Appendix A). 
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5.2.2 Immunological Studies 
The antibodies to the 3 classes of transferases were prepared as 
described in Appendix B method IIIA and characterized as shown in 3.2.5.5. 
The concentration of each transferase was determined by radial 
immunodiffusion (Mancini et al, 1965) (Fig. 5.1). Full details of the methodology 
are given in Appendix B method IIIC. 1.2% Agar Noble, 0.1 % sodium azide and 
antibody at dilution of 1/100 for the basic and near-neutral transferases and 1/50 
for the acidic transferase in 0.1 M veronal buffer, pH 8.6, were used. 0.01 ml of 
the 105 000 g supernatants of the 30% homogenates of the various tissues was 
placed in each well. Each assay was performed in duplicate. Each plate 
contained standards consisting of at least 4 dilutions of purified protein ranging 
from 0.0048 - 0.155; 0.0062 - 0.1 and 0.0125 - 0.1 mg/ml for the basic, near-neutral 
and acidic GSH S-T respectively. When necessary, the supernatant was 
appropriately diluted or concentrated to ensure that all measurements fell within 
the standard curve derived from that plate. Plates were kept at 25°C for 4 days in 
a moisture chamber before reading the results. The results were calculated as 
described by Roitt et al (1985). 
5.2.3 Human Tissue 
In this study specimens of liver, testis, kidney, adrenal, jejunum, 
pancreas, duodenum, ileum, stomach, brain, lung, colon, heart, salivary gland, 
spleen, bladder, muscle and thyroid were obtained within 12 h of death and were 
stored at -70°C if not used immediately. The subjects, victims of motor vehicle 
accidents, were subjected to full autopsy for medico-legal purposes and showed 
no evidence of pre-existing disease. 
Fig. 5.1 Radial immunodiffusion using rabbit antiserum to basic liver GSH S-T at 1/100 
dilution. Wells 1 - 6 contain standards of basic GSH S-T from 0.155 mg/ml to 
0.0048 mg/ml. Other wells contain cytosol from different tissues ( assayed in 
duplicate). Well 7 contains no cytosol. The 2 wells in the second row with no 
visible immunoprecipitation rings contained bladder cytosol with a low 
concentration of basic GSH S-T. The sample was concentrated and re-assayed. 
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5.2.4 Erythrocyte GSH S-T 
Erythrocyte GSH S-T was partially purified in order to assess 
cross-reactivity between the erythrocyte transferase and the antibody raised to 
the acidic lung transferase. 
Partial Purification of Human Erythrocyte Transferase 
The red cell lysate was prepared essentially as described by Marcus et 
al (1978). 
200 ml of heparinised blood was centrifuged at 500 g for 20 min. The 
red cells were removed and washed 4 times by centrifugation for 30 min at 
1 500 g with 5 times their volume of saline. 1.25 volumes of H20 were then added 
and after vigorous shaking the mixture was allowed to stand at room temperature 
for 1 h. After spinning at 13 500 g for 1 h, the supernatant was removed and 
frozen overnight. The thawed lysate was centrifuged at 105 000 g for 1 h and the 
precipitate discarded. 
The supernatant was dialysed against 3 x 5 litres 0.01 M Tris/HCl over 
24 h arid then applied to a S-hexylglutathione affinity column as described in the 
purification protocol of the basic and near-neutral GSH S-T (see Chapter 3.2.3) . 
The post-affinity fraction when run on SDS-PAGE revealed a strong 
band of molecular weight similar to the acidic lung transferase and a weak higher 
molecular weight contaminant (Fig. 5.2). The "dot blotting" technique was 
employed to test cross-reactivity of this fraction with the lung acidic antibody. 
The absorbance at 410 nm was used to measure the contamination of 
the cytosol supernatants with haemoglobin (Warholm et al, 1981a). 







Fig. 5.2 . SDS-polyacrylamide gradient gel (7.5% - 17.5%) showing the subunit composition 
of acidic lung GSH S-T (lane 1); partially purified erythrocyte GSH S-T (lane 2); 
and molecular weight markers (lane 3). 
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5.3 RESULTS 
The concentrations of the 3 classes of transf erases in the tissues of 9 
male subjects are shown in Table 5.1. Values for the basic, the acidic and, when 
present, the near-neutral GSH S-T are expressed as mean ± standard deviation. 
The basic transferases were detectable in all 18 tissues of the 9 individuals 
studied. The highest concentration of the basic GSH S-T was found in liver, 
testis, kidney, adrenal, and jejunum while low levels were found in bladder, 
muscle and thyroid. The concentration in liver was 230 times higher than that in 
thyroid. In the liver, the testis and kidney, variation of the basic transferases was 
from 15.9 - 36.5, 14.8 - 23.9 and 9.2 - 23.4 .ug/mg cytosol, respectively. The 
near-neutral GSH S-T were absent in all tissues of 5 of the 9 individuals studied. 
In those subjects where the near-neutral GSH S-T were detectable the GSH S-T 
were widely distributed, the highest concentrations being found in liver, testis, 
muscle, adrenal and brain, with lowest levels in thyroid, lung, duodenum, 
stomach, heart and kidney. When present, the concentration of the near-neutral 
GSH S-T was 90 times higher in the liver than in the thyroid. In the liver, testis 
and muscle, the inter-individual variation of the near-neutral transferase, when 
present, ranged from 5.0 - 11.0, 3.1 - 6.3 and 1.5 - 3.6 .ug/mg cytosol, respectively. 
The acidic GSH S-T were present in all the individuals studied 
although they were undetectable in the liver of a single subject. The highest 
concentrations were present in colon, jejunum, ileum, bladder, spleen, 
duodenum and lung and low concentrations were found in liver. The 
concentration of the acidic GSH S-T was 16 times higher in the colon than in the 
liver. In the colon, jejunum and ileum the individual variation of the acidic 
transferase varied from 3.9 - 10.6, 5.0 - 8.4 and 3.9 - 9.4 llg/mg cytosol, 
respectively. 
Table 5.1 
TISSUE CONCENTRATION OF THE BASIC, NEAR-NEUTRAL 
AND ACIDIC GSH S-T 
Organ Basic GSH S-T Near-neutral GSH S-T 
ug per mg protein 
Liver 23.8±6.1 9.0±2.8 
Testis 18.6±3.4 4.8±1.4 
Kidney 14.9±5.3 0.8±0.2 
Adrenal 10.3± 1.9 2.1±0.9 
Jejunum 4.7±2.0 1.0±0.1 
Pancreas 2.7±1.5 1.0±0.2 
Duodenum 1.8 ± 1.0 0.7±0.1 
Ileum 1.6±0.4 1.2±0.5 
Stomach 0.9±0.5 0.7±0.2 
Brain 0.5±0.3 2.0±0.2 
Lung 0.4±0.1 0.6±0.1 
Colon 0.4±0.1 1.4±0.5 
Heart 0.3±0.2 0.7±0.3 
Salivary gland 0.2±0.1 0.8±0.2 
Spleen 0.2±0.1 1.4±0.4 
Bladder 0.1±0.01 1.7±0.4 
Muscle 0.1±0.02 2.3±0.9 
Thyroid 0.1±0.02 0.1±0.03 



















Concentration of basic, acidic and where present, near-neutral GSH S-T (mean ± S.D.) in the 
cytosol of 18 organs from each of 9 male subjects. 
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Erythrocyte GSH S-T 
Since the antibody to the acidic lung transferase recognised the GSH 
S-T in erythrocytes as demonstrated by "Dot Blotting" (Fig. 5.3), the maximal 
amount of contaminating blood was estimated by measuring the absorbance at 
410 nm of the tissue cytosols. When the contribution of erythrocyte GSH S-T to 
tissue acidic GSH S-T was estimated, these calculations suggested that the 
erythrocyte transferase accounted for < 1 % of the tissue acidic transferase 
measured. 
5.4 DISCUSSION 
This study aimed at determining the concentration of the 3 classes of 
GSH S-T in the various organs of the same individuals. Multiple forms of GSH 
S-T almost certainly exist within each group (Kamisaka et al, 1975; Awasthi et al, 
1980; Board, 1981a; Strange et al, 1984; Vander Jagt et al, 1985; Singh et al, 
1986). Thus there are at least 5 forms of basic GSH S-T which were thought to 
be the product of a single gene locus (Kamisaka et al, 1975) and more recently of 
2 loci (Stockman et al, 1985; Rhoads et al, 1987). The basic transferase 
preparation used in this study yielded several bands on isoelectric focusing over 
the pH range 8.4 - 9.0 (Fig. 3.5) and is likely to contain dimers of both subunits 
described by Stockman et al. Futhermore, Western blots of isoelectrofocusing 
gels revealed several bands, pH range 8.4 - 9.0 (Fig. 5.4), which react to the 
antibody raised to the basic GSH S-T suggesting that the antibody used does 
indeed recognise these forms. 
As discussed in Section 3.3.3.5, Western blotting failed to reveal any 
1 2 
3 4 
Fig. 5.3 "Dot blot" of acidic lung GSH S-T (1-3) and erythrocyte GSH S-T (4) . Blots 1, 3, 
and 4 were incubated with antiserum against acidic lung GSH S-T whereas (2) 




"Western blot" of basic liver GSH S-T, after flat bed isoelectric focusing, using 
antiserum to basic liver GSH S-T, (lane 1). Lane 2 represents the non-immune 
control (incubated with normal rabbit serum). 
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evidence of cross-reactivity between the antisera used to determine the 
concentration of each of the 3 classes of transferases. 
Radial immunodiffusion was chosen to measure the concentration of 
the 3 classes of transferases since it allowed the use of a single technique for the 
measurement of all 3 classes. The concentrations of the GSH S-T, when present, 
were always within the range of standards on each plate and the close agreement 
of duplicate measurements suggested that the method was adequately sensitive. 
All tissues were obtained within 12 h of death. The subjects, victims of motor 
vehicle accidents, were subjected to full autopsy for medico-legal purposes. 
None had evidence of pre-existing disease. However, no medical histories were 
available, thus factors such as drug or alcohol abuse, in addition to factors such 
as diet and smoking cannot be ruled out as possible explanations for some of the 
variations noted. In the rat, treatment with phenobarbital caused a significant 
increase in the GSH S-T levels in the liver, kidney and small intestinal mucosa 
(Bass et al, 1977b ), and Sparnins et al (1982) showed that in mice, an increase in 
the liver and intestinal mucosa GSH S-T levels resulted from an intake of diets of 
brussels sprouts, cabbage, coffee beans or tea leaves. For obvious reasons, 
induction in humans is difficult to study and it is not known whether any or all of 
the human enzymes are inducible. However, it is improbable that induction 
alone can explain the wide inter-organ and inter-individual variation found in this 
study. 
This study provides quantitative data on the distribution and 
concentration of the 3 classes of GSH S-T in human tissues. The data confirm 
the presence of inter-organ and inter-individual variation differences in the GSH 
S-T suggested in earlier studies (Warholm et al, 1980; Board, 1981a; Sherman et 
al, 1983b; Strange et al, 1984; Laisney et al, 1984). Board, using starch gel 
electrophoresis to study genetic variation in human liver cytosol, described 3 loci, 
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one of which corresponds to the near-neutral GSH S-T he claimed had a "null" 
allele. Our finding that 5 of the 9 individuals studied lack the near-neutral 
transferases in all the tissues studied would support this claim. 
The data also demonstrate marked differences m the tissue 
distribution of the 3 classes of transferases. Thus the liver has the highest 
concentration of the basic and near-neutral transferase but the lowest 
concentration of the acidic GSH S-T. The acidic GSH S-T, while showing the 
least inter-organ variation, appear to differ markedly from the basic and 
near-neutral GSH S-T in their distribution. 
The concentration of acidic GSH S-T in hepatic cytosol was in a 
similar range to the levels described by Soma et al (1986). A recent publication 
by Tateoka et al (1987) described the GSH S-T tr content in selected organs. 
These results were expressed as 11g/g of tissue and were thus not directly 
comparable. However, their fmdings that the lowest levels of the acidic GSH 
S-T were found in the liver is in agreement with the finding in this study. 
While there is considerable overlap of substrate specificity, e.g. all 3 
classes catalyse the conjugation of CDNB with GSH, each class appears to 
favour certain substrates. The near-neutral GSH S-T exhibit high specific 
activity with the substrates trans-4-phenyl-3-buten-2-one, benzo(a)pyrene-4,5-
oxide and styrene-7,8-oxide, while the acidic GSH S-T have high specific activity 
with ethacrynic acid. The basic transferases account for most of the 
selenium-independent glutathione peroxidase activity. Thus it is possible that 
apart from serving their function as catalysts in the conjugation of a broad group 
of electrophilic substrates, each class may also serve a more specific catalytic 
function. If this were so, these findings may assist in explaining such functional 
differences since the demands in terms of xenobiotic metabolism made on the 
body may be expected to vary from tissue to tissue. The data presented 
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here strengthen the hypothesis that inter-individual and inter-organ variations in 
the GSH S-T may explain individual susceptibility to drug toxicity and to 
chemical carcinogenesis and mutagenesis. 
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CHAPTER6 
IMMUNOIDSTOLOGICAL LOCALIZATION OF THE BASIC. NEAR-
NEUTRAL AND ACIDIC GSH S-T IN HUMAN TISSUES 
6.1 INTRODUCTION 
The presence of the basic, near-neutral and acidic GSH S-T in a wide 
variety of organs has been demonstrated utilizing the technique of radial 
immunodiffusion (see Chapter 5). These results, which are in agreement with 
the semi-quantitative studies of earlier workers (Board et al, 1981a; Hussey et al, 
1986b), demonstrate wide inter-organ and inter-individual variation. 
Initial studies by workers using immunofluorescence demonstrated the 
widespread distribution of ligandin (basic GSH S-T) in rat liver and its presence 
in particular cells of the kidney, small intestinal mucosa (Fleischner et al, 1977) 
and in the rat gonads (Bannikov and Tchipyseva, 1979). In 1980, Campbell et al, 
using the indirect immunoperoxidase sandwich method (PAP) and an antibody 
to ligandin, described the localization of ligandin in a variety of tissues. However 
little work has focused on the distribution and cellular localization of all 3 classes 
of GSH S-T in different tissues, apart from a very recent publication by Hayes et 
al (1987) which was limited to the liver. Apart from the obvious physiologic 
implications which would follow the accurate description of the cellular 
distribution of the 3 classes of transferases, there is also the possibility that they 
may act as markers in neoplastic or preneoplastic lesions (see Section 2.4.1; 2.10). 
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6.2 MATERIALS AND METHODS 
6.2.1 Chemicals 
All chemicals used were of the highest grade available. 
6.2.2 Human Tissues 
In this study, surgical biopsy material was used almost exclusively, as 
post mortem material yielded variable results which were difficult to interpret. 
All tissue was, on removal, immediately fJXed in buffered formalin and after 
processing, embedded in paraffin wax. 
6.2.3 Antibodies 
The basic, near-neutral and acidic GSH S-T were purified from liver 
and lung as described in Chapter 3 (Sections 3.2.3 and 3.2.4). Polyclonal 
antibodies to these GSH S-T were raised in rabbits as previously described (see 
Chapter 3, Section 2.5.5). Immunodiffusion and "Western Blotting" confirmed 
the specificity and lack of cross-reactivity of these three antibodies. 
6.2.4 Immunohistological Localization 
The indirect peroxidase anti-peroxidase (PAP) method used was 
essentially that of Taylor (1976), with a few minor modifications (see Appendix B 
method IIIH). This highly sensitive method involves 3 successive 
antibody-antigen reactions. The first antibody (made in rabbit) selectively binds 
to the antigen in the tissue (see Fig. 6.1 step 1). The second antibody (swine 
STEP 1 
STEP 2 
tissue antigen X 




STEP 311------- }-o 
~Q Q PO - rabbit anti - PO 
~ b--< complex 
Fig. 6.1 Schematic representation of the Peroxidase-antiperoxidase (PAP) immune 
complex method. 
Step 1 diluted rabbit antiserum specific to constituent X. 
Step 2 excess of antiserum to IgG of rabbit produced in swine. 
Step 3 PAP 
Step 4 localization of PAP using 3.3' -diaminobenzidine 
tetrahydrochloride (not shown). 
(Adapted from Sternberger, 1974). 
102 
anti-rabbit IgG) binds to the rabbit IgG from the first step (Fig. 6.1 step 2), and, 
due to the bivalency of IgG, can also bind to the rabbit IgG in the third reaction 
mixture, viz. rabbit anti-peroxidase linked to peroxidase (PAP) (Fig. 6.1 step 3). 
Bound peroxidase is then reacted with the substrates hydrogen peroxide and 
3.3' -diaminobenzidine tetrahydrochloride, resulting in a brown colour which can 
be localized microscopically (not shown in Figure). 
Non-immune control serum was obtained from non-immunized 
rabbits. Further controls used to test for any non-specific reaction included: 
a) Phosphate buffered saline (PBS) substituted for each antibody or 
PAP (one at a time). 
b) specific antiserum absorbed out with its specific antigen prior to use 
(see Appendix B, method IIIH). 
The 3 antisera were each used at a dilution of 1/500 in a 48 h 
incubation at 4°C. All subsequent incubations were at room temperature. 
6.3 RESULTS 
Immunohistochemical staining was not demonstrable when sections 
were exposed to normal rabbit serum or to any of the controls listed above (see 
Fig. 6.2 A - C) . 
The basic GSH S-T were shown to be present in all specimens of liver, 
kidney, adrenal, testis, ovary, pancreas, gastro-intestinal tract, salivary gland and 
skin. Apart from the stomach, colon and salivary gland, the near-neutral GSH 
S-T were present in the above organs in certain individuals, and absent in 
others. The acidic GSH S-T were present in all organs examined. 
Fig. 6.2 PAP-staining of pancreas with: (A) non-immune control rabbit serum; 
(B) absorbed-out antiserum to acidic lung GSH S-T (C) antiserum to 





The cytoplasm and nuclei of normal hepatocytes from all wedge and 
needle biopsies, stained strongly for the basic GSH S-T, less strongly (when 
present) for the near-neutral GSH S-T and negatively for the acidic GSH S-T 
(see Fig. 6.3 A - C). In contrast to the other two classes of GSH S-T, the 
antibody to the acidic GSH S-T showed a moderately strong reaction in the large 
and medium-sized bile ducts. In addition, positive staining was found in many 
smaller ductules, some of them within the lobule (Fig. 6.3 C). 
The antisera to the 3 classes of transferases also reacted differently 
with a variety of neoplasms. A specimen of liver, containing a metastatic deposit 
from an adenocarcinoma of the pancreas, when examined with antibody to the 
basic transferases, revealed strong staining of the normal hepatocytes and no 
staining in the carcinoma. Staining for the near-neutral GSH S-T was weak to 
moderate in both tissues. However, in complete contrast to the basic GSH S-T, 
the antibody to the acidic GSH S-T stained the carcinoma strongly but left the 
hepatocytes unstained. In another hepatic metastasis, involving a granulosa 
theca cell tumour of the ovary, the non-malignant cells stained positively for the 
basic GSH S-T with weak staining in some of the granulosa cells of the tumour 
(Fig. 6.4 A). The antibody to near-neutral GSH S-T stained the non-malignant 
liver cells moderately strongly (Fig. 6.4 B), whereas the antibody to the acidic 
GSH S-T failed to stain all elements apart from the bile ducts (Fig. 6.4 C). In 3 
cases of primary hepatocellular carcinoma, positive staining for the basic GSH 
S-T varied from moderate to strong in well differentiated areas in 2 of the 
tumours and weak to moderate in the third. In all 3 cases normal liver cells 
stained strongly with this antibody. The antibody to the near-neutral GSH S-T 
failed to produce any staining of the tumours although there was weak to 
Fig. 6.3 PAP-staining of liver with antiserum to: (A) basic liver GSH S-T; (B) 
near-neutral liver GSH S-T; and (C) acidic lung GSH S-T. The arrow in 
Fig. C indicates a small ductule. Magnification A - C, X 150. 
C 
Fig. 6.4 PAP-staining of liver showing a metastatic deposit from a granulosa theca 
cell tumour of the ovary, with antiserum to: (A) basic liver GSH S-T; (B) 
near-neutral liver GSH S-T and (C) acidic lung GSH S-T. Magnification 





moderate staining of the surrounding tissue in one case. Antibody to the acidic 
GSH S-T stained the large and the small bile ducts in both liver, and where 
present, in tumour. In one case positive staining of the centrally placed and 
degenerate tumour cells was found. 
In a single case of focal nodular hyperplasia, antibody to the basic 
GSH S-T stained the normal liver cells strongly and the neoplasm to a moderate 
degree. Weak staining of a few cells under the capsule and around the edges 
with the near-neutral antibody was suggestive of a negative result. Antibodies to 
the acidic GSH S-T failed to stain the trabecular structures. 
In a single case of bile duct carcinoma strong staining was observed 
with antibody to the acidic GSH S-T. Staining for the basic and near-neutral 
GSH S-T was not observed. 
Renal Tissues 
In the normal kidney, the antibody to the basic GSH S-T stained the 
proximal convoluted tubules and thick Henle's loops strongly, leaving the 
collecting tubules and calyceal epithelium negative. These findings are similar to 
those of Campbell et al, 1980. When present, the near-neutral GSH S-T stained 
weakly and were usually confined to the calyceal epithelium and the distal 
convoluted tubules. The antibody to the acidic GSH S-T, which yielded a more 
diffuse and less intense tubular staining than the basic GSH S-T, tended to select 
the distal convoluted tubule and stained the collecting tubules and the calyceal 
epithelium strongly. One clear cell renal carcinoma reacted strongly with 
antibodies to both acidic and basic GSH S-T but showed essentially negative 
staining with the near-neutral GSH S-T (Fig. 6.5 A - C). A papillary carcinoma 
of the kidney showed variable, moderate to strong staining for the basic 
Fig. 6.5 PAP-staining of clear-cell renal carcinoma with antiserum to: (A) basic 
liver GSH S-T; (B) near-neutral liver GSH S-T; and (C) acidic lung GSH 





GSH S-T, negative staining for the near-neutral GSH S-T and strong staining 
with the acidic antibody. 
Endocrine Tissues 
Adrenal 
The deep reticular layers of the adrenal gland stained selectively and 
strongly for the basic GSH S-T. When present, near-neutral GSH S-T were 
detected in small amounts in the deep reticular and vacuolated vesicular layers. 
A compressed normal adrenal gave a moderate reaction with the near-neutral 
antibody and 1 adenoma showed weak to moderate staining. Staining for the 
acidic GSH S-T was more diffuse and weaker than the basic GSH S-T and 
occasional weak staining of the medullary cells occurred. Staining in the 2 
adrenal carcinomas studied was moderate to strong, weak to moderate, and 
weak, for the basic, the near-neutral and acidic GSH S-T, respectively. In the 2 
phaecochromocytomas studied there was moderate staining limited to the acidic 
GSHS-T. 
Testis. 
In the interstitial cells of the testis a strong positive reaction occurred 
for both basic and acidic GSH S-T. When present, weak to moderate staining 
for the near-neutral GSH S-T was found in the germinal tubules and the 
interstitial cells. A strong positive reaction in the epididymis was limited to the 
acidic GSH S-T. Fig. 6.6 A - C shows staining of the epididymis with the 3 
antibodies. 
Weak staining, limited to the acidic GSH S-T, was present in the single 
Fig. 6.6 PAP-staining of epididymis with antiserum to: (A) basic liver GSH S-T; 
(B) near-neutral liver GSH S-T and (C) acidic lung GSH S-T. 
Magnification A - C, X 400. 
C 
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embryonal carcinoma of the testis and in the only seminoma of the testis studied. 
Antibody to the basic GSH S-T stained the luteinized cells strongly, 
whereas the reaction in the Graafian follicle was variable depending on the stage 
of development. One of the 4 cases examined with the near-neutral antibody 
gave a weak positive reaction in the old fibrocytic stroma and in a few vessels. 
The luteinized cells, the walls of the arterioles and capillaries, stained strongly 
for the acidic GSH S-T, whereas the mature Graafian follicles were negative. 
Primitive follicles stained weakly and the old fibrocytic stroma gave a strong 
result. 
Placenta 
No positive staining with the basic and near-neutral antibodies was 
recorded (Fig. 6.7 A - B). In agreement with the findings of Shiratori et al 
· (1987), early placental cytotrophoblasts stained strongly with the antibody to the 
acidic GSH S-T, whereas syncytiotrophoblasts were unstained (Fig. 6.7 C). 
Fallopian Tubes 
Using the basic and near-neutral antibodies, negative results were 
recorded for all sections examined. In a tubal pregnancy, the fallopian tube 
epithelium stained strongly with the antibody to the acidic GSH S-T. Fallopian 
tubes removed during sterilization showed moderate positive staining of the 
epithelium. 
Fig. 6.7 PAP-staining of placenta with antiserum to: (A) basic liver GSH S-T; (~) 
near-neutral liver GSH S-T; and (C) acidic lung GSH S-T. Magnification 





In single cases of carcinoma in situ of the cervix, grades II and III, both 
specimens reacted weakly to moderately with antibody to the basic GSH S-T, 
whereas staining in the case of the squamous carcinoma with this antibody was 
moderate. The reaction with the near-neutral antibody varied from negative in 
carcinoma in situ of the cervix grade II, through weak in carcinoma in situ of the 
cervix in situ grade III, to moderate in the squamous carcinoma. In all 3 cases a 
strong positive reaction was recorded with the acidic antibody. Fig. 6.8 A-C 
shows the staining of a squamous carcinoma with the 3 antibodies. 
Thyroid 
In the single case of thyroid tissue examined from a patient with 
medullary carcinoma of the thyroid, moderate to strong positive staining in 
normal thyroid vesicles was limited to the acidic GSH S-T. Antibody to this 
protein stained both the cytoplasm and nuclei of many vesicular cells moderately 
to strongly. 
Pancreas 
In the pancreas, antibody to the basic GSH S-T stained ducts consistently and 
acini varingly, with the centroacinar system probably stained in areas. The 
antibody to the near-neutral GSH S-T gave essentially negative results apart 
from diffuse positive staining in compressed tissue around a cyst. Staining for 
the acidic GSH S-T outlined the centroacinar and ductular structures and left 
the acini and islets unstained (see Fig. 6.9 A - C). 
Fig. 6.8 PAP-staining of squamous carcinoma of the cervix with antiserum to: (A) 
basic liver GSH S-T; (B) near-neutral liver GSH S-T; and (C) acidic lung 




Fig. 6.9 PAP-staining of pancreas with antibody to: (A) basic liver GSH S-T; (B) 
near-neutral liver GSH S-T; and (C) acidic lung GSH S-T. Magnification 






In an irradiated salivary gland, basic GSH S-T staining was weak or 
negative in the striated, large and intercalated ducts and negative in the acini, 
whereas in 2 cases of chronic sialadenitis, basic staining was weak and limited to 
the intercalated ducts. The near-neutral GSH S-T were not detected in the 3 
cases studied. With the acidic GSH S-T there was clear staining of ductular cells 
as in the pancreas. Once again the large striated ducts stained strongly. This 
was in contrast to the acini which were usually unstained. The intercalated ducts 
gave a variable, usually weak, response. Fig. 6.10 A - C shows the staining of an 
irradiated salivary gland with the 3 antibodies. 
Gastro-intestinal Tract 
In the 2 cases examined, the small intestinal epithelium stained with 
antibodies to both basic and acidic GSH S-T, but was negative with antibodies to 
the near-neutral GSH S-T. In the 2 stomachs examined, the oxyntic cells stained 
strongly with antibody to the basic GSH S-T and negatively for the near-neutral 
GSH S-T. The staining for the acidic GSH S-T tended to concentrate in the 
mucosal cells. As described previously (Kodate et al, 1986), staining in the 
normal colon, where present, was weak and limited to the acidic antibody. 
In the 2 gastric carcinomas examined, staining was moderate, weak and 
strong, for the basic, near-neutral and the acidic GSH S-T respectively, while 
carcinoma in situ and intestinal metaplasia stained moderately and strongly with 
the antibody to the basic and acidic GSH S-T respectively. A weak result was 
recorded for the near-neutral GSH S-T in carcinoma in situ and a negative result 
in the intestinal metaplasia. Weak to moderate staining, limited to the acidic 
Fig. 6.10 PAP-staining of irradiated salivary gland with antibody to: (A) basic liver 
GSH S-T (B) near-neutral liver GSH S-T and (C) acidic lung GSH S-T. 
Magnification A - C, X 150. 
A 
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GSH S-T, was found in a Leiomyoblastoma. 
Staining for 3 carcinomas of the colon was essentially negative for both 
the basic and near-neutral GSH S-T. Reaction with the acidic antibody varied 
from weak to strong. 
Weak staining of the hair shaft and strong staining of fibrous tissue 
occurred with antibody to the basic GSH S-T. When a benign intradermal 
naevus was present, a weak or negative result was recorded with this antibody. 
The antibody to the near-neutral GSH S-T stained the hair shafts moderately 
and the epidermis weakly. Staining of the cytoplasm and nuclei in the benign 
intradermal naevus varied from weak to strong. A variable weak reaction for the 
sweat glands was recorded and some vessels showed a positive reaction in the 
muscle coat. The antibody to the acidic GSH S-T stained the hairshafts, sweat 
glands and the media of some vessels strongly, whereas epidermal staining was 
weak to moderate. As with the near-neutral antibody, nuclei and cytoplasm 
stained strongly in the benign intradermal naevus. In the single case of malignant 
melanoma examined, staining was moderate and variable with the antibody to the 
acidic GSH S-T. The results recorded with the other 2 antibodies were 
essentially negative (in agreement with the immunodiffusion studies of 
Mannervik et al, 1987). 
In a single post mortem case the basic antibody failed to stain any structures, 
whereas both the near-neutral and acidic antibodies gave moderate reactions 
with glial cells and small vessels. The neurones remained unstained with all 3 
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antibodies. Normal choroid plexus was not available for examination. A choroid 
plexus papilloma gave essentially negative results with the basic and near-neutral 
antibodies, but positive staining was recorded in the cell cytoplasm and the 
plasma membrane with antibody to the acidic GSH S-T. 
A spleen from a patient with myeloid leukemia who had received 
treatment with cytotoxic agents showed negative staining for the basic GSH S-T 
and weak/moderate staining of the littoral cells of the red pulp, and the 
lymphocytic cells in the white pulp with both the near-neutral and acidic 
antibodies. 
Miscellaneous 
A carcinoma of the breast stained strongly for the basic GSH S-T, 
negatively for the near-neutral GSH S-T and moderately for the acidic GSH S-T. 
A carcinoma of the bladder gave a negative result for the basic GSH 
S-T, whereas staining was strong for the near-neutral GSH S-T and weak for the 
acidic GSH S-T. 
Squamous carcinoma of the tongue which had metastasized to a lymph 
node, stained weak/moderately with the antibody to the basic GSH S-T, whereas 
staining for the near-neutral and acidic GSH S-T was diffuse and strong. 
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6.4 DISCUSSION 
In this study antibodies to the 3 classes of GSH S-T have been 
employed to localize the GSH S-T at the light microscopic level, using the 
indirect peroxidase anti-peroxidase staining technique, and has demonstrated 
their presence in a variety of normal and abnormal tissues. 
In tissues such as liver, kidney, pancreas and salivary gland the acidic 
GSH S-T appear to occur in relative abundance in various ductular structures as 
opposed to parenchymal cells. This finding may be of use in identifying ductular 
structures in conditions affecting these tissues. 
The lack of positive staining for the basic GSH S-T in organs such as 
brain, colon and thyroid, where their presence has previously been described 
(see Chapter 5), may be due to the low levels of these GSH S-T or in the case of 
the brain, to post mortem autolysis. 
The absence of the near-neutral GSH S-T in certain specimens of 
tissue, and their presence in other specimens of the same tissue, confirms the 
results obtained in Chapter 5 and the suggestions of earlier workers (Board et al, 
1981a, Warholm et al, 1980) that a proportion of the population fails to express 
this form. The inability to demonstrate the presence of the near-neutral GSH 
S-T in the salivary gland, colon and stomach, may well be due to the small 
number of specimens studied. 
The presence of the near-neutral GSH S-T in tumour tissue has 
previously been shown immunohistologically only in the liver and cervix (Hayes 
et al, 1987; Shiratori et al, 1987). In addition to these tissues, the results above 
demonstrate their presence in carcinoma of the bladder, adrenal, stomach, and 
metastatic squamous carcinoma. Further studies to increase the numbers of the 
tumours studied may well reveal the presence of this class of GSH S-T in some 
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of the other tumours studied. 
In conclusion, the 3 classes of GSH S-T have been localized 
immunohistologically in formalin fixed, paraffin wax embedded human tissue in a 
variety of organs and tumours. This information, when coupled to the 
quantitative information provided may allow new insight into the functions of 
these enzymes. The strong expression of an acidic form(s) in a number of 
tumours e.g. bile duct carcinoma; papillary carcinoma of the kidney; all 
carcinomas of the cervix studied and adenocarcinoma of the pancreas metastatic 
to the liver, and its weak expression in others e.g. adrenal carcinoma and 
carcinoma of the bladder, has been demonstrated. The strong expression of the 
basic e.g. carcinoma of the breast and near-neutral forms e.g. carcinoma of the 
bladder was occasionally demonstrated. 
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Chapter? 
PRODUCTION OF A MONOCLONAL ANTIBODY 
TO THE ACIDIC LUNG TRANSFERASE 
7.1 INTRODUCTION 
Prior to 1975, the antibodies available to researchers were made in a 
variety of animals, and were all polyclonal. However, since the potential of 
hybridoma technology was expanded by Kohler and Milstein (1975), monoclonal 
antibodies produced in mice, rats or man, have become increasingly important 
tools for research. In comparison to conventional polyclonal antibodies, the 
production of a monoclonal antibody may be very time and money consuming. 
However, when comparing the characteristics and applications of the two 
antibodies, the monoclonal antibody has several advantages. During the initial 
animal immunization period, polyclonal antibody requires the innoculation of far 
greater amounts of antigen than for monoclonal antibodies, and the antigen must 
be of greater purity. Another advantage is that once a suitable clone of 
antibody-secreting cells has been selected, it can be stored in liquid N2 and 
regrown when additional antibody is required, whereas animals are mortal, and 
the supply of polyclonal antiserum is therefore limited. Antibody affinity varies 
considerably from bleed to bleed with conventional antibody, whereas with the 
monoclonal antibody, affinity can be selected for during the cloning technique. 
The concentration of the specific and required antibody in serum from 
innoculated animals is low, while ascitic fluid from innoculated mice contains a 
high titre of specific antibody and serum-free harvest fluid from cultured 
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hybridoma cells contains only specific antibody (Campbell, 1984). Of great 
importance is that polyclonal antibodies may give extensive cross-reactivity, 
which is generally a disadvantage. The monoclonal antibody is normally selected 
for its ability to bind to a determinant unique to one antigen. This high 
specificity reduces non-specific background cross-reactivity, so that in techniques 
such as immunohistology, localization of distinct antigens may be much 
improved. Quantitative techniques such as radioimmunoassay (RIA) and 
enzyme-linked immunoassay (ELISA) require a high affinity antibody, which can 
be selected for during the monoclonal antibody production. However, one must 
be aware that these antibodies also have several disadvantages, e.g. they are 
more expensive to produce and cross-reaction problems may occur. The 
determinant may be present on other molecules not tested in the screening 
procedure e.g. as with two proteins which have the same prosthetic group or 
when the antibody reacts with two totally different determinants (Campbell, 
1984). In addition, a monoclonal antibody cannot be used in a clinical 
radioimmunoassay of a protein which exhibits polymorphism in the population 
unless it is ascertained that the antibody is directed against an invariant 
determinant (Campbell, 1984). 
In this study difficulty was experienced initially in obtaining a specific 
polyclonal antibody to the acidic lung transferase, and thus the production of a 
monoclonal antibody seemed prudent. 
7.2 MATERIALS AND METHODS 
7.2.1 Chemicals 
All chemicals used were of the highest grade available. 
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7.2.2 Antibody production 
A monoclonal antibody to the human acidic lung transferase was 
raised according to the standard procedure of Kohler and Milstein (1975). 
Cells from the spleen of an immunized Balb/c mouse were fused with 
myeloma SP2f0Ag14 cells using polyethylene glycol. Antibody producing cells 
(screened by an ELISA) were cloned twice and then innoculated into a Balb/c 
mouse for ascites production (for details see Appendix B method XVI). 
7.2.3 Mouse lg lsotyping using an Enzyme-linked Immunosorbent Assay 
(ELISA) 
Harvest fluid from clone 49/21/')9 was employed for mouse lg 
isotyping using an Elisa as described in Appendix B method XVIII. 
7.2.4 Antibody specificity 
lgG from the ascitic fluid obtained after injecting passaged cells ( ex 
clone 99) into pristane primed mice was extracted by precipitation with an equal 
volume of 70% saturated ammonium sulphate (see Appendix B method IIIF). 
The precipitate was resuspended in PBS in a volume equal to the original volume 
of ascites. After dialysis against 4 x 5 litres of PBS the lgG was stored at -70°C. 
Western blotting as described in Appendix B method IIID was 
utilized to examine the specificity of the monoclonal antibody produced. The 
IgG extracted was tested against the acidic and basic lung, the near-neutral and 
basic liver GSH S-T (purified as described in sections 3.2.3 and 3.2.4). As a 
nonspecific control, lgG extracted from ascitic fluid containing antibody to 
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human serum angiotensin converting enzyme, was utilized. 
7.3 RESULTS 
7.3.1 Mouse lg isotyping using an ELISA 
The harvest fluid from clone 49/21J99 was tested against the isotyping 
sera lgA, IgM, IgGl, IgG2a, IgG2b and IgG3 and a positive result was obtained 
with the anti-IgG2b serum. 
7.3.2 Antibody specificity 
Western blotting (see Fig. 7.1) demonstrated reactivity of the 
monoclonal antibody with the acidic lung transferase. No cross-reactivity with 
the basic and near-neutral liver enzymes was shown. The non-specific control 
IgG did not react with any of the transferases. 
7.4 DISCUSSION 
A monoclonal antibody specific for an acidic GSH S-T has been 
produced using purified human acidic lung GSH S-T as antigen. The antibody is 
of the immunoglobulin IgG class and is of type 2b. It has been well documented 
that IgG2 subclasses will bind to protein A ( derived from Staphylococcus 
aureus) (Barret, 1983). This will allow for ready purification of antibody and 
further purification of the antigen. 
Shortly after the production of this antibody a specific polyclonal 
Fig. 7.1 
A. 
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(A) SDS-polyacrylamide gradient gel (7.5% - 17.5%) showing in lane 1, acidic 
lung GSH S-T lane 2, near-neutral GSH S-T; lane 3, basic liver GSH S-T, 
and lane 4, basic lung GSH S-T. 
(B) "Western blot" of the polyacrylamide gel shown in A incubated with IgG 
from control ascitic fluid. 
(C) "Western blot" of the polyacrylamide gel shown in A incubated with 
anti-human acidic GSH S-T monoclonal antibody (purified IgG). 
.. 
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antibody to the acidic lung transferase was successfully raised in a rabbit. In 
order to provide comparative data of the tissue distribution of the acidic, 
near-neutral and basic transferases, it was decided to use polyclonal antibodies 
and radial immunodiffusion for all three enzymes. Therefore the monoclonal 
antibody was not used in this study. However, the antibody is currently being 
used for affinity chromatography which is facilitating the preparation of large 
quantities of the acidic transferase from a mixture of proteins. The antibody is 
also being used to develop an ELISA for measuring the concentration of the 
human lung acidic GSH S-T. 
118 
Chapter 8 
CONCLUDING DISCUSSION AND DIRECTIONS FOR FUTURE RESEARCH 
While research on the GSH S-T in the rat has reached an advanced 
stage, much of the data available for the rat GSH S-T was not available for the 
human forms of these enzymes. Since species differences are known to occur in 
this enzyme system it was considered important to attempt to provide data 
concerning the tissue concentration and distribution of the 3 classes of GSH S -T 
mman. 
A prerequisite for these studies was a homogeneous preparation of the 
protein in a well preserved state. Thus the purification of representatives of the 
3 classes of GSH S-T was undertaken. The human basic and near-neutral GSH 
S-T were purified from human liver by a combination of affinity chromatography, 
chromatofocusing and immunoaffinity chromatography. For purification of lung 
acidic and basic GSH S-T, ion exchange was used following the affinity 
chromatography step. The purified enzymes had similar physicochemical and 
immunological characteristics to the enzymes described by other workers, 
although some differences in specific activity and kinetic parameters were 
observed. 
Apart from differences in their affinity for various substrates the acidic 
GSH S-T was found to differ from the basic and near-neutral GSH S-T in that 
the catalytic activity was markedly decreased after incubation with the synthetic 
substrates CDNB and ethacrynic acid. 
The finding that CDNB caused a strikingly effective apparently 
irreversible inactivation of the acidic lung transferase led to an examination of 
the mechanism of this reaction. This study has shown that while CD NB binds 
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covalently to all 3 classes of GSH S-T, only the acidic lung transferase is rapidly 
inactivated in the absence of the co-substrate GSH. The time-dependent 
inactivation is pseudo-first order and demonstrates saturation kinetics suggesting 
that inactivation occurs from an EI complex. The enzyme was protected against 
CDNB inactivation by GSH. Incubation with [14C]-CDNB indicated covalent 
binding to all 3 classes of transferase. One peptide fraction was found to be 
radiolabelled in both the basic and the acidic transferases when they were 
incubated with [14C]-CDNB and GSH, cleaved with cyanogen bromide, and 
chromatographed by HPLC. Incubation in the absence of GSH yielded 1 and 2 
additional peptide fractions for the basic and the acidic GSH S-T, respectively. 
The results suggest that while CDNB arylates all 3 classes of human GSH S-T, 
only the acidic GSH S-T posesses a specific GSH-sensitive CDNB binding site, 
binding to which leads to time-dependent inactivation. It would be of interest if 
the exact amino acid residue(s) to which the CDNB is binding in each of these 
transferases could be determined. The finding that CDNB binding to the acidic 
GSH S-T differs from that of the basic GSH S-T may provide a model which 
could be used to determine the parts of the molecule to which CDNB and GSH 
bind. As electrophilic challenge (Sugiyama and Kaplowitz, 1984) may cause 
GSH levels to be depleted, it is possible that this susceptibility of the acidic GSH 
S-T to irreversible inactivation may have important physiological and 
pathological implications. 
The second part of this thesis provides data concerning the distribution 
of the 3 classes of GSH S-T in man. Antibodies to representatives of these 3 
classes of GSH S-T were raised in rabbits and radial immunodiffusion employed 
to measure the concentration of the various groups of GSH S-T in 9 individuals. 
These data confirm the presence of inter-organ and inter-individual variation 
suggested by earlier studies (Warholm et al, 1980, Board et al, 1981a, Sherman et 
al, 1983b). The absence of the near-neutral GSH S-T in all tissues of 5 
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of the 9 individuals confirms the suggestion of Board et al (1981a), of a "null" 
allele for this enzyme. The basic and near-neutral GSH S-T, when present, were 
demonstrated in all the tissues studied. Marked differences in the distribution of 
the 3 classes were found as demonstrated in the liver, which had the highest 
concentration of basic and near-neutral GSH S-T but the lowest concentration of 
the acidic GSH S-T. The acidic GSH S-T showed the least inter-organ 
variation. The possibility exists that the marked inter-individual and inter-organ 
variation demonstrated in this study may explain individual and organ 
susceptibility to drugs, carcinogens and toxins. 
The tissue distribution of each class of transferases has also been 
studied immunohistologically. Differences in distribution at a cellular level have 
been identified. In addition, the presence of various forms of GSH S-T in 
tumour tissue may be of interest to those studying the development of such 
lesions. 
The monoclonal antibody to the acidic GSH S-T described in this study 
is currently being used to develop an ELISA, which will be used in the 
measurement of this GSH S-T in the serum of patients with various diseases. 
It is hoped that this study may stimulate further interest in this field and 





MATERIALS AND SUPPLIERS 
Unless otherwise stated all reagents used were of analytical grade. 
Aldrich Chemical Company, Milwaukee, U.S.A. 
3,4-Dichloronitrobenzene and trans-4-phenyl-3-buten-2-one. 
Amersham International £le, Buckinghamshire, U.K. 
l-Chloro-2,4-dinitro[U-1 C]benzene. 
Amicon Ireland Ltd, Limerick, Ireland. 
Diaflo ultrafiltration membranes (PMlO). 
Bayer-Miles (Pty) Ltd., Isando, SA. 
Bovine serum albumin (Fraction V), Human serum albumin, Immuno-
globulin Isotyping antisera and Aprotinin. 
Becton Dickinson and Co, Oxnard, California, U.SA. 
Falcon Micro Test flexible assay plates. 
Bio-Rad Laboratories, D 8000, Munchen, West Germany. 
Bio-Rad dye reagent concentrate, Affi-Gel 10. 
BDH Chemicals Ltd, Poole, England. 
Acetic acid, Acrylamide, Ammonium persulphate, Ammonium sulphate, 
Barbitone sodium, bromophenol blue, 3.3'di-aminobenzidine tetrahydro-
chloride, DPX mountant, Ethanol, Ethanolamine, Glutathione reduced, 
Glycerol, Haematoxylin, Imidazole (general purpose reagent), Methanol, 
Sodium azide, Sodium hydrogen carbonate, Sodium hydroxide, 
Tris(hydroxymethyl) methylamine,Trypan Blue, Nicotinamide-adenine 
dinucleotide phosphate (reduced) sodium salt (NADPH), NN'Methylene-
bisacrylamide (laboratory reagent), NNN'N'-Tetramethylethylene (Temed) 
and Xylol. 
Cooper Biomedical, Inc., West Chester, P.A., U.SA. 
Cappel peroxidase conjugated IgG fraction goat anti-rabbit (heavy and light 
chain specific). 
Dako-Immunoglobulins, 22 Guldborgveg, DK-2000, Copenhagen F. Den-
mark. 
PAP complex and swine anti-rabbit IgG. 
Difeo Laboratories, Detroit, Michigan, U .SA. 
Agar Noble, Complete Freund's adjuvant and Incomplete Freund's 
adjuvant. 
E.I. du Pont de Nemours and Co. Inc., Wilmington, Delaware, U.SA. 
Photra graphics arts film (C-41). 
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Fluka AG., Buchs, Switzerland. 
Cumene hydroperoxide (70% in cumene). 
Gibco Ltd., Paisley, Scotland. 
Aminopterin, Foetal calf serum, Hypoxanthine, Penicillin, RPMI 1640 tissue 
culture medium, Streptomycin and Thymidine. 
Hopkins and Williams, Chadwell, Essex, U .K. 
Barbitone (general purpose reagent). 
May and Baker Ltd, Dagenham, U .K. 
Trichloacetic acid. 
Merck, Darmstadt, Germany. 
Amido black, 4-Chloro-1-naphthol, Dimethylsulphoxide, disodium 
hydrogen phosphate, Ethylenediaminetetra-acetic acid disodium salt, 
Guanidine hydrochloride, Hydriodic acid (55% HI), 1-lodohexane, 
Polyethylene glycol 4000, Potassium chloride, Potassium hydroxide, Sodium 
carbonate, Sodium chloride, Sodium dodecyl sulphate, Sodium dihydrogen 
phosphate, Sodium hydrogen carbonate and Tween 20. 
Millipore Corporation, Bedford, MA, U.SA. 
0.45um Millex HA filter unit. 
Nunc, D.K. 4000, Roskilde, Denmark. 
96 Well Microwell plates (flat bottomed) and 24 Well Multidishes. 
Packard Instrument Co. Inc., Downers Grove, Illinois U.SA. 
Insta-gel, Soluene 350 tissue solubilizer, scintillation vials with plastic insets 
in tops. 
Pharmacia Fine Chemicals, Uppsala, Sweden. 
Epoxy-activated Sepharose 6B, PBE 94 polybuffer exchanger, polybuffer 96 
and Sephadex G-75. 
Schleicher and Schuell D-3354, Dassel, W. Germany. 
Membrane filters, 0.45)1Dl (nitrocellulose paper). 
Spectrum Medical Industries, Inc., Los Angeles, U.S.A. 
Spectraphor membrane tubing molecular weight cut off 12 000 - 14 000 
daltons. 
Sigma Chemical Co., St.Louis, Missouri, U.S.A. 
2,2'-Azinobis(3-ethylbenzthiazoline-sulfonic acid) Diammonium salt, 
1-Chloro- 2,4-dinitrobenzene, Coomassie Brilliant blue R, Dithiothreitol, 
Dithioerythritol, Ethacrynic acid, Glutathione reductase Type 111 from 
Bakers Yeast, 2-Mercapto ethanol, S-methylglutathione, Phenylmethyl-
sulfonyl fluoride and Pristane. 
Whatman Ltd, Maidstone, Kent, U .K. 
Filter paper no.1. 
Zymed Lab. Inc., San Francisco, U.SA. 
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I Sodium Dodecylsulphate Polyacrylamide Gel Electrophoresis 
ref. Laemmli (1970). 
Apparatus 
a) Hoefer Scientific Instruments S.E. 600 vertical slab gel electrophoresis 
unit 
b) Hoefer Scientific Instruments PS 1200 DC power supply. 
A 3.6% stacking gel in 0.125 M Tris/HCl, pH 6.8 and a 7.5% - 17.5% linear 
acrylamide gradient gel in 0.35 M Tris/HCl pH 8.8 are used. 
17.5% resolving solution 
To a 20 ml measuring cylinder add: 
a) 7 ml "High" buffer (1 M Tris/HCI, pH 8.8/30% glycerol) 
b) 12 ml of A-Bis-A solution (30% acrylamide/0.8% bisacrylamide) 
c) 0.3 ml 10% SDS 
d) Make up to 20 ml with H20 and mix well. 
7.5% resolving solution 
To a 20 ml measuring cylinder add: 
a) 7 ml of "Low'' buffer (1 M Tris/HCl, pH 8.8n.5% glycerol) 
b) 5 ml of A-Bis-A solution 
c) 0.3 ml of 10% SDS 
d) Make up to 20 ml with water and mix well. 
Spacer solution 
To a 10 ml volumetric flask add: 
a) 1.2 ml A-Bis-A solution 
b) 8.6 ml spacer buffer (0.125 M Tris/HCl, pH 6.8) 
c) 0.1 ml 10% SDS. 
Preparation of samples 
ref. Maize! (1971). 
Boil samples for 5 min with an equal volume of 2% SDS, 0.2% 
2-mercaptoethanol, 20% glycerol and 0.002% bromophenol blue in 0.125 M 
Tris/HCI pH 6.8. 
1. To each resolving solution add 0.1 ml of freshly prepared 5% ammonium 
persulphate and 0.01 ml of TEMED immediately before use. Mix well. 
2. Pour 16 ml of the 17.5% solution into the gradient mixer. 
3. Pump the 7.5% resolving solution into the gradient mixer at half the rate at 
which the solution in the mixer is pumped into the space between the two 
glass plates mounted in the gel pouring stand. 
4. Using a syringe, introduce water on to the top of the gel. 
5. Once the gel has set add 0.1 ml of 15% ammonium persulphate (freshly 
prepared) and 0.01 ml TEMED to the spacer solution. Mix and pour onto 
top of gel. Insert sample bay comb and allow gel to set. 
6. Assemble tank on top of gel plate. 
7. Fill tank with buffer (0.025 M Tris/HCI/0.2 M glycine, pH 8.8 containing 
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0.1% SOS). 
8. Using a Hamilton syringe introduce the samples into the sample bays. 
9. Run gels at 65 volts ( constant) for 16 h or until the tracker dye has 
advanced to approximately 1 cm from the bottom of the plate. 
10. Remove gel from between the plates and stain using 0.1 % Coomassie 
Brilliant Blue R250 in 30% methanol, 10% trichloroacetic acid, with 
constant shaking for 2 h. 
11. Destain using 25% ethanol, 8% trichloacetic acid. 
12. Dry gels between Whatman 3M chromatography paper and graphics art 
film using heat and vacuum. 
Determination of molecular weight 
The molecular weights were determined by comparison with standards of 
known molecular size (Pharmacia Electrophoresis Calibration Kit) viz. 
Phosphorylase b (94 000), Bovine serum albumin (67 000), Ovalbumin (43 
000), Carbonic anhydrase (30 000), Soybean Trypsin Inhibitor (20 100) and 
alpha-Lactalbumin (14 400). 
The relative migration values (Rf) were calculated for each standard using 
the formula: 
Rf = Distance protein has migrated from origin 
Distance from origin to reference point 
The protein which had travelled the furthest was used as the reference point 
and the top of the resolving gel taken as the origin. The logs of the 
standard molecular weights were plotted against these values to obtain a 
straight line. This line was used to determine the molecular weights of the 
unknowns. 
II Amino Acid Analysis 
ref. Moore and Stein (1963). 
Preparation of hydrolysate 
1. Dialyse the protein to be analysed against 3 x 5 litres of double distilled 
deionised water. 
2. Lyophilise 0.5 mg in an acid washed ( concentrated H2S04) hydrolysis tube. 
3. Add 0.3 ml of double distilled deionised water to the hydrolysis tube 
followed by concentrated HCl to 6 M. 
4. Add 1 mg dithiothreitol. 
5. Flush the hydrolysis tube with N2, freeze using a mixture of dry ice/ethanol 
and seal tube immediately. 
6. Hydrolyse for 24 h at 110°C. 
7. Evaporate the hydrolysate to dryness using a vacuum pump and KOH trap. 
Analysis 
Analysis of the amino acids was performed on a Beckman model 12 M 
Amino Acid Analyser and the traces manually integrated. Norleucine was 
used as an internal standard. Appropriately diluted standards were run in 
the same batch as the samples and used for quantitation. 
III Immunological Techniques 
A Antiserum production 
ref. Kirsch et al (1975). 
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Antibodies to the three classes of GSH S-T were raised in New Zealand 
white rabbits. 
Procedure 
1. Emulsify 100 llg of protein in 1 ml 0.15 M NaCl, 0.05 M sodium phosphate 
buffer pH 7.4 with 1.5 ml complete Freunds adjuvant and inject 
subcutaneously into the rabbit at multiple sites. 
2. After 3 weeks give a booster injection in incomplete Freunds Adjuvant (100 
llg protein). 
3. Repeat the booster injection at 10 day intervals. 
4. At 10 day intervals after booster innoculations remove 30 ml of blood from 
ear vein of rabbit. 
5. Allow to stand at room temperature for 1 h to allow clotting. 
6. Store blood at 4°C for 2 h. 
7. Spin blood at 2 500 g for 30 min. 
8. Remove serum and store at -70°C using 0.02% sodium azide as preservative. 
Immunodiffusion (IIIB) and Western blotting (IIID) were employed to 
check the specificities of the antibodies raised. 
B Immunodiffusion 
ref. Ouchterlony (1958). 
Apparatus 
a) Horizontal platform 
b) LKB 2117 Multiphore template and punch. 
c) Spirit level. 
Procedure 
1. Dissolve 1.2 g of Agar Noble/0.1 % sodium azide in 100 ml of 0.15 M NaCl, 
0.05 M sodium phosphate buffer pH 7.4 in a conical flask, with heating and 
constant stirring to prevent boiling. 
2. Using a 10 ml pipette pour 10 ml of molten agar on to a warmed, 
ethanol-cleaned glass plate (9 cm x 8.3 cm x 1.5 mm) on a horizontal 
platform. Ensure that the entire surface of the plate is evenly covered with 
agar. 
3. Allow agar to set for 30 min. 
4. Store at 4°C until used, in a moist, airtight box to prevent drying. 
5. Using a template and punch, cut 4 mm diameter wells in a rosette. 
6. Using a Gilson pipette, place 0.01 ml of antiserum in the central well and 
0.01 ml of antigen in the peripheral wells. 
7. Keep plates in a strictly horizontal position in a moisture box at 25°C for 48 h. 
8. Wash plates in several changes of 0.9% NaCl/0.1 % sodium azide over 3 
days to remove unprecipitated protein. 
9. Wash plates in distilled water for 4 h. 
10 Stain for 2 h in 0.2% Amido Black/5% acetic acid. 
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11. Destain gel using 5% acetic acid. 
12. Place the gel on graphics art film. Cover with moist filter paper and allow 
to dry at room temperature. 
C Radial Immunodiffusion 
ref. Mancini et al (1965). 
Apparatus 
a) As in method IIIB plus 
b) Calibration viewer (Transidyne General Corporation, Kallestad Lab., 
Inc., Chaska, Minnesota, U.S.A. 
Procedure 
1. Dissolve 1.2 g Agar Noble in 100 ml 0.05% sodium azide, 0.1 M veronal 
buffer pH 8.6, by heating with constant stirring. 
2. Allow agar to cool to 50°C. 
3. Place gel pouring apparatus in 50°C oven for 30 min. 
4. Add 0.1 - 0.2 ml antiserum to U ml test tube and place in oven. 
5. When molten agar has cooled to 50°C, remove gel pouring apparatus and 
antiserum from oven. 
6. Add molten agar to antiserum in tube to volume of 10 ml. Cover with 
paraftlm and mix. 
7. Pour agar onto ethanol cleaned plate (size as in method IIIB) on horizontal 
platform. Extreme care is taken to ensure that the plate is in a strictly 
horizontal position. Ensure that the whole surface of the plate is covered 
with agar. 
8. Allow agar to set for 1 h. 
9. Using the Multiphore and punch, cut wells in rows. Avoid the edges of the 
gel, thus ensuring that the thickness of the gel remains constant. 
10. Using a Gilson pipette apply 0.01 ml of standards or cytosolic supernatants 
to the wells. 
11. Keep plates in an airtight moisture box in a strictly horizontal position for 5 
days. 
Calculation of results 
ref. Raitt et al (1985). 
1. Using the calibration viewer, measure the diameter of the precipitin rings of 
both the unknowns and the standards. 
2. Plot a standard curve of ( diameter )2 versus standard concentration. 
3. Determine unknown values from standard curve. 
4. Measure the cytosol protein concentration using the method of Lowry. 
5. Express results as .ug/mg cytosolic protein. 
D Western Blotting 
ref. Towbin et al (1979). 
Principle 
This technique involves the electrophoretic transfer of protein from a 
polyacrylamide gel to a nitrocellulose sheet using the following steps. 
a) The non-specific binding sites are blocked using an excess of albumin. 
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b) The specific antibody is then bound. 
c) A second antibody directed against the first and conjugated to 
peroxidase is then used. 
d) The bound peroxidase is then reacted with its substrates 
4-chloro-1-naphthol and hydrogen peroxide which yield a black colour. 
Apparatus 
a) G.T. Series Gel Electrophoresis unit with a Transphor Power-Lid 
model TE 50 from Hoefer Scientific Instruments, San Francisco 
b) Scotch-Brite pad 
c) Wbatman chromatography paper 
d) nitrocellulose paper 
Procedure 
1. Run 3 sets of samples on an SOS Polyacrylamide gel leaving spaces 
between the sets so that the gel can be divided into 3 identical sections. 
2. Cut one set of samples of the gel and stain. Blot the remaining two thirds of 
the gel. 
3. Fill tank with transfer buffer ( 4000 ml of 0.1 % SOS, 0.025 M Tris/0.2 M 
glycine, pH 8.8 and 1000 ml methanol) and place in polystyrene container 
surrounded by ice. 
4. Soak Scotch-Brite pad, chromatography paper and nitrocellulose paper in 
tank buffer prior to making the sandwich. 
5. Make a sandwich on one half of the tank casette consisting of the 
Scotch-Brite pad, 3 layers of chromatography paper, the nitrocellulose 
paper, the polyacrylamide gel, followed by 3 further layers of 
chromatography paper. 
6. Use a roller to remove any air bubbles between the layers which may 
hamper transfer. 
7. The second half of the casette is clipped into place and the casette inserted 
into the slots of the tank such that the polyacrylamide gel is closest to the 
anode. 
8. Place lid on top of the tank in such a way that the anode faces the operator 
and allows the proteins to be transferred towards the cathode. 
9. Set the voltage to 90 volts and allow transfer to proceed for 1 h. 
10. After removing casette from tank, stain the polyacrylamide gel to ensure 
that transfer has taken place, and divide nitrocellulose paper into two 
identical pieces. 
11. Incubate the nitrocellulose paper with 1 % foetal calf serum, 0.3% Tween 20 
in 0.2 M NaCl, 0.05 M Tris/HCl pH 7.4 for 1 h (blocking buffer). Steps 
11-15 were carried out on a shaker. 
12. Incubate the one half of nitrocellulose paper with an appropriate dilution of 
antiserum in blocking buffer for 1 h ( a 1/500 dilution of all 3 antisera to the 
GSH S-T was used). The second half of paper is incubated with a similar 
dilution of normal rabbit serum in blocking buffer. This serves as a 
non-immune control. 
13. Wash the nitrocellulose paper in 0.05% Tween 20 in 0.2 M NaCl, 0.05 M 
Tris/HCl pH 7.4 (Tris buffered saline) for 30 min (6 changes). 
14. Expose the nitrocellulose paper to goat anti-rabbit immunoglobulin 
peroxidase-conjugated for 1 h (1/500 dilution in blocking buffer). 
15. Repeat step 13. 
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16. Dissolve 24 mg 4-Chloro-1-Naphthol in 8 ml methanol. Add 40 ml Tris 
buffered saline and 0.005 ml hydrogen peroxide. 
17. Immediately incubate the nitrocellulose paper in the substrate. 
18. Once the colour reaction has developed sufficiently, rinse the nitrocellulose 
paper in H20 and dry on graphics art film in the dark. 
E Dot Blotting 
ref. Hawkes et al (1982). 
The same procedure as in the Western blotting technique is followed, 
except that the protein is dotted directly onto small squares of nitrocellulose 
paper. Allow to dry at room temperature for at least 1 h before proceeding 
with blocking step. This eliminates the electrophoretic transfer on to the 
nitrocellulose paper. 
F Preparation of IgG 
ref. Hebert et al (1973). 
Procedure 
1. A volume of serum is gently stirred while an equal volume of 70% saturated 
ammonium sulphate is slowly added. 
2. Mix gently and allow to stand at room temperature for 4 h. 
3. Centrifuge at 2 500 rpm for 15 min. 
4. Resuspend the precipitate in 0.9% NaCl (adjusted to pH 8 with NaOH) to 
the original volume of the serum. 
5. Repeat this procedure twice allowing only 30 min standing time prior to 
centrifugation. 
6. The final precipitate is resuspended in a volume of 0.1 M NaHC03, pH 8.5 
equal to the original volume of serum. 
7. Dialyse against 4 x 5 litres of 0.1 M NaHC03. 
G Immunoaffinity Chromatography 
Apparatus 
Coulter mixer (Coulter Electronics Ltd, Hertfordshire, U.K.) 
Procedure 
a) Coupling of antigen to gel 
1. Wash 5 ml of Affi-Gel 10 with 3 column volumes of H20 in a 10 ml syringe 
with a sintered disc in the bottom of the barre~ followed by 3 column 
volumes of coupling buffer (0.1 M NaHC03, pH 8.5). 
2. Transfer the moist gel cake to a 50 ml test tube and combine with 7.5 ml of 
anti-human basic or near-neutral GSH S-T IgG which has been prepared 
as described previously (3F). IgG concentration of approximately 25 mg 
per ml is used. For maximum coupling ensure that the washing procedure 
is completed and the ligand combined with the gel within 20 min. 
3. Cover the top of the test tube with parafilm, ensuring that it is well sealed 
and allow to rotate on Coulter mixer, for 4 h at 4°C. 
4. To determine the efficiency of coupling, absorbance of the eluate 
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is measured at 280 run prior to and post coupling. The pH of the sample to 
be measured is lowered by dilution with 0.01 N HCl to quench succinyl 
absorbance. 
5. 0.5 ml of 1 M ethanolamine ( adjusted to pH 8.0 with HCl) is added to the 
coupling buffer to block any unreacted sites. Rotate on Coulter mixer for 1 
h. 
6. Return gel to the syringe and wash extensively with 0.1 M NaHC03, pH 8.5 
until no detectable absorbance at 280 run remains. 
7. Wash with 3 column volumes of 2 M NaC~ 0.1 M glycine, pH 2.9. 
8. Equilibrate the gel with 3 volumes of buffer. (0.01 M phosphate buffer pH 
7.5 for removal of the basic GSH S-T from the near-neutral preparation and 
0.01 M imidazole/HCl, pH 7.0 for removal of the near-neutral from the 
acidic GSH S-T preparation). 
b) Absorption procedure 
1. Combine the mixture of GSH S-T with the gel and allow to rotate on 
Coulter mixer for 4 h at 4°C. 
2. Separate the eluate from the gel by returning to a 10 ml syringe with a 
sintered disc in the bottom. 
3. The absorbed antigen is removed by washing the gel with 3 column volumes 
of 2 M NaCl, 0.1 M glycine, pH 2.9. 
4. Re-equilibrate the gel and when not in use store in the presence of 0.2% 
sodium azide. 
H lmmunohistological Localization of the GSH S-T 
ref. Taylor (1976). 
An indirect immunoperoxidase sandwich (PAP) method was used to locate 
the GSH S-T in formalin fixed, paraffin wax embedded human tissue. The 
method involves 3 successive antibody-antigen reactions. 
Procedure 
Unless otherwise stated all procedures were at room temperature. 
1. Place glass mounted paraffin wax sections in staining rack. 
2. Dewax sections in xylol for 5 min. 
3. Place slides in absolute ethanol for 1 min. 
4. Block endogenous peroxide by incubation for 30 min in 0.3% H202 in 
methanol. 
5. Wash for 30 min with gentle stirring in 0.14 M NaCl, 0.05 M phosphate 
buffer, pH 7.5 (phosphate buffered saline). 
6. Expose sections to normal swine serum (1/10 dilution in phosphate buffered 
saline) for 10 min. Drain excess swine serum from slides. 
7. Incubate sections with antiserum to the human transferase (1/500 dilution in 
phosphate buffered saline) for 48 hat 4°C. Wash as in step 5. 
8. Incubate sections with swine anti-rabbit (1/50 dilution in phosphate 
buffered saline) for 30 min. Wash as in step 5. 
9. Expose the sections to the PAP complex (1/80 dilution in phosphate 
buffered saline) for 30 min. Wash as in step 5. 
10. Add 5 mg of 3.3'di-aminobenzidine tetrahydrochloride to 10 ml phosphate 
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buffered saline. Add 0.15 ml of 1 % hydrogen peroxide. Mix and 
immediately expose sections to the substrate. Allow reaction to proceed for 
Sm.in. 
11. Wash sections in water. 
12. Counterstain sections in Mayers haematoxylin for 10 min. 
13. Blue sections in Scotts tap water for 2 min. 
14. Rinse in tap water. 
15. Dehydrate sections in graded alcohols for 30 seconds each. 
16. Clear sections in Xylol. 
17. Mount sections in DPX mountant. 
Controls included sections incubated with: 
a) non-immune serum 
b) PBS substituted for each antibody or PAP, one at a time 
c) specific antiserum absorbed out with its specific antigen prior to use. 
Absorbing out of specific antiserum 
1. Incubate 0.01 ml antiserum to GSH S-T with 0.2 ml antigen (0.5 mg/ml) at 
4°C for 48 h. 
2. Spin at 4 000 g for 30 min and remove the supernatant. 
3. Before use dilute further to 1/500 dilution. 
IV Molecular Sieve Chromatography 
Preparation of Sephadex G-75 column 
Apparatus 
a) 1.5 x 100 cm glass column (Pharmacia Fine Chemicals, Uppsala, 
Sweden) 
b) Gel reservoir (Pharmacia Fine Chemicals Uppsala, Sweden) 
c) Spirit level 
Procedure 
1. Swell 20 g of Sephadex G-75 in water in a 90°C water bath for 3 h. 
2. Allow the slurry to cool to 4°C and decant the fines. Suck off the water and 
replace with eluent buffer (0.2 mM dithioerythritol, 0.05 M phosphate 
buffer, pH 7.5) until the volume of the supernatant liquid is approximately 
half the volume of the sedimented gel. 
3. Mount the column with reservoir attached in a vertical position at 4°C. 
4. Inject equilibration buffer into the outflow tubing to flush out any air 
bubbles present beneath the bed support. 
5. Pour the mixed gel suspension gently into the column. 
6. Fill the reservoir flask with eluent buffer and screw on lid. 
7. Allow the gel to settle for 5 min before opening the outlet. 
8. Adjust the outlet tubing so that the packing pressure does not exceed 160 
cmH20. 
9. Open outlet and pack under gravity. 
10. Allow the gel to pack so that there are approximately 4 cm of clear eluent at 
the top of the column. 
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11. Clamp off outlet tubing. 
12. Loosen the adaptor tightening mechanism and screw the top piece on to the 
column end piece. Slide the plunger down slowly until it reaches the top of 
the gel, ensuring that all the air in the adaptor above the net is displaced by 
the eluent. Lock the adaptor in position with tightening mechanism and 
locking screw. 
13. Invert the column, open outlet and start the eluent flow. 
14. Equilibrate the column with at least 3 bed volumes of eluent buffer. 
15. A sample volume of less than 5% is applied to the column. 
16. The column is eluted with upward pump-driven eluent flow at a flow rate 
less than that at which the column was packed. 
17. When not in use the column is stored in eluent buffer containing 0.02% 
sodium azide. 
V S-hexylglutathione Affinity Chromatography 
A) Preparation of S-hexylglutathione 
ref. Vince et al (1971). 
Procedure 
This procedure is carried out at room temperature with constant stirring. 
1. Dissolve 0.614 g of GSH (red) in 2 ml of H20 (2 mmoles) in a 25 ml beaker. 
2. Add 2 ml of 2 N NaOH (4 mmoles). 
3. Add ethanol, dropwise, to "cloud" point (approximately 10 ml). 
4. Add 0.301 ml 1-iodohexane (2 mmoles) slowly over 30 min. 
5. Cover with parafilm and stir overnight. 
6. Reduce pH to 3.5 by dropwise addition of 47% hydrogen iodide. 
7. Chill in fridge for 4 h. 
8. Remove solid by filtration and wash with 20 ml of H20. 
9. Dissolve solid in a minimum volume of 90°C water and recrystallize by 
addition of an equal volume of ethanol. 
10. Store at -20°C overnight. 
11. Harvest crystals by filtration. 
12. Dry crystals between pieces of Whatman filter paper. 
13. Store S-hexylglutathione in desiccator at -20°C. 
B) Preparation of S-hexylglutathione Sepharose 6B 
Apparatus 
a) Incubator (Gallenkamp model IH 100) 
b) Vertical rotating mixer 
c) 1 x 10 cm glass column (Pharmacia Fine Chemicals, Uppsala, Sweden) 
Procedure 
1. Wash 15 g of epoxy-activated Sepharose 6B on a sintered glass funnel with 2 
litres of H20. 
2. Dissolve, with stirring, 235 mg S-hexylglutathione in 30 ml of 0.1 M 
NaHC03, pH adjusted to 10.6 with NaOH. 
3. Readjust the pH of the solution to 10.6 using 1 M NaOH. 
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4. Add the ligand solution to the gel suspension and rotate end over end for 30 
h in incubator at 30°C. 
5. Wash gel on a sintered glass funnel with each of the following: 
a) 500 ml 0.1 M NaHC03, pH 8.6 
b) 500 ml 0.5 M NaCl, 0.1 M Sodium borate buffer, pH 8.0 
c) 500 ml 0.5 M NaCl, 0.1 M Sodium acetate buffer, pH 4.0 
d) 1 litre H20. 
6 Pack the column at 4°C with the gel. Clamp column in a vertical position in 
the cold room. Inject the equilibration buffer (0.2 mM dithioerythritol, 0.01 
M Tris/HCI, pH 7.8) into the outlet tubing to remove all air bubbles in the 
lower bed support and then clamp off tubing outlet. Gently pour the gel 
into the packing extension. Allow 10 min before opening the column 
outlet. Packing is initially by gravity and subsequently by downward 
pumping with a flow rate of 20 m.1/h. Equilibrate with at least 3 column 
volumes of equilibration buffer. When not in use store column in 0.02% 
sodium azide in the same buffer. 
C) Elution of the GSH S-T 
1. Add 16 ml of 0.2 M NaCl, 0.2 mM dithioerythritol, 0.01 M Tris/HCl, pH 7.8 
to 97 mg S-hexylglutathione in a glass homogenizer. 
2. Add 18 drops 1 M Tris/HCl, pH 8.8 and homogenize well. 
3. Once dissolved, make up to 50 ml and mix well. 
The hexylglutathione buffer is used for elution of the GSH S-T. 
VI Ion Exchange Chromatography 
Preparation of DE-52 Column 
Apparatus 
a) 2.6 x 40 cm glass column (Pharmacia Fine Chemicals, Uppsala, 
Sweden) 
b) Res~rvoir (Pharmacia Fine Chemicals, Uppsala, Sweden.) 
c) Minipuls 11 peristaltic pump (Gilson, France, Villiers le Bel, France) 
d) Mixograd gradient mixer (Gilson, France, Villiers le Bel, France) 
Procedure 
1. Swell 100 g of the resin in H20. 
2. After gently stirring, allow the resin to stand for 30 min and suck off the 
fines. 
3. Add eluent buffer (0.2 mM dithioerythritol, 0.01 M imadazole/HCl, pH 7.0 
to make a slurry and adjust the pH of the slurry to 7.0 with HCI. 
4. Wash the resin on a sintered funnel with 10 litres of eluent buffer at 4°C. 
5. Degas the slurry in a vacuum flask. 
6. Mount the column in a vertical position and pack under gravity flow as 
described for the Sephadex G-75 molecular sieve. 
7. Elute the column by pump driven downward flow. 
8. Equilibrate the column at 4° C for 48 h with eluent buffer. Check that the 
pH and the conductivity of the effluent and the eluent buffers are the same. 
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9. Using a gradient mixer, apply a linear 0.2 M NaCl gradient over 12 h to 
elute those proteins which do not elute in the void volume. 
VII Chromatofocusing 
ref. Sluyterman and Elgersma (1978). 
Apparatus 
a) 0.9 x 30 cm column (Pharmacia Fine Chemicals, Uppsala, Sweden) 
b) Packing extension 
c) Minipuls 11 peristaltic pump (Gilson France, Villiers le Bel, France) 
Procedure 
Degas all buffers before use. 
1. Make a slurry of PBE 94 in a small amount of eluent buffer (0.2 mM 
dithioerythritol, 0.025 M ethanolamine/HCl pH 9.5) and degas the slurry in 
a vacuum flask. 
2. Mount the column, with a packing extension attached, in a vertical position 
and pack the column as described for the Sephadex G-75 molecular sieve 
chromatography, ensuring that the tubing outlet is ± 50 cm below the top 
of the column. 
3. Once the column is packed, clamp off the outlet and attach the top piece to 
the column ensuring that all the air bubbles above the gel are removed. 
4. Continue to pack the column by pump driven downward flow at a flow rate 
of 100 cm/h until the gel bed is completely settled. 
5. Equilibrate the column with 15 bed volumes of eluent buffer at 37 ml/h. 
Check that the conductivity of the effluent is the same as that of the eluent 
buffer. 
6. 5 ml of polybuffer 96 (1/10 dilution, pH adjusted to 6.0) is applied to the 
column at a flow rate of 37 ml/h. 
7. Apply the protein sample (equilibrated with eluent buffer) to the column. 
8. Elute the ,Protein with 400 ml of the diluted polybuffer at the same flow rate. 
9. Regenerate the column by washing with 3 bed volumes of 1 M NaCl which 
will remove any protein still bound to the column. 
10. Immediately re-equilibrate the column in eluent buffer and store column in 
25% ethanol in eluent buffer. 
VIII GSH S-Transferase Assays 
ref. Habig et al (1974b). 
Principle 
Spectrophotometric measurement of the rate of thioether formation from 
electrophilic substrates by the GSH S-T. 
Apparatus 
Hitachi U 3200 spectrophotometer (Protea Nuclear Instruments, S.A. Pty, 
Ltd) or 
Unicam SP 1700 spectrophotometer (Phillips Pty Ltd S.A.) 
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Procedure 
All assays were performed at 25°C. 
1. To a 3 ml cuvette add: 
a) 2.75 ml 0.1 M potassium phosphate buffer 
b) 0.1 ml stock substrate, freshly prepared in 95% ethanol and kept in the 
dark (See Table B I) 
c) 0.15 ml GSH (red), freshly prepared in degassed H20 (see Table B1) 
d) enzyme (0.005 - 0.05 ml) 
2. Mix well and monitor change of absorbance (see Table B I) over 1 min. 
Read against an assay blank which includes all the reactants except 
enzyme. This corrects for the small amount of non-enzymatic activity. 
Calculation of specific activity 
Specific activities were calculated from the equation: 
.6.A/min 
(.6.£) 
x final assay vol. 
sample vol. 
X 1o3 
protein cone. (mg/ml) 
where .6.A = change in absorbance and .6.£ = the difference in molar extinction 
coefficient (M-1 cm-1). Results are expressed as).lllloVmin/mg prqtein. 
IX GSH Peroxidase Enzyme Assay 
ref. Prohaska and Ganther (1977) 
Principle 
The rate of GSH oxidation by the peroxide substrate is measured, as 
catalysed by the GSH peroxidase present. The rate of GSSG formation is 
measured by following the disappearance of NADPH at 340 nm ~£= 6000 
M-lcm-1) 
1 enzyme .unit is defined as 1 µmol of NADPH oxidised per minute. 
Procedure 
1. To a 1 ml cuvette add: 
a) 0.55 ml 0.1 M KCl, 0.1 M potassium phosphate pH 7.0 
b) 0.1 ml EDTA (30 mM) 
c) 0.1 ml 10 mM GSH (red)(lO mM) 
d) 0.1 ml NADPH (1.1 mM) 
e) 0.1 ml GSH reductase ( 40µg/ml) 
f) 0.05 ml enzyme 
2. Mix well and allow to incubate for 10 min at 25°C. 
3. Add 0.01 ml 0.2 g% cumene hydroperoxide (70% in cumene) in 10% ethanol. 
4. Mix and read change of absorbance at 340 nm against a reference blank which 
contains all the above reactants apart from enzyme. 
Calculation of results 
.6.Nmin X 
~6) 
Ev x 1000 
Sv 1 
Table BI 
CONDITIONS FOR GSH S-T ENZYME ASSAYS 































CONDITIONS FOR FLAT BED ISOELECTRIC FOCUSING 
Anode electrode solution 





pH range 3.5 - 9.5 
lMH3P04 
lNNaOH 
30 watt (initial) 
1000 volts (initial) 
50 mA (constant) 
1.5 hour 
pH range 4- 5 
lMH3P04 
1 M Glycine 
30 watt(initial) 
1400 volts (initial) 
50 mA (constant) 
3 hour 
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where 6.A = change in absorbance 
6. E= difference in molar extinction coefficient M-!cm-1 
Ev = final assay volume 
Sv = sample volume 
Results are expressed as ).lillOVmin/ml 
X CDNB Inactivation Assays 
Apparatus 
a) Shaking water bath (Gallenkamp and Co. Ltd.) 
b) Unicam SP 1700 spectrophotometer (Phillips Pty. Ltd., S.A.) 
Procedure 
1. Prepare a stock solution of 1-chloro-2,4-dinitrobenzene in 95% ethanol and 
protect from light (when the inhibitor concentration is varied a constant 
amount of ethanol is maintained). The final ethanol concentration in the 
incubate is 1.9%. . 
2. Add 0.5 ml - (x+y) cold 0.04 M Tris/HCl, pH 8.2 (incubation buffer) to a 
small glass test tube (rinsed in ethanol and dried) where x = volume of 
CDNB in ethanol or ethanol alone (for the control) and y = volume of 
enzyme. In certain experiments GSH or S-methylglutathione are added to 
the incubate and the initial volume of incubation buffer is appropriately 
adjusted. 
3. Vortex mix 0.01 ml CDNB/ethanol into the incubation buffer for 1 min. 
4. Add enzyme to incubation mixture and mix. 
5. Keeping incubation mixture at 4°C, assay quadruplicate 0.05 ml samples of 
the incubation mixture in the standard assay procedure for the 
measurement of GSH S-T activity towards CDNB (method VIII). The 
change in absorbance at 340 nm is monitored over 1 min. Care is taken to 
adjust the amount of enzyme added so that the change in absobance /min at 
time O is v,ery close to, and not greater than 0.05. 
6. Incubate the mixture at 25°C in a shaking water bath (70 cycles per minute) 
for 15 min. 
7. Place the incubation mixture on ice to stop the reaction, and assay in 
quadruplicate 0.05 ml aliquots of the incubation mixture. 
8. When GSH, S-methylglutathione or albumin are added to the incubation 
mixture their addition is prior to that of enzyme. The GSH and 
S-methylglutathione are prepared as stock solutions in degassed water and 
the pH adjusted to pH 7.0 with Tris. 
Calculation of results 
The % Activity remaining is determined by: 
change in absorbance/min at time 15min 
change in absorbance/min at time O min 
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XI Binding of [14C]-CDNB to GSH S-Transferases 
Apparatus 
a) Beta scintillation counter (Tricarb 4640 Packard Instrument Co., 
Downers Grove, Illinois, U.S.A.) 
b) Fraction collector (Retriever 111, Isco Inc., Lincoln, Nebraska, U.S.A.) 
c) Absorbance/fluorescence monitor · (Isco Inc., Lincoln, Nebraska, 
U.SA.) 
d) Instagel (Packard Instrument Co., Downers Grove, Illinois, U.SA.) 
e) Scintillation vials (Packard Instrument Co, Downers Grove, Illinois, 
U.SA.) 
Procedure 
1. Dissolve 1-chloro-2,4-dinitro[U-14C]benzene (250 µCi, 23.5 mCi/mmol) in 
0.35 ml ethanol. Flush with nitrogen and store in a sealed hypodermic vial. 
2. Add 1.5 ml - (x+y) 0.04 M Tris/HCl pH 8.2 to glass test tube, where x = 
volume of CDNB added and y = volume of enzyme added. 
3. Add 0.6 mM [14C]-CDNB (final concentration) to incubation buffer and 
vortex mix for one min. 
4. Add enzyme (1.2 µM) to incubation mixture and mix. 
5. After removing small fraction (for "O" time assay study) incubate the mixture 
in a shaking waterbath for 15 min at 25°C. 
6. Remove a small fraction (for 15 min assay study) and apply the incubation 
mixture to a Sephadex G-75 column (0.7 x 28cm) equilibrated with 0.04 M 
Tris/HCl, pH 8.2 (eluent buffer). 
7. Elute the column with eluent buffer using gravity flow and collect fractions 
on a fraction collector. 
8. Monitor the elution profile by dissolving 0.002 ml of the fractions in 10 ml of 
scintillation liquid and counting the radioactivity in a Beta scintillation 
counter. 
9. Those fractions constituting the 2 radioactive peaks are pooled separately 
and protein estimations (Bio-Rad Micro assay) are done on the 2 peaks. 
10. Determine the amount of radioactivity in the protein peak by counting a 
small fraction in 10 ml scintillation fluid in the Beta counter and the number 
of moles bound per mole enzyme is then calculated. 
11. Divide the radiolabelled protein fraction into 3 parts. 
12. The 3 fractions are treated as follows: 
a) Incubate fraction 1 with 6 M guanidine/HCl (final concentration) for 1 
hat 25°c. 
b) Incubate fraction 2 with GSH (1 mM final concentration) for 15 min at 
2S0 c. 
c) Incubate fraction 3 with unlabelled CDNB (1 mM final concentration) 
13. After treatment re-chromatograph each fraction on Sephadex G-75 as 
described in steps 6 - 8. 
14. Count aliquots of the pooled radiolabelled protein fraction and determine 
the protein concentration. 
15. Calculate the number of moles bound per mole of protein. 
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XII Trichloroacetic acid Precipitation of Reaction Mixture after Incubation of 
GSH S-T with f14C]-CDNB 
Procedure 
1. Prepare incubation mixture as described in steps 1-3 in method XI. In 
certain experiments add GSH (1.2 mM final concentration) to the 
incubation mixture. 
2. Incubate, with shaking, in a water bath at 25°C for 15 min. 
3. Place incubation mixture on ice to stop the reaction. 
4. Add an equal volume of 20% TCA at 4°C to the incubation mixture. Mix 
well and allow to stand at 4°C for 1 h. 
5. Centrifuge the mixture at 100 000 g for 1 h. 
6. Wash the precipitate with 7 ml of 20% TCA, mix and allow to stand at 4°C 
for 1 h. 
7. Centrifuge the mixture at 100 000 g for 1 h. 
8. Repeat steps 6 and 7 and dissolve the precipitate in 0.1 N NaOH. 
9. Determine the radioactivity present by counting an aliquot and determine 
the protein concentration. 
10. Calculate the number of moles of CDNB bound per mole of protein. 
XIII Demonstration of Covalent Binding using SDS-PAGE 
a) SDS Polyacrylamide Gel Electrophoresis equipment (See method I) 
b) Beta scintillation counter (See method XI) 
c) Counting vials with plastic cap inserts (Packard Instrument Co., 
Downers Grove, Illinois, U.S.A.) 
Procedure 
1. Run 0.1 ml of the first post Sephadex G-75 fraction of the incubation 
mixture of enzyme incubated with 0.6 mM [14C]-CDNB (as described in 
method XI) on a SDS polyacrylamide gel (see method I). 
2. Stain the gel as described in method I. 
3. Cut a 1.5 cm strip down the length of the gel below the bay where the 
protein was loaded. 
4. Place strip on glass plate and cut the strip into 1.5 mm sections and place 
them in counting vials noting sections containing the protein. 
5. Add 5 ml soluene to each counting vial. 
6. Cap the vials and heat in water bath at 50°C for 6 h. 
7. Add 9 ml of 9 parts Instagel scintillant /1 part 0.5 M HCl. Cap the vials, 
shake well, and count the vials in a Beta scintillation counter. 
XIV Flat Bed Isoelectric Focusing 
Apparatus 
a) Multiphore 2117 
b) Power supply 2197 
c) Ampholine PAGplates (pH range 3.5 - 9.5 and 4 - 5) 
(LKB, Bromma, Sweden). 
140 
Procedure 
Isoelectric points of proteins were determined by comparison with 
standards of known pl. An isoelectric calibration kit range 3 - 10 was used 
containing the standards: 
Ill 
Amyloglucosidase 3.50 
Soybean trypsin inhibitor 4.55 
Beta-lactoglobulin A 5.20 
Bovine carbonic anhydrase B 5.85 
Human carbonic anhydrase B 6.55 
Horse myoglobin 6.85 
Horse myoglobin 7 .35 
Lentil lectin 8.15 
Lentil lectin 8.45 
Lentil lectin 8.65 
Trypsinogen 9.30 
Focusing is carried out at 4°C 
1. Allow water to circulate rapidly through the cooling plate. 
2. Cover cooling plate of Multiphore with a thin layer of water. 
3. Slowly lower template on to the cooling plate eliminating bubbles and thus 
prevent overheating. 
4. Cover template with a thin layer of water. 
5. Slowly lower PAGplate onto template, again avoiding the presence of 
bubbles. 
6. Cut the electrode wicks to the correct size as shown by the template. 
7. Moisten the electrode strips with electrode solution (see Table BIi). Blot 
off excess fluid and place on template in correct position. 
8. Using forceps, position the sample wicks on the gel in a row 5 mm apart 
and 2 cm from the cathode strip. 
9. Place electrofocusing lid in position ensuring that the electrodes are in 
contact with the electrode wicks. Plug in electrodes. 
10. Place cover with electrode leads in position. 
11. Switch on power using the settings shown in Table BIi. 
12. Prefocus the gel for 10 min. 
13. Switch off power and using a Gilson pipette, apply samples (0.010 - 0.020 
ml) and standard markers (0.015 ml) to the sample wicks. 
14. Reconnect power supply. 
15. Remove sample wicks after 1 h. 
16. Allow focusing to continue for length of time described in Table B2 
17. Disconnect power, remove PAGplate. 
18. When using a P AGplate over the pH range 4 - 5, cut a 1 cm strip across the 
pH gradient of the gel and divide the strip into 0.5 cm segments. Agitate 
the segments in 0.01 M KCl for 2 h and read the pH. 
19. Fix the gel for 1 h in 11.5% TCA, 3.4% sulphosalycylic acid. 
20. Wash gel in 25% ethanol, 8% acetic acid (destaining solution). 
21. Stain gel for 2 h in 0.12% Coomassie Brilliant Blue R-250 in destaining 
solution. 
22. Destain gel in destaining solution. 
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Determination of lsoelectric Point 
To determine the pl of the protein sample on the pH 3.5 - 9.5 plates, the 
distance from the cathode to each pl marker was measured and plotted 
against the known pl value. The points were connected to obtain the pH 
gradient profile. The pl of the protein sample was then determined from 
the profile. For the pH 4 - 5 PAGplates, the pH profile was drawn from the 
readings obtained in step 18. 
XV Protein Concentration Determination 
A ref. Lowry et al (1951). 
Procedure 
Reagent A 
1. 3% Na2C03 in 0.1 N NaOH 
2. 2% CuS04 
3. 2% Potassium sodium tartrate. 
Mix 2 ml of 3, 2 ml of 2 and 96 ml of 1 (make up immediately before use). 
1. Prepare standards (in triplicate) by pipetting 0.1 ml, 0.075 ml, 0.050 ml, 
0.020 ml, 0.010 ml of human serum albumin (1 mg/ml) into test tubes. Make 
volume up to 0.5ml with H20. Include blanks of 0.5 ml H20 in the assay. 
2. Samples are prepared by diluting 0.2 ml up to 0.5 ml with water. 
3. Add 5 ml of reagent A to each tube. Mix and allow to stand for 10 min. 
4. Add 0.5 ml of Falin and Ciocalteu's phenol reagent (diluted 1)1 before use) 
and vortex mix immediately. 
5. After 30 min read absorbance of samples at 660 nm. 
Calculation of results 
Construct a standard curve by plotting absorbance versus protein 
concentration. Linear regression analysis was used to calculate the best line 
fit. Unknowns were read from the curve. 
B Bio-Rad Microassay Procedure 
1. Prepare triplicate standards of human serum albumin ranging from 1 - 14 
ug/ml in an appropriate buffer and add 0.8 ml of each to test tubes. Blanks 
consisting only of buff er are included in the assay. 
2. Samples are prepared by diluting samples up to 0.8 ml with buffer. 
3. Add 0.2 ml of Bio-Rad dye reagent concentrate and vortex carefully, 
avoiding excessive foaming. 
4. Allow to stand for 10 min and read at 595 nm against the reagent blank. 
Calculation of results 
The absorbance at 595 nm was plotted against the concentration of 
standards, and linear regression was used to calculate the best line fit. 
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Unknowns were calculated from the standard curve. 
XVI Monoclonal Antibody Production 
Apparatus 
a) sterile hood (Laminaire, Pty Ltd ,S.A.) 
b) CO2 incubator (Labotec, Forma Scientific, Pty Ltd, SA.) 
Stock reagents 
Penicillin and streptomycin (P and S) lOOx 
10 000 u/ml penicillin, 10 000 ug/ml streptomycin in sterile PBS (0.14 M 
NaCl, 2.6 mM KCl, 8 mM Na2HP04, 1.5 mM KH2P04) (frozen in 
aliquots). 
HUCS-human unbilical cord serum, heated for 30 min at 56°C, filtered and 
sterilized. 
"HT" lOOx stock 
a) hypoxanthine 0.68 g 
b) thymidine 0.1935 g 
c) glycine 0.011 g 
d) sodium pyruvate 5.503 g 
1. Add 250 ml water to hypoxanthine powder and add up to 5 ml 10 N NaOH 
dropwise until dissolved. 
2. Add remaining reagents and make up to 500 ml with water. 
3. Filter sterilize and store frozen. 
Aminopterin lOOx stock 
(1.76 mgllOOml H20) 
1. Add 25 ml H20 to aminopterin followed by 0.5 ml 5 N NaOH. 
2. Neutralize with 5 N HCl and make up to volume. 
3. Filter and store protected from light at -20°C. 
A Immunization of Mouse 
1. Inject 30 .Ug of acidic lung transferase emulsified in complete Freund's 
adjuvant intraperitoneally into mouse. 
2. After 2 weeks boost mouse with 30 llg of acidic lung GSH S-T emulsified in 
incomplete Freund's adjuvant. 
3. After 2 weeks test for the presence of antibody using an ELISA assay. 
4. 3 days prior to the fusion inject the mouse with 50 ug of acidic lung 
transferase in PBS intraperitoneally. 
1. Have available 2 - 3 100 mm petri dishes with myeloma SP2f0Ag14 cells of 
good viability. 
2. Remove the supernatant medium and after pelleting the cells, filter through 
a 0.45 um sterile filter and store as "conditioned medium". 
3. To the dishes containing the viable myeloma cells add 10 ml of Versene 
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solution (0.69 mM EDTA in 0.14 M NaCl, 2.6 mM KCl, 1.5 mM KH2P04, 
6 mM Na2HP04, pH 7.4). 
4. After incubation at 37°C for 10 min dislodge the cells by pipetting and 
transfer to centrifuge tubes. 
5. After spinning at 500 g for 15 min, resuspend the cells in RPMI 1640 tissue 
culture medium. 
6. Count the cells and check the viability with Trypan blue. 
7. Sacrifice the immunized mouse and remove the spleen under sterile 
conditions. Place in a petri dish in RPMI at 37°C. 
8. Using the plunger of a 2 ml syringe mash the spleen through a sterile 
stainless steel sieve into RPMI in the dish. 
9. Break up clumps by pipetting the suspension up and down several times 
and transfer to a 50 ml centrifuge tube. 
10. Allow to stand for 3 min and transfer the supernatant ( approximately 10 ml) 
to clean tube. 
11. Spin at 500 g for 5 min and resuspend the pellet in 30 ml RPMI. 
12. Wash the cells once with RPMI and count the cells after making a dilution 
in white cell diluting fluid (2% acetic acid) which lyses the red cells. 
13. Add 9 parts of spleen cells to 1 part of SP-2 cells in RPMI in a 50 ml 
centrifuge tube. 
14. Centrifuge at 500 g for 5 min. 
15. Pour off supernatant leaving a little behind in which to gently loosen the 
pellet. 
16. Autoclave 2 g polyethylene glycol (PEG 4000) and add 2 ml warm (37°C) 
RPMI while liquid. 
17. Slowly add polyethylene glycol (1.5 ml) at 37°C, dropwise, over 1.5 min with 
gentle mixing. 
18. Continue to mix gently for 0.5 min. 
19. Add 1 ml RPMI (37°C) slowly over 1 min to the suspension with gentle 
mixing. 
20. Add another 1 ml RPMI (37°C) to the suspension over 1 min. 
21. Add 8 ml RPMI (37°C) to the suspension over 2 - 3 min 
22. Make the volume up to 45 ml. 
23. Spin the suspension at 500 g for 3 min and remove the supernatant. 
24. Gently resuspend the pellet in HAT-HUCS-Condi Medium (1 ml of lOOx 
HT/ 1ml lOOxA/ 5ml HUCS/ 1ml lOOx P and S/20 ml SP2 conditioned 
medium/72 ml RPMI) and make volume up to 50 ml. 
25. Pipette 0.5 ml aliquots into wells of 24 well plates and then add 0.5 ml of 
HAT-HUCS Condi Medium. This volume of cell suspension is for a yield 
of ± 1o8 spleen cells. If yield differs adjust volume accordingly. 
26. When filling wells add a drop of SP2 (unfused) to a well. This is to check 
that the SP2 cells are unable to grow in HAT medium. 
27. Incubate plates at 37°C in 5% CO2 and 100% humidity. 
28. Clones should grow within 10 - 14 days. When medium starts to turn yellow 
test supernatants for antibody by ELISA assay. 
29. Clone a good positive well and freeze the contents of a few positive wells at 
-70°C. Suspend cells in 20% FCS (foetal calf serum pooled, heated 56°C for 
30 min, filtered and sterilized) in RPMI, without antibiotics and cool on 
ice. Add equal volume cold 20% DMSO in RPMI, without antibiotics, and 
transfer to cryotubes. Wrap in paper towel and place in -70°C overnight and 
then transfer to liquid nitrogen. 
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C Cloning of Cells 
1. Dislodge the cells by pipetting and transfer to sterile test tube. Count the 
number of cells using a counting chamber. Feed the remaining cells with 
HT-HUCS (1 ml lOOx HT/5 ml HUCS/1 ml lOOx P and S /93 ml RPMI) and 
return them to the incubator. 
2. Count ± 200 cells accurately and calculate cell concentration. Dilute cells 
to give 1 - 2 cells/0.05 ml. 
3. Add 0.05 ml per well followed by 0.05 ml of medium to a 96-well 
flat-bottomed microtiter tray. Include a focusing well by adding a drop of 
higher concentration of cell suspension. 
4. Allow cells to settle and check under microscope that most wells have 1 cell 
per well. (First focus on "focusing" well and then look for single cells). 
5. Freeze remaining cells in one cryotube. Keep harvest fluid as positive 
control for testing by ELISA. Once cells in 24 well dish have grown freeze 
them as well. 
6. Incubate the plate in CO2 incubator at 37°C. 
7. After 1 week add 0.1 ml HT-HUCS Medium. When medium starts to tum 
yellow screen harvest fluid for production of antibody. 
8. Select strong positives and expand to 24 well plate. 
9. Choose strong positive and redone, freezing others as before. 
10. When final clones have been frozen expand some of the cells in 100 mm 
dishes in 10% FCS in order to obtain sufficient cells for making ascites. 
11. Inject 5-10 x 106 cells in 0.5 ml PBS intraperitoneally to a mouse primed ± 
10 days previously with 0.5 ml pristane intraperitoneally. 
12. Examine mouse daily for abdominal swelling and when abdomen is well 
swollen sacrifice mouse. 
13. After sterilizing abdomen with absolute alcohol, carefully open abdomen 
and suck out ascites using a pasteur pipette. 
14. Spin down cells (500 g for 5 min). Suck off supernatant and filter through a 
0.45 um filter and store at -70°C. 
15. Wash remaining cells with PBS and spin at 500 g for 5 min. 
16. Resuspend cells in PBS and reinject 5 - 10 x 106 in 0.5 ml into pristane 
primed mice. The ascites obtained from the passaged cells usually contains 
higher titer antibody. 
D Maintenance of Myeloma Cells 
1. Grow myeloma cells in 10% FCS in RPMI containing antibiotics and 
passage 3 times per week. 
2. Dislodge the semi-adherent cells by vigorous pipetting and discard if not 
used for fusing. 
3. Add fresh medium to those cells remaining in dish. Cells should not be 
passaged for longer than 30 days. 
E Thawing of Cells 
1. Thaw cells in 37°C waterbath and remove when a small ice crystal is still 
visible. 
2. Place in 15 ml centrifuge tube and dilute slowly with 10% FCS at room 
temperature. 
145 
3. Centrifuge at 500 g for 5 min. 
4. Suspend cells in fresh medium and place in CO2 incubator. 
XVII ELISA Assay for Screening Hybridoma Supematants 
ref. Engvall and Perlman (1971); Van Weemen and Schuurs (1971). 
Apparatus 
a) Falcon 3911 Micro Test flexible assay plates 
b) Titertek Multiskan MCC/340 (Flow Lab., Ltd, Ayrshire, Scotland, 
U.I{.) 
Procedure 
During all incubations the ELISA plate is tightly covered with plastic 
wrapping. 
1. Dilute antigen (human lung acidic transferase) in PBS-9 (150 mM NaCl, 
10 mM NazHP04, pH 9.0) to 10 ug/ml. 
2. Dispense 0.05 ml of diluted antigen into wells of ELISA plate, using a 
Gilson Repetman. 
3. Incubate the plate overnight at 4°C. 
4. Flick antigen out of plates. 
5. Block unbound sites by dispensing 0.2 ml of 1 % foetal calf serum in 
PBS-9 into each well. Incubate 15 - 30 min at room temperature. 
6. Flick blocking solution out of plates. 
7. Add 0.05 ml hybridoma supernatant to wells. Include a known positive 
control ie. a known positive antibody, a negative control e.g. PBS and a 
non immune control ie. control mouse hybridoma supernatant. 
8. Incubate plates for 1 h at room temperature. 
9. Wash the wells ten times with "TST" (Tris-saline-tween) washing solution 
(0.1 M NaCl, 0.05 M Tris/HCl pH 8.0, 0.05% Tween 20). 
10. Add 0.05 ml of peroxidase conjugate to each well and allow to stand at 
room temperature for 30 min (Peroxidase-conjugated goat anti-mouse 
immunoglobulins (IgA, IgM, IgG) diluted 1/10 in 4% bovine serum 
albumin in 0.5 M NaCl, 0.01 M Na2HP04, 0.5% Triton-X-100 (diluent) 
and stored frozen at -20°C. Dilute 1/30 in diluent for use). 
11. Wash plates 10 times with "TST" washing solution. 
12. Add 0.1 ml of substrate solution to each well ( 40 mM 
2,2'azino-di(3-ethyl-benzthiazoline)sulfonic acid dissolved in water and 
stored frozen in aliquots protected from light. Dilute 1/100 with 0.1 M 
sodium citrate buffer adjusted to pH 4.0 with 3 N NaOH and add 1/100 
volume of 30% hydrogen peroxide). Once hydrogen peroxide is added 
use immediately. 
13. Allow colour reaction to proceed for 15 min. Read absorbance at 414 
nm on ELISA reader. 
XVIII Mouse lg Isotyping using an ELISA Assay 
1. Repeat steps 1-6 as described for ELISA assay in method XVII . 
• 
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2. Add 0.05 ml of harvest fluid to wells of ELISA plate (include a series of 
control wells to which PBS is added) and incubate at room temperature for 
1 h. 
3. Wash the wells 10 times with "TST" washing solution. 
4. Dispense 0.05 ml of the isotyping sera (IgA, IgM, IgGl, IgG2a, IgG2b and 
IgG3) diluted 1/20 in PBS to wells exposed to harvest fluid, and to the 
control wells. Incubate for 1 h at room temperature. 
5. Wash the wells 10 times with "TST" washing solution. 
6. Add 0.05 ml peroxidase conjugated goat anti-rabbit immunoglobulins 
(made up and diluted as in step 10 of method XVII) and allow plates to 
incubate for 30 min. 
7. Wash the wells 10 times with ''TST" washing solution. 
8. Add 0.1 ml substrate as described in step 12 of method XVII. 
9. Allow colour reaction to proceed for 15 min and read absorbance at 414 nm 
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